Recommendations for Scientific Research & Prevention Program (SRPP) Committees

Scientific Review Council Ad Hoc Members

- Andrea Califano, Ph.D.
- X. Shirley Liu, Ph.D.

Product Development Research Peer Review Panels

- Michael Cheng, MD
- Arnab Ghosh, MD, PhD
- Mickey C-T. Hu, MS, PhD
- Rachel Humphrey, MD
- Walter Stadler, MD, FACP
- Neil Vasan, MD, PhD

OMB No. 0925-0001 and 0925-0002 (Rev. 3/2020 Approved Through 02/28/2023)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: ANDREA CALIFANO

eRA COMMONS USER NAME: CALIFANOA

POSITION TITLE: Clyde and Helen Wu Professor of Chemical and Systems Biology, Departments of Systems Biology, Biochemistry & Molecular Biophysics, Biomedical Informatics, and Medicine

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE	Completion Date	FIELD OF STUDY
University of Florence, Italy	Equiv B.S.	05/1982	Physics
University of Florence, Italy	Laurea	04/1985	Physics
Istituto Nazionale di Ottica, Florence	Res. Assoc.	07/1986	Physics
Massachusetts Institute of Technology, MA	Post-doc	03/1986	Information Mechanics

A. Personal Statement

I am the Clyde and Helen Wu Professor of Chemical and Systems Biology and the founding Chair of the Department of Systems Biology at Columbia University. I was trained as a physicist and have applied physics-based approaches, including extensive use of information theory, to reverse engineering and interrogation of gene regulatory networks. I have pioneered use of mammalian networks as models for the quantitative analysis of cancer related phenotypes and for identification of driver genes, driver mutations, and small-molecule modulators of tumor vulnerabilities. In particular, I have demonstrated that (a) tumor specific transcriptional and signaling networks can be inferred accurately using information theoretic principles from large collections of molecular profile data of patient-derived tumor samples, using algorithms developed by my lab such as ARACNe[4 – 7]; (b) these networks can be interrogated using tumor derived signatures to discover master regulators (MRs) of tumor progression and drug sensitivity[8 – 11]; (c) computational analysis of *de novo* inferred networks, upstream of such MRs, can systematically elucidate the repertoire of genetic alterations and germline variants responsible for aberrant disease activity[12 –13]. Finally, (d) my lab has shown that inhibition of MRs using individual compounds or synergistic compound combinations, as computationally inferred from perturbational signatures, can abrogate tumor viability *in vitro* and *in vivo* [14 –17]. Since MR analysis can be performed on an individual gene expression profiles, this methodological approach is uniquely suited to the dissection of tumor mechanism heterogeneity, either from individual patient samples or even from single cells. Together, these methodologies represent one of the most extensive and validated toolkits for the systems biology based elucidation of novel cancer targets, small-molecule inhibitors, and biomarkers, having resulted in significant translation. Discoveries supported by these approaches have been used as a rationale for several clinical studies, including use of combination therapy in relapsed HER2+ following trastuzumab therapy (NCT02066532), in metastatic breast cancer (NCT02632071), and in several N of 1 studies, where MR-based tumor vulnerabilities are identified and targeted pharmacologically on an individual patient. They are thus poised to provide valuable and complementary approaches to current mutational bases approaches.

B. Positions and Honors

1986 – 1993 Research Staff member, Exploratory Computer Vision Group, IBM TJ Watson Research Center
1993 – 1997 Manager, Computational Biology Group, IBM TJ Watson Research Center
1997 – 2000 Program Director, IBM Computational Biology Center
1997 – 2007 Fellow of the Institute of Electrical and Electronic Engineers (IEEE)
2000 – 2003 Founder, EVP and Chief Technology Officer, First Genetic Trust, Inc.
2003 – pres. Professor of Biomedical Informatics, Columbia University

2005 – pres. Fellow of the New York Academy of Sciences
2005 – 2019 Assoc. Director for Bioinformatics, Herbert Irving Cancer Center, Columbia University
2005 – 2017 Director, Center for the Multiscale Analysis of Genomic Networks (MAGNet)
2005 – pres. Co-Director, Center for Computational Biology and Bioinformatics (C2B2)
2008 – 2016 Member, Board of Scientific Advisors, National Cancer Institute
2008 – pres. Fellow of the New York Academy of Medicine
2009 – 2013 Founding Director of the Systems Biology Initiative, Columbia University
2010 – pres. Director, JP Sulzberger Columbia Genome Center, Columbia University
2012 – pres. Clyde and Helen Wu Professor of Chemical and Systems Biology, Columbia University
2013 – pres. Founding Chairman of the Department of Systems Biology, Columbia University
2014 – pres. Member, SAB, Koch Cancer Center, MIT
2014 – pres. Scientific Editor, Cancer Discovery and Cell Systems
2015 – pres. NCI Outstanding Investigator Award
2015 – pres. Fellow, American Association for the Advancement of Science
2015 – pres. Cofounder and Chief Scientific Advisor, DarwinHealth, Inc.
2017 – pres. Fellow of the International Society of Computational Biology
2017 – pres. Chair, Columbia Committee for Precision Cancer Medicine
2017 – pres. The Pershing Square Foundation, Scientific Review Council
2018 – pres. Member, National Academy of Medicine
2018 – pres. Advisor, Frederick National Laboratory Advisory Committee (FNLAC)

C. Contributions to Science (* indicates co-Sr. authorship)

Functional Characterization of Mutations Using Network-based Inference of Protein Activity: Identifying oncoproteins whose dysregulated activity is necessary for tumor maintenance on an individual patient basis is crucial for developing personalized treatment plans. However, this is challenging as genetic alterations are only partially predictive and there are no direct assays to measure protein activity. To address this problem, the Califano lab recently published the *Virtual Proteomics by Enriched Regulon analysis* (VIPER) algorithm [1]. VIPER computes a highly accurate measurement of protein activity, on an individual sample basis, from the expression of their transcriptional targets (*regulon*). VIPER is uniquely suited for the identification of novel cancer targets, to functionalize genomic alterations of unknown relevance, and to assess compound activity on the full repertoire of regulatory proteins in a cancer cell. It has helped elucidate MR proteins in several human malignancies, from leukemia, and lymphoma, to prostate cancer, breast cancer, and glioma [2]. It has also been extended to single cell analysis, where it solves the gene-dropout problem caused by low sequencing depth [3].

1. Alvarez MJ, Shen Y, Giorgi FM, Lachmann A, Ding BB, Ye BH, **Califano A**. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. *Nat Genet*. 2016 Aug;48(8):838-47. PMCID: PMC5040167.
2. **Califano A**, Alvarez MJ. The recurrent architecture of tumour initiation, progression and drug sensitivity. *Nat Rev Cancer*. 2017 Feb;17(2):116-130. Review. PMCID: PMC5541669.
3. Ding H, Douglass EF Jr, … , **Califano A.** Quantitative assessment of protein activity in orphan tissues and single cells using the metaVIPER algorithm. *Nat Commun*. 2018 Apr; 9(1), 1471. PMCID: PMC5902599.

Reverse Engineering of Mammalian Regulatory and Signaling Networks (interactomes): The Califano lab has pioneered use of information theoretic and Bayesian methods to reverse engineer genome-wide, tissue-specific regulatory network (interactomes), including (a) the first transcriptional network of a human cell reconstructed by the ARACNe algorithm [4]; (b) the first network representing post-translational modulators of transcription factor activity in human cells, using the MINDy algorithm [5]; (c) the first protein-protein interaction network based on 3D protein structure information, using the PrePPI algorithm [6]; and (d) a novel regulatory layer implemented by competitive endogenous RNA species, using the Hermes and Cupid algorithms [7]. These algorithms have shown accuracy and sensitivity comparable—and often exceeding—those of medium and high-throughput experimental assays.

4. Basso K, …, **Califano A**. Reverse engineering of regulatory networks in human B cells. *Nat Genet*. 2005;37(4):382-90. PMID: 15778709.
5. Wang K, …, **Califano A**. Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. *Nat Biotechnol*. 2009;27(9):829-39. PMCID: PMC2753889.
6. Zhang QC, …, **Califano A***, **Honig B***. Structure-based prediction of protein-protein interactions on a genome-wide scale. *Nature*. 2012;490(7421):556-60. PMCID: PMC3482288.

7. Sumazin P, …, **Califano A**. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. *Cell*. 2011;147(2):370-81. PMCID: PMC3214599.

Elucidation of Master Regulators of Tumor-related Phenotypes: The Califano lab has developed algorithms for the quantitative interrogation of tissue-specific interactomes, using signatures representing phenotypic transition between two states (e.g., primary vs. metastatic cancer). The Master Regulator (MR) Inference algorithm (MARINa) and its most recent extension (VIPER), in particular, have been instrumental in elucidating MR proteins that mechanistically implement tumor cell state. For instance, they were used to elucidate CEBPB and STAT3 as synergistic MRs of the mesenchymal subtype of human glioma [8]. In collaboration with Dr. Adolfo Ferrando, MARINa helped elucidate MR proteins effecting glucocorticoid resistance in T-cell acute lymphoblastic leukemia [9]. Similarly, application to prostate cancer was instrumental in elucidating FOXM1 and CENPF as synergistic MRs of aggressive/metastatic prostate cancer [10], while analysis of two independent neuroblastoma cohorts identified a 10-protein MR module controlled by a TEAD4-MYCN positive feedback loop as the key mechanistic driver of a subtype of the disease associated with poor prognosis [11].

8. Carro MS, …, **Califano A***, Iavarone A*. The transcriptional network for mesenchymal transformation of brain tumours. *Nature*. 2010;463(7279):318-25. PMCID: PMC4011561.
9. Piovan E, …, **Califano A***, Ferrando A*. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. *Cancer Cell*. 2013;24(6):766-76. PMCID: PMC3878658.
10. Aytes A, …, **Califano A***, Abate-Shen C*. Cross-species analysis of genome-wide regulatory networks identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. *Cancer Cell*. 2014;25(5):638-51. PMCID: PMC4051317.
11. Rajbhandari P, …, **Califano A**. Cross-cohort analysis identifies a TEAD4 ↔ MYCN positive-feedback loop as the core regulatory element of high-risk neuroblastoma. *Cancer Discovery*. 2018 May;8(5):582-599. PMCID: PMC5967627

Network-based Identification of Driver Mutations: Tumor initiation, progression, and drug sensitivity are determined by a large, diverse repertoire of genetic alterations and germline variants, which differ between tumors and even between cells within a tumor. Yet, analysis of large cancer genome databases reveals that only a small fraction of tumors is characterized by two or more recurrent genetic alterations. This suggests that most cancer mutations may represent rare or even private events. The Califano lab proposed that MR proteins implement regulatory bottlenecks that integrate the effect of complex genetic alteration patterns to implement the key genetic programs necessary for tumor cell state maintenance (i.e., tumor bottleneck hypothesis) [12]. This approach led to discovery of novel mutational events that were experimentally validated as causal in lymphomagenesis and gliomagenesis. For instance, network-based analysis of mesenchymal glioma samples identified only two alterations—the homozygous deletion of the E3 culling ligase adapter protein KLHL9 (in ~60% of subtype) and the focal amplification of the CEBPD developmental transcription factor (in ~30% of subtype) [13]. Experimental validation showed that KLHL9 is necessary for E3 Cullin-mediated ubiquitylation of both CEBPB and CEBPD (two previously validated MRs of mesenchymal glioma) and for their proteasomal degradation, and that rescue of KLHL9 expression in homozygously deleted mesenchymal patient derived xenografts abrogated tumor viability *in vivo*. The same approach was used to discover novel variants and mutations in Alzheimer's and Breast Cancer.

12. **Califano A**, Alvarez MJ. The recurrent architecture of tumour initiation, progression and drug sensitivity. Nat Rev Cancer. 2017;17(2):116-30. PubMed PMID: 27977008. PMCID: PMC5541669.
13. Chen JC, …, **Califano A**. Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. *Cell*. 2014;159(2):402-14. PMCID: PMC4194029.

Systematic Identification of Small Molecule Inhibitors of Master Regulator Activity: We hypothesized that analysis of gene expression profiles following compound perturbation in cells representative of a specific tumor subtype, using MARINa, can elucidate a compound's functional effectors and potential targets (both inhibited and activated). More importantly, compounds whose effectors match the MR profile of a tumor subtype (i.e. inhibit positive MRs and activate negative MRs) should induce critical loss of tumor viability. Finally, compounds with complementary effect in inverting a tumor MR pattern (e.g., where each compound inverts a non-overlapping component of the overall MR pattern) should elicit significant synergy [14]. We validated this approach using a large dataset of profiles of DLBCL cells. We then developed the SynGEN algorithm to identify synergistic compounds based on analysis of overlap of individual MARINa MR signatures [15]. Following SynGEN ranking of all compound pairs (91 in total) by predicted synergy, we experimentally validated their synergistic interaction in LY3 cells. Remarkably, SynGEN predicted 50% of true synergistic pairs at 5% false discovery rate (FDR). The

ability to match drugs to individual patients based on their computationally inferred ability to invert the activity of the top MR proteins controlling tumor state was recently demonstrated in the context of gastroenteropancreatic neuroendocrine tumors, leading to NY CLIA certification of two RNA-based tests (OncoTarget and OncoTreat) [16]. There are currently several clinical and pre-clinical trials that are enrolling patients based on the availability of these MR-based methodologies, including (a) a phase 2 trial to test the combination of trastuzumab and ruxolitinib in HER2+ relapsed breast cancer patients, (b) a SWOG study to identify VIPER-inferred pharmacologically-actionable dependencies in breast cancer patients with significant residual tumor, following neoadjuvant chemotherapy (c) the Columbia N of 1 study where patients representing 14 malignancies who had progressed on 3 to 7 lines of therapy are being transplanted in PDX models, which are then treated with drugs predicted by OncoTreat and OncoTarget (d) a PCF-funded challenge award for an N of 1 in metastatic CRPC (e) a phase 2 trial of entinostat in gastroenteropancreatic neuroendocrine tumors and (f) a Lustgarten-foundation funder N of 1 trial in pancreatic cancer. These studies also led to the development of novel methodologies for elucidating drug mechanism of action from compound-mediated perturbational profiles, such as DeMAND [17].

14. Mitrofanova A, …, Abate-Shen C*, **Califano A***. Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models. *Cell Reports*. 2015;12:1-12. PMCID: PMC4591242.
15. Bansal M, …, Stolovitzky G*, **Califano A***. Predicting compound synergy from first principles, a crowdsourcing approach. *Nat Biotech*. 2014;32(12):1213-22. PMCID: PMC4399794.
16. Alvarez MJ, …, Modlin I*, **Califano A***. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. *Nat Genet*. 2018 Jul;50(7):979-989. PMID: 29915428.
17. Woo JH, …, **Califano A**. Elucidating compound mechanism of action by network dysregulation analysis in perturbed cells. *Cell*. 2015;162:441-451. PMCID: PMC4506491.

A full list of publications can be found at:
http://www.ncbi.nlm.nih.gov/sites/myncbi/andrea.califano.1/bibliography/43566462/public/?sort=date&direction=descending

D. Research Support
Selected Ongoing Research Support

NIH 1 U01 CA217858-03 Califano (PI) 08/01/17 - 07/31/22
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
To develop the first mechanistic approach for precision cancer medicine, where therapeutic targets, associated inhibitors, and population stratification biomarkers are systematically derived from precise, mechanistic understanding of tumor state regulation and of its drug-induced modulation.

NIH 1 R35 CA197745-05 Califano (PI) 08/14/15 - 07/31/22
Outstanding Investigator Award: Elucidating the dependencies of tumor initiating and drug-resistant niches in human malignancies by genome-wide molecular profiling of single cells
To develop a novel methodological framework integrating both experimental and computational approaches to study the impact of tumor heterogeneity on progression and drug resistance at the single cell level.

NIH 1 U54 CA209997-04 Califano (PI) 08/08/16 - 07/31/21
Centers for Cancer Systems Therapeutics (CaST)
To leverage proven methodologies and novel and integrative systems biology approaches to foster a highly innovative framework for the rapid, patient-centric prioritization and evaluation of cancer therapeutic strategies targeting target tumor homeostasis, including single agent and combination therapy.

NCI 3 P30 CA13696-45 (Rustgi) 07/01/14 - 06/30/20
Cancer Center Support Grant
To support the leadership of Columbia University's lab, clinical and population-based cancer research programs and the shared resources serving the University's Cancer Center members.
Role: Director

NIH 5R01HD085904-03 (Shen) 07/10/16 - 04/30/21
NIH/NICHD

Systems analysis of mouse gastrulation The specific aims in this project are: 1) identification of master regulators of mouse epiblast during gastrulation, 2) analysis of the transcriptional network that regulates mouse gastrulation, and 3) functional analyses of the regulatory network for gastrulation.
Role: Investigator

Foundation Grant
Price Family Foundation (Johannessen) 08/01/17 – 07/31/21
A research collaboration underway between Columbia's Department of Systems Biology, the Broad Institute of MIT and Harvard and Columbia Medical Center is working to accelerate the discovery of new cancer drug combinations targeted at esophageal cancer.
Role: Principal Investigator (Subaward)

Lustgarten Foundation (Olive, Califano) 04/01/18 – 03/31/21
Clinical translation of regulatory network-based precision medicine for pancreatic cancer The Lustgarten Foundation has awarded a three-year grant, as part of its Translational Clinical Program, to test a new precision medicine approach to the treatment of metastatic pancreatic cancer.
Role: Co-PI

Hyundai Hope on Wheels (Yamashiro) (Califano) 05/01/18-04/30/23
Hyundai Hope on Wheels
Targeting Master Regulator Dependencies in High-Risk Osteosarcoma (OS)
We propose to use computational biology strategies to elucidate universal tumor dependencies that will not only help prioritize therapy for the individual patient, but also maximize the opportunity to innovate treatment for the disease as a whole.
Role: Co-Investigator

Selected Completed Research Support

NIH R01 CA193837-05 (Sawyers) 04/01/15 - 03/31/20
Defining the Role of ERG in Modulating the AR Cistome and Antiandrogen Sensitivity
To analyze RNA-Seq data generated by the Sawyers group to identify critical regulators within the interaction network between PTEN, ERG, and AR.
Role: Principal Investigator (Subaward)

NCI/CTDD U01 CA168426-04 Califano (PI) 06/01/12 - 04/30/17
Systems Biology of Tumor Progression and Drug Resistance
To build a successful pipeline for the discovery and validation of master regulator modules that implement functional bottlenecks that integrate aberrant signals from multiple alterations, thus constituting actionable tumor dependencies.

NIH 5 U54 CA121852 Califano (PI) 09/26/05 - 07/31/16
National Center for the Multi-Scale Analysis of Genomic and Cellular Networks (MAGNet)
To build a National Center for Biomedical Computing providing advanced algorithms and databases for Cellular Networks.

Leidos 15x36-269 Califano (PI) 02/01/15 - 01/31/17
Integrative Analysis of Genomic and Proteomic data from The Cancer Genome Atlas
To jointly analyze TCGA data, using interactome-based, integrative algorithms, to coherently reorganize our knowledge of cancer around MR genes representing mechanistic tumor dependencies and their upstream genomic determinants, on an individual patient basis.

Chan Zuckerberg Initiative (Califano) 02/01/18 - 08/31/19
Assembly of context-specific gene regulatory networks for the systematic reconstruction of single-cell states and their molecular determinants
The goal is to complement the individual cell states identified by our analysis with an Atlas of matched, single-cell derived interactomes, eventually extending to all Human Cell Atlas entries. These will support key analyses, including identification of lineage markers and reprogramming factors.
Role: Principal Investigator

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Liu, Xiaole Shirley

eRA COMMONS USER NAME (credential, e.g., agency login): SHIRLEY_LIU

POSITION TITLE: Professor of Biostatistics and Computational Biology

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	Completion Date MM/YYYY	FIELD OF STUDY
Peking University, Beijing, China		07/1994	Biochemistry
Smith College, Northampton, MA	B.A./B.A.	05/1997	Biochemistry/Computer Science
Stanford University, Stanford, CA	Ph.D./Ph.D. minor	06/2002	Biomedical Informatics/Computer Science
Harvard School of Public Health, Dana-Farber Cancer Institute	Research Fellow	06/2003	Biostatistics and Computational Biology

A. Personal Statement

I am a **computational and systems biologist in cancer research**, with expertise in **algorithm development, data integration, cancer gene regulation, and precision cancer medicine**. I am an associate member at the Broad Institute, and the co-director (with Myles Brown) of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute. I am a member of the mod/ENCODE consortia (NHGRI) and Information Technology for Cancer Research initiative (NCI), and the principal investigator of the Cancer Immunologic Data Commons as part of the NCI Cancer Moonshot project on cancer immunotherapy. My group **developed many widely used and cited algorithms** for transcription factor (TF) motif finding (5), ChIP-chip (6) / ChIP-seq (7, 8), MNase (10) / DNase-seq (12), CRISPR screen (17, 19), immune repertoire (22, 24), and scRNA-seq/scATAC-seq (MAESTRO) data analysis. Through integrating genome-wide transcription factor binding, chromatin dynamics, and gene expression profiles, we modeled the specificity and function of transcription factors (3, 13, 14, 16), chromatin regulators (11) and lncRNAs (Du et al, NMSB 2013; Du et al Nat Comm 2016) in tumor development and progression. We have a long-standing interest and track record in **big data integration and bias correction in genomics**, being at the forefront of identifying and correcting biases in microarray and next-generation sequencing data to facilitate better integration (1, 2, 12). We conducted the first comprehensive integrative analyses to annotate the C. elegans genome (modENCODE, Science 2010; Nature 2014), were among the earliest to integrate epigenetic profiles with GWAS (Ahmadiyeh et al, PNAS 2010) and QTL (Trynka et al, Nat Genet 2013) studies, and were the pioneers to integrate ENCODE and TCGA data (3). Recently my group is transitioning into translational aspects of cancer genomics, by integrating large-scale public data to understand the mechanism of action and predict response to **targeted and immunotherapies** (4, 21-24). I have an **H-index of 94** and published over 60 papers in Nature, Science, or Cell series journals. I have a total citation over 40K according to Google Scholar statistics, and was rated as a 2019 Highly Cited Author by Web of Science. Since becoming a faculty in 2003, I have successfully **mentored eighteen trainees to start tenure track faculty positions**, including 1 K22 and 3 K99 awardees, 1 Damon Runyon Fellow, 3 Texas CPRIT scholars, and 1 NIH Earl Stadtman Investigator.

1. Jiang P, Freedman ML, Liu JS, **Liu XS** (2015). Inference of transcriptional regulation in cancers. ***Proc Natl Acad Sci U S A*** 112(25):7731-6. PMCID: PMC4485084.

2. Meyer CA*, **Liu XS*** (2014). Identifying and mitigating bias in next-generation sequencing methods for chromatin biology. ***Nat Rev Genet*** 15(11):709-21. PMCID: PMC4473780.
3. Chen C, Zheng R, Tokheim C, Dong X, Fan J, Wan C, Tang Q, Brown M, Liu JS, Meyer C*, Liu XS* (2020). Determinants of transcription factor regulatory range. ***Nat Commun.*** 11:2472. PMCID: PMC7235260
4. Applications of immunogenomics to cancer. **Liu XS*** and Mardis ER* (2017). ***Cell.*** 168(4):600-612.

B. Positions and Honors

Positions and Employment

2002–2003 Independent Research Fellow, Department of Biostatistics, Harvard School of Public Health, Dana-Farber Cancer Institute
2003–2007 Assistant Professor, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health
2008-2012 Associate Professor, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health
2009-2019 Visiting Professor, Department of Bioinformatics, Tongji University, Shanghai, China
2011-present Associate Member, Broad Institute of MIT and Harvard
2011-present Co-director, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
2012-present Professor of Biostatistics and Computational Biology, Department of Data Science, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health
2013-2019 Visiting professor, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China
2015-present Professor of Statistics, Harvard University

Other Experiences

2001 Conference Chair, Biomedical Computation at Stanford (BCATS2001)
2003 Conference Organizer, Workshop Chair, Symposium on Computational Biology, Harvard University, Radcliffe Institute for Advanced Study
2005-present Steering Committee, International Bioinformatics Workshop
2012-2018 Scientific advisory board at the Chinese Academy of Science-Max Plank Society Partner Institute for Computational Biology
2014-present Organizer, Cold Spring Harbor Asia meeting in Systems Biology of Gene Regulation and Genome Editing
2017 Chair, Gordon Research Conference on Cancer Genetics and Epigenetics
2018, 2020 AACR Annual Meeting Program Committee
Editorial Board for: Genomics (2006-2008), BMC Bioinformatics (2010-2014), Biostatistics (2010-2014), Annals of Applied Statistics (2010-2014), Genome Biol (2011-), Quantitative Biology (2012-), Molecular Cancer Research (2014-), Genome Research (2014-), Nucleic Acids Research (2016-2019), Cell systems (2019-), Genomics, Proteomics, and Bioinformatics (2020-)
Reviewer for: Grants: National Institute of Health (GCAT regular member 2011-2017, chair 2015-2017; NCI Integrative Cancer Biology Program 2004; GCAT 2009; GGG 2010; GGG chair 2019)

Honors and Awards

1997 *summa cum laude*, Highest Departmental Honors in Biochemistry, *Sigma Xi*, *Phi Beta Kappa*, Smith College
1997-2000 Lucille P. Markey Biomedical Research Predoctoral Fellowship, Stanford University
2005, 2014 Claudia Adams Barr Award for Innovative Basic Cancer Research, Dana-Farber Cancer Institute
2008-2010 Alfred P. Sloan Research Fellowship
2013-2019 The National Distinguished Expert (type B), Thousand Talent Program, China
2014 Claire W. and Richard P. Morse Research Award
2016 Richard E Weitzman Outstanding Early Career Investigator Award, Endocrinology Society
2017-present Breast Cancer Research Foundation Investigator
2019 Fellow, International Society of Computational Biology
2020 Innovator Award, International Society of Computational Biology
2021 Benjamin Franklin Award for Open Access in the Life Sciences, Bioinformatics.org

C. Contribution to Science

Complete bibliography: https://www.ncbi.nlm.nih.gov/myncbi/xiaole.liu.1/bibliography/public/
Google Scholar profile: https://scholar.google.com/citations?user=8XNfVucAAAAJ&hl=en
Selected from over 200; *Co-corresponding authors.

I. **ChIP-chip / seq data analysis.** We are the pioneers in algorithm development for ChIP-chip (6), ChIP-seq (7) peak calling, downstream motif (5) and integrative (8) analyses. These four algorithms were **cited by over 10K with a user base of over 10K**. Liu Lab also recently published a computational pipeline for the integrative analysis of scRNA-seq and scATAC-seq (MAESTRO, Wang et al, Genome Biol 2020).

5. **Liu XS**, Brutlag DL, Liu JS (2002). An algorithm for finding protein-DNA binding sites with applications to chromatin immunoprecipitation microarray experiments. ***Nat Biotechnol***. 20(8):835-9.
6. Johnson WE, Li W, Meyer CA, Gottardo R, Carroll JS, Brown M, **Liu XS** (2006). MAT: Model-based Analysis of Tiling-arrays for ChIP-chip. ***Proc Natl Acad Sci U S A***. 103(33): 12457-62. PMCID:PMC1567901.
7. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein B, Nusbaum C, Myers RM, Brown M, Li W*, **Liu XS*** (2008). Model-based analysis of ChIP-Seq (MACS). ***Genome Biol***. 9(9):R137. PMCID:PMC2592715.
8. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, Gene Shin HG, Wong SS, Ma J, Lei Y, Pape UJ, Poidinger M, Chen Y, Yeung K, Brown M, Turpaz Y*, **Liu XS*** (2011). Cistrome: an integrative platform for transcriptional regulation studies. ***Genome Biol***. 12(8):R83. PMCID:PMC3245621.

II. **Epigenetics and chromatin.** We are pioneers to use the dynamics of nucleosomes (10) and chromatin accessibility profiles (12; He et al, Genome Res, 2012) to predict transcription factor binding changes during a biological process. We generated the first high throughput nucleosome map in the human genome (9), and are the first to report the functional switch of EZH2 from a polycomb repressor to a transcriptional co-activator (11) in cancers. Through ChIP-chip/seq and MNase-seq, we identified the epigenetic signatures that are associated with embryonic pluripotency and zygotic genome activation (Vastenhouw et al, Nat 2010; Zhang et al, Genome Res 2014).

9. Ozsolak F, Song JS, **Liu XS***, Fisher DE* (2007). Global chromatin structure mapping of human promoters. ***Nat Biotechnol***. 25(2):244-8.
10. He HH, Meyer C, Shin H, Bailey S, Wei G, Wang Q, Zhang Y, Xu K, Ni M, Lupien M, Mieczkowski P, Lieb JD, Zhao K, Brown M*, **Liu XS*** (2010). Nucleosome dynamics defines transcriptional enhancers. ***Nat Genet***. 42(4):343-7. PMCID:PMC2932437.
11. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey M, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, **Liu XS***, Brown M* (2012). EZH2 Oncogenic activity in castration resistant prostate cancer is polycomb-independent. ***Science***. 338(6113):1465-9. PMCID:PMC3625962.
12. He HH, Meyer CA, Hu SS, Chen MW, Zang C, Liu Y, Rao PK, Fei T, Xu H, Long H*, **Liu XS***, Brown M* (2014). Refined DNase-seq protocol and data analysis reveals intrinsic bias in transcription factor footprint identification. ***Nat Methods*** 11(1):73-8. PMCID:PMC4018771.

III. **Nuclear receptor function:** We were among the earliest pioneers to use ChIP-chip and later ChIP-seq to investigate the genome-wide binding, target genes, interacting factors, and function of nuclear receptors. We are the first to conduct genome-wide ChIP-chip study of enhancer-binding transcription factors in mammalian system (13) and discovered FoxA1 as the pioneering factor for estrogen receptor (Carroll et al, Cell 2005; Lupien et al, Cell 2008). Our work advanced the mechanistic understanding of nuclear receptor function in cancers (13, 14, 16), metabolic syndromes (15) and other physiological processes (Tang et al, Cancer Res 2011). Due to these contributions, I received the Endocrinology Society Richard E. Weitzman Award in 2016.

13. Carroll JS, Meyer CA, Song J, Li W, Brodsky AS, Hall G, Geistlinger TR, Eeckhoute J, Wang QB, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, **Liu XS***, Brown M* (2006). Genome wide analysis of estrogen receptor binding sites. ***Nat Genet***. 38(11):1289-97.
14. Wang Q, Li W, Zhang Y, Yuan X, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Chinnaiyan AM, Rubin MA, True L, Giorentino M, Fiore C, Loda M, Kantoff PW, **Liu XS***, Brown M* (2009). Androgen receptor regulates a distinct

transcription program in androgen-independent prostate cancer. ***Cell***. 138(2):245-56. PMCID:PMC2726827

15. Feng D, Liu T, Sun Z, Bugge A, Mullican SE, **Liu XS**, Lazar MA (2011). A circadian rhythm orchestrated by histone deacsetylase 3 controls hepatic lipid metabolism. ***Science***. 331(6022):1315-9. PMCID:PMC3389392
16. Ni M, Chen Y, Bailey ST, Imai Y, **Liu XS***, Brown M* (2011). Targeting androgen receptor in estrogen receptor-negative breast cancer. ***Cancer Cell***. 20(1):119-31. PMCID:PMC3180861

IV. CRISPR screens: CRISPR screen is a powerful technique for systematic genetic analysis to identify key genes for tumorigenesis and progression, biomarkers of drug response, and mechanisms underlying drug resistance. We developed a number of algorithms for experimental biologists to overcome computational challenges and adopt the CRISPR technology. They include how to design a good gRNA library (18), how to quality control and analyze the CRISPR screen data (17; Li et al Genome Biol 2015), and how to prioritize the CRISPR screen hits for functional validation (Jiang et al, Genome Biol 2015). The MAGeCK suite of algorithms has been **downloaded by over 85K** and become the standard method for CRISPR screen analyses. We have also been conducting CRISPR screens to identify functional lncRNAs in cancer (19) and gene modulating T-cell mediated tumor killing (20).

17. Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, Irizarry RA, Liu JS, Brown M, **Liu XS** (2014). MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. ***Genome Biol*** 15(12):554. PMCID:PMC4290824.
18. Xu H, Xiao T, Chen CH., Li W, Meyer CA, Wu Q, Wu D, Cong L, Zhang F, Liu JS, Brown M, **Liu XS** (2015). Sequence determinants of improved CRISPR sgRNA design. ***Genome Res*** 25(8):1147-57. PMCID: PMC4509999.
19. Zhu S, Li W, Liu J, Chen C, Liao Q, Xu P, Han Xu H, Xiao T, Cao Z, Peng J, Yuan P, Brown M, **Liu XS***, Wei W* (2016). CRISPR/Cas9-mediated genomic deletion screening for long non-coding RNAs using paired-gRNAs. ***Nature Biotech***. 34(12):1279-1286. PMCID: PMC5592164.
20. Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma A, Tsoucas D, Qiu X, Lim K, Rao P, Long HW, Yuan GC, Doench J, Brown M, **Liu XS***, Wucherpfennig K* (2018). A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. ***Science*** 359(6377):770-775. PMCID: PMC5953516.

V. Cancer immunology and therapeutics. We developed a number of algorithms integrating large-scale public genomic data to make novel discoveries related to cancer therapies, especially related to targeted and immunotherapies (22, 24). These translational cancer genomics projects include predicting anti-cancer drug response from large-scale cancer cell line drug screens (Zhang et al, PLoS Comp Bio 2015), deconvolve tumor-infiltrating immune cells (Li et al, Genome Bio 2016; Li et al Cancer Res 2017), infer tumor T-cell repertoires (21) and B cell repertoires (23) from TCGA tumor bulk RNA-seq data. We also collaborate with immunologists to study the role of AID in B-cell receptor diversity and genomic instability (Meng et al, Cell 2014).

21. Li B, Li T, Pignon JC, Wang B, Wang J, Shukla SA, Dou R, Chen Q, Hodi FS, Choueiri TK, Wu C, Hacohen N, Signoretti S, Liu JS*, **Liu XS*** (2016). Landscape of tumor-infiltrating T cell repertoire of human cancers. ***Nat Genet.*** 48(7):725-32. PMCID:PMC5298896.
22. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW*, **Liu XS*** (2018). Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. ***Nat Med.*** 24(10):1550-1558. PMCID: PMC6487502
23. Hu X, Zhang J, Wang J, Fu J, Li T, Zheng X, Wang B, Gu S, Jiang P, Fan J, Ying X, Zhang J, Carroll MC, Wucherpfennig KW, Hacohen N, Zhang F, Zhang P, Liu JS*, Li B*, **Liu XS*** (2019). Landscape of B cell immunity and related immune evasion in human cancers. ***Nat Genet.*** 51(3):560-567. PMCID: PMC6773274
24. Cader FZ, Hu F, Goh W, Wienand K, Ouyang J, Mandato E, Redd R, Lawton L, Chen PH, Weirather J, Schackman RC, Li B, Ma W, Armand P, Rodig SJ, Neuberg D, **Liu XS***, Shipp M*. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. ***Nat Med***. 2020 Epub ahead of print.

D. Research Support

Ongoing Research Support

NIH/NCI R01 CA234018 (PI: Liu XS / Wucherpfennig KW) 05/15/19 – 04/30/23
Regulators of Cancer Immunotherapy Response
We propose to integrate computational modeling and functional genomics to refine immunotherapy response biomarkers, identify novel regulators of immunotherapy response, and elucidate their underlying mechanisms.
Role: Contact PI

NIH/NCI U01 CA226196 (PI: Liu XS) 04/06/18 – 03/31/21
Bioinformatics technology to characterize tumor infiltrating immune repertoires
We propose to develop the computational algorithms and resources to investigate T cell and B cell related immunity in tumors by utilizing tumor RNA-seq data.
Role: PI

NIH/NCI, U24 CA237617 (Liu XS / Meyer CA) 03/15/19 – 02/29/23
Developing Informatics Technologies to Model Cancer Gene Regulation
We propose to develop bioinformatics tools to integrate and visualize ChIP-seq and chromatin accessibility profiles with transcriptome data to investigate cancer gene regulation.
Role: Contact PI

NIH/NCI, U24 CA224316 (PI: Liu XS / Cerami E) 09/30/17 – 06/30/22
Cancer Immunologic Data Commons (CIDC)
We propose to build the infrastructure for a centralized biomarker data repository and state-of-the-art informatics tools for NCI-sponsored immunoncology clinical trials.
Role: Contact PI

Foundation for the NIH, Inc. (PI: Liu XS / Cerami E) 09/30/17-06/30/22
Partnership for Accelerating Cancer Therapies (PACT)
This is a supplement for U24CA224316 from Foundation of the NIH where pharmaceutical companies collaborate with the CIMAC-CIDC network to profile and analyze their immunotherapy trial data.
Role: Contact PI

Department of Defense (CDMRP) W81XWH1910551 (PI: Choueiri T / Liu XS) 09/15/19-09/14/21
Host Immune Signatures as Therapy Response Biomarkers in Metastatic Renal Cell Carcinoma
We propose to evaluate whether clonal expansion of tumor-infiltrating T cell receptors and B cell receptors in the blood can be a biomarker for kidney cancer response to immunotherapy.
Role: Co-PI.

Breast Cancer Research Foundation BCRF-19-100 (PI: Liu XS) 10/1/17 – 9/30/20
Improve the treatment of triple negative breast cancer
We propose to integrative genomic technologies and computational modeling to improve the understanding and treatment of triple negative breast cancers.
Role: PI

NIH/NHGRI U24 HG009446 (PI: Weng Z) 09/01/12 – 01/31/21
EDAC: ENCODE Data Analysis Center
We propose to support and enhance the integrative analyses of data from the ENCODE project.
Role: Co-Investigator

NSFC 81872290, China (PI: Liu XS) 01/01/19 – 12/31/22
Molecular characterization of minimally invasive adenocarcinoma (MIA) of the lung
We propose to use RNA-seq of MIA and adjacent normal lung tissues to study the tumor immune microenvironment of early lung cancers.
Role: PI

2017YFC0908500, China (PI: Sun S.) 07/2017 – 12/2021
National key research and development plan: Building a translational clinical system to evaluate personalized medicines for malignant head and neck cancers.
Role: Collaborator

CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

Nominations for Product Development Peer Review Panels

The following individuals have been recommended by Jack Geltosky, PhD (Chair, Product Development Review Council) to serve as peer reviewers for the Product Development Research Program:

Nominee	Title	Organization/Institution
Rachel Humphrey, MD	Chief Medical Officer	Black Diamond Therapeutics
Arnab Ghosh, MD, PhD	Medical Oncologist	Memorial Sloan Kettering Cancer Center
Michael Cheng, MD	Attending Physician	Dana-Farber Cancer Institute
Mickey C-T. Hu, MS, PhD	Director in discovery oncology/Principal Investigator	Panorama Institute of Molecular Medicine
Neil Vasan, MD, PhD	Assistant Attending Physician	Breast Medicine Service at Memorial Sloan Kettering Cancer Center
Walter Stadler, MD, FACP	Dean for Clinical Research	University of Chicago

Rachel Humphrey, MD

Rachel Humphrey is a medical oncologist with more than 22 years as a pharmaceutical executive. Among her many roles, she has served as both Board Director and as Chief Medical Officer for CytomX, a biotech company based in South San Francisco where she supervised the clinical development of Probody™ Therapeutics for the development of cancer. Prior to this, she held various senior level roles in cancer drug development including AstraZeneca (SVP, Head of the Immuno-oncology department), and Bristol Myers Squibb (VP, Clinical Development). Dr. Humphrey's career is notable for, among other things, overall supervision of the (early and late-stage) clinical development of ipilimumab (Yervoy) at BMS and sorafenib (Nexavar) at Bayer. She is also the lead singer and one of the co-founders of the band, The Checkpoints, a blues band made up of luminaries in immuno-oncology, including the Nobel Laureate, Jim Allison, and is featured in the movie "Jim Allison: Breakthrough", which was released in the fall of 2019.

Curriculum Vitae

Rachel Wallach Humphrey, MD

Current address Princeton, NJ 08540,

Educated Harvard College, Cambridge, MA, 1979-1984
CWRU Medical School, Cleveland, Ohio 1985-1989

Postgraduate Johns Hopkins Hospital (Internal Medicine) 1989-1992
National Cancer Institutes (Medical Oncology) 1992-1997

Summary of Experience

- Senior pharmaceutical executive with extensive experience in product development at the level of biotech Board Director of a small private company, biotech Chief Medical Officer and large pharma Therapeutic Area Head.

- Extensive experience interacting externally with investors, analysts, scientific leaders and large and small pharma collaborators. This includes key participation in the CytomX IPO and follow-on financing as Chief Medical Officer.

- In the role of Director in the CytomX Board: supervision of company activities during a robust period of growth, Mezzanine financing and pre-IPO activities. The transition to the role of CMO within that first year, and at the time the S1 was filed, was designed to support the IPO roadshow and provide full-time attention in order to help ensure the success of the pipeline.

- Proven success in managing Product Development strategy and tactics for over 22 years: small molecules, cytotoxics and biologics from pre-IND to compound commercialization in immuno-oncology and oncology, including senior-most oversight and successful development of 2 new molecular entities in oncology: YERVOY (*ipilimumab)* and NEXAVAR (*sorafenib)*.

- In the role of Chief Medical Officer at CytomX, supervised the evolution of the company from “research only” to “clinical stage” with the creation of a high performing, full-service clinical development organization with over 40 employees, and concurrent evolution of the organizational processes, structure and culture required for success.

- As Senior Vice President and Head of Immuno-Oncology at AstraZeneca, created the late-stage Immuno-Oncology department and supervised the clinical development of INFINZI (*durvalumab*), directing the design and initiation of multiple registrational studies in the first year, including the successful PACIFIC study, which led to global approval and helped AstraZeneca achieve commercial success in NSCLC.

- Featured in the film Breakthrough, a documentary which details the life and work of Jim Alison and his key partners in the development of YERVOY. The film opened country-wide in select theaters in September, 2019.

Positions held

2019 – Present	Pharmaceutical Consultant
2020	Head of R&D, TIO Bioventures Discovery Engine
2015 - 2019	Chief Medical Officer, CytomX
2015	Board of Directors, CytomX
2015	Vice President, Head of IO, Lilly and Company
2013 - 2014	Senior Vice President, Head of IO, Astrazeneca
2012 – 2013	Executive Vice President, Chief Medical Officer, Mirati Therapeutics (formerly MethylGene Inc).

2005 – 2012	Vice President, Product Development, BMS
2003 – 2005	Executive Director, Product Development, BMS
2002 - 2003	Director, Global Clinical Development, Bayer Pharmaceuticals
1998 - 2002	Deputy Director, Global Clinical Development, Bayer Pharmaceuticals
1997 - 1998	Associate Director, Global Clinical Development, Bayer Pharmaceuticals
1995 - 1997	Staff Physician-Scientist, National Cancer Institute, HIV and AIDS Malignancy Branch
1992 - 1995	Clinical Oncology Fellow, National Cancer Institute
1989 - 1992	Internal Medicine Resident, The Johns Hopkins Hospital

Pharmaceutical Industry Experience Details

CytomX Therapeutics (San Francisco, California)
Chief Medical Officer (Aug 2015 – Aug 2019)

- Member of the CEO's Executive Team
- Member of the IPO roadshow team (Sept 2015)
- Built the global clinical development organization with all relevant development functions, including marketing
- Oversaw of all aspects of global clinical development of the CytomX portfolio, including the clinical and pre-clinical compounds
- Supervised the IND submissions, designs, initiations and conduct of all phase I, Ib and II studies for the first 3 Probody therapeutics to enter the clinic, as well as the overall global development strategy: CX-072 (PD-L1 probody), CX-2009 (CD166 probody drug conjugate), CX-2029 (CD71 probody drug conjugate), CX-188 (PD-1 probody), and other pipeline programs

CytomX Board of Directors (Mar 2015 – Aug 2015)

AstraZeneca Pharmaceuticals (Gaithersburg, MD)*:*
Senior Vice President, Head Immuno-Oncology (Nov 2013 - Nov 2014)

- Member of the CMO's Senior Executive Team and Oncology Operating Committee

- Accountable for overall late-stage strategy for all Immuno-Oncology agents in development: IMFINZI *(durvalumab), tremelimumab* and the combination of IMFINZI and *tremelimumab*

- Created a full-sized late-stage development team and initiated a large full-scale development program for both major assets and the combination all within the first year.

- Supervised and/or directly participated in routine interactions with global Regulatory Authorities, Investors and Analysts

Mirati Therapeutics (formerly MethylGene Inc; Montreal Canada)
Executive Vice President, Chief Medical Officer (Jan 2012 – Sept 2013)

- Supervised all drug development functions, rebuilding the team after a meaningful contraction.

- Oncology and Infectious disease portfolio; *glesatinib* (MEK and AXL inhibitor; anti-cancer; phase I/II), *sitravatinib* (Tyrosine kinase inhibitor; anti-cancer; preclinical), *mocetinostat* (HDAC inhibitor, anti-cancer; phase II) and MGCD290 (hos inhibitor, anti-fungal; phase II)

Bristol-Myers Squibb (Lawrenceville, NJ)
VP, Clinical Development and Head of Ipilimumab Program (May 2005 – Jan 2012)

- Supervised all aspects of the clinical development of the CTLA-4 antagonist monoclonal antibody (YERVOY, *ipilimumab)* in melanoma, with over 100 dotted-line reports, BLA submissions, interfacing with global regulatory authorities and simultaneous NEJM publications with plenary presentations at ASCO (2010 and 2011)

- Supervised the Medarex Alliance in the strategic and tactical management of Phase I – III

- Developed the "immune-related response criteria" for the measurement of efficacy in patients receiving immunotherapies such as YERVOY (*ipilimumab*).

- Supervised the in-licensing of *vinflunine* and personally supervised all aspects of clinical development through the initiation and/or conduct of phase II and III.

- Supervised the in-licensing of CABOMETYX (*cabozantinib)* and clinical development in the Alliance between BMS and Exelixis, including introduction of the highly successful randomized discontinuation design into the clinical development program.

Bayer Pharmaceuticals (West Haven, Connecticut)
Associated Director (1997 – 1998) Deputy Director (1998 – 1999) Director (1999 – May 2003)

- Supervised the global and US Phase I, II and III Clinical Research in oncology for multiple clinical assets

- Supervised all aspects of phase I - III clinical development for NEXAVAR (*sorafenib*) in renal cell cancer (in collaboration with Onyx Pharmaceuticals) and phase I in melanoma for the IL-2 selective agonist (to "no go") including IND submissions, post-phase 2 Regulatory interactions, design/ conduct of pivotal program

- Introduced the “randomized discontinuation study” design into clinical development of NEXAVAR (*sorafenib)*

Publications: over 40 peer-reviewed articles or abstracts (available on request), including a seminal paper on Ipilimumab in the New England Journal of Medicine, and senior authorship on the first introduction of the new Immune-Related Response Criteria in Clinical Cancer Research, and a summary of ongoing research activities during the COVID-19 pandemic in The Cancer Letter.

Outside of work: Founder of the Checkpoints Blues Bands and lead singer since 2007, performing at the Chicago House of Blues and/or Buddy Guys during ASCO week. We also perform at a variety of venues during other annual congresses, and periodically by invitation to non-congress events in the US and Europe. The band is composed of Immuno-oncology experts (scientists and doctors), all of whom collaborated in some form in the development of ipilimumab, including the Nobel prize recipient, Jim Alison (on blues harmonica).



Arnab Ghosh, MD, PhD

I am a medical oncologist in the adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center. I attended medical school in Mysore, India and obtained a PhD in Molecular Medicine from Medical School in Hannover, Germany. I study how responses to immunotherapies in cancer are affected by interactions between the immune cells, the tumors and their microenvironment. In the past, my research has focused on adoptively transferred cell therapies including chimeric antigen receptor T cells. More recently, I have focused on using small molecule therapies to reprogram the tumor microenvironment to augment the effects of immune checkpoint blockade and T cell based immunotherapies.

Date Of Preparation: 7/2020

Arnab Ghosh MD, PhD

Assistant Attending Physician
Adult BMT service/ Department of Medicine
Memorial Sloan Kettering Cancer Center, NY
1275 York Av,
New York, New York 10065
E-Mail: GhoshA@MSKCC.org

Education

M.B.B.S. (U.S. M.D. equivalent) **05/2003**
Mysore Medical College,
Rajiv Gandhi University of Health Sciences, India

Ph.D. **06/2007**
Immunology
Medizinische Hochschule Hannover, Germany

Residency **07/2013- 06/2015**
Internal Medicine Program-Research Track
Icahn School of Medicine at Mount Sinai, NY

Clinical Fellow **07/2015- 06/2019**
Hematology/Medical Oncology
Memorial Sloan Kettering Cancer Center, NY

Professional Experience

Assistant Attending Physician **07/2019- Current**
Adult BMT/ Div of Hematologic Malignancies
Department of Medicine
Memorial Sloan Kettering Cancer Center, NY

Postdoctoral Associate **05/2008- 06/2013**
Immunology, Memorial Sloan-Kettering Cancer Center, NY
Supervisor: Dr. Marcel R.M. van den Brink, M.D.,Ph.D, Head, Div. of Hematologic Oncology.

Doctoral Student **10/2003- 05/2008**
Bone Marrow Transplantation, Medizinische Hochschule Hannover, Germany
Supervisor: Dr. Martin Sauer, M.D.,Ph.D., Dept. of Pediatric Oncology.
Thesis: *Adoptive transfer of immunologically engineered T cells as immunotherapeutic agents for hematological malignancies*

Senior Research Fellow **08/2002-09/2003**
Immunology, Advanced Center for Training, Research and Education of Cancer
Tata Memorial Center, Mumbai, India
Supervisor: Dr. Shubhada Chiplunkar, Ph.D., Immunology

Grants/ Fellowship

Merck Immunotherapy Clinical Fellowship, Society for Immunotherapy of Cancer **2017**
Fellowship, Lymphoma Research Foundation **2011**
Dr. Judah Folkman Award, American Association of Cancer Research **2010**
Dr. Mildred-Scheel Fellowship, German Cancer Aid, Germany **2008**
Senior Research Fellowship, Council for Scientific and Industrial Research, India **2003**

Awards

SITC MeTIOR, Society for Immunotherapy of Cancer **2018**
Young Investigator Symposium, ECOG-ACRIN **2015**
Trainee Abstract Award, American Association of Immunologists **2013**
Abstract Achievement Award, American Society of Hematology (ASH) **2012**
Abstract Achievement Award, American Society of Hematology (ASH) **2011**
Travel Award, American Society of Hematology (ASH) **2010**
Best Outgoing Graduate, Mysore Medical College, India **2002**

Academic Profile

Publications

Original Research

Maluski M, **Ghosh A,** Herbst J, Scholl V, Baumann R, Huehn J, Geffers R, Meyer J, Maul H, Eiz-Vesper B, Krueger A, Schambach A, van den Brink MR, Sauer MG. Chimeric antigen receptor-induced BCL11B suppression propagates NK-like cell development. J Clin Invest. 2019 Dec 2;129(12):5108-5122

Ghosh A, Smith M, James S, Davila ML, et al. Donor CD19 CAR T cells exert potent graft-versus lymphoma activity with diminished graft-versus-host activity. *Nat Med.* 2017 Feb;23(2):242-249

De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, **Ghosh A**, Pink M, Tchaicha J, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. *Nature.* 2016 Nov 17;539(7629):443-447

Hübner J, Hoseini SS, Suerth JD, Hoffmann D, Maluski M, Herbst J, Maul H, **Ghosh A** et al. Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an optimized alpharetroviral vector platform. *Mol Ther*. 2016 Aug;24(7):1216-26

Ghosh A, Dogan Y, Moroz M, Holland AM et al. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. *J Clin Invest.* 2013 Jun 3;123(6):2654-62

Ghosh A, Holland AM, Dogan Y, Yim N et al. PLZF Confers Effector Functions to Donor T Cells That Preserve Graft-versus-Tumor Effects while Attenuating GVHD. *Cancer Res.* 2013 Aug 1;73(15):4687-4696.

Tsai JJ, Dudakov JA, Takahashi K, Shieh JH, Velardi E, Holland AM, Singer NV, West ML, Smith OM, Young LF, Shono Y, **Ghosh A** et al Nrf2 regulates haematopoietic stem cell function. *Nat Cell Biol.* 2013 Mar;15(3):309-16

Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, **Ghosh A** et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. *Immunity*. 2012 Aug 24;37(2):339-50

Dudakov JA, Hanash AM, Jenq RR, Young LF, **Ghosh A** et al. Interleukin-22 Drives Endogenous Thymic Regeneration in Mice. *Science.* 2012 Apr 6;336(6077):91-5

Jenq RR, Ubeda C, Taur Y, Khanin RM, Dudakov JA, Liu C, West ML, Singer NV, Equinda MJ, Gobourne A, Lipuma L, Young LF, Smith OM, **Ghosh A**, Holland AM et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. *J Exp Med.* 2012 May 7;209(5):903-11

del Rio ML, Kurtz J, Perez-Martinez C, **Ghosh A,** Rodriguez-Barbosa J. BTLA Targeting Protects against the Acute Phase of GvHR by Inhibiting Donor anti-Host Cytotoxicity *Transplantation.* 2011 Nov 27;92(10):1085-93

Penack O, Henke E, Suh D, King CG, Smith OM, Na IK, Holland AM, **Ghosh A**, et al. Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. *J Natl Cancer Inst.* 2010 Jun 16;102(12):894-908

Na IK, Markley JC, Tsai JJ, Yim NL, Beattie BJ, Klose AD, Holland AM, **Ghosh A**, et al. Concurrent visualization of trafficking, expansion and activation of T lymphocytes and T-cell precursors in vivo. *Blood*. 2010 Sep 16;116(11):e18-25

Na IK, Lu SX, Yim NL, Goldberg GL, Tsai J, Rao U, Smith OM, King CG, Suh D, Hirschhorn-Cymerman D, Palomba L, Penack O, Holland AM, Jenq RR, **Ghosh A**, et al. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. *J Clin Invest.* 2010 Jan;120(1):343-56

Penack O, Smith OM, Cunningham-Bussel A, Liu X, Rao U, Yim N, Na IK, Holland AM, **Ghosh A,** et al. NOD2 regulates hematopoietic cell function during graft-versus-host disease. *J Exp Med.* 2009 Sep 28;206(10):2101-10

Ghosh A, Koestner W, Hapke M, Schlaphoff V, Langer F, Baumann R, Koenecke C, Cornberg M, Welte K, Blazar B, Sauer MG: Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft versus leukemia effects across MHC barriers in full chimeras. *Blood.* 2009 Apr 30;113(18):4440-8

Ghosh A, Wolenski M, Klein C, Welte K, Blazar BR, Sauer MG. Cytotoxic T cells reactive to an immunodominant leukemia-associated antigen can be specifically primed and expanded by combining a specific priming step with nonspecific large-scale expansion. *J Immunother*. 2008 Feb-Mar;31(2):121-31

Rathinam C, Sauer M, **Ghosh A,** et al. Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential. *Leukemia*. 2006 May;20(5):870-6

Sauer M, Bettoni C, Lauten M, **Ghosh A,** et al. Complete substitution of cyclophosphamide by fludarabine and ATG in a busulfan-based preparative regimen for children and adolescents with beta-thalassemia. *Bone Marrow Transplant*. 2005 Sep;36(5):383-7

Reviews:

Ghosh A, Barba P, Perales MA. Checkpoint inhibitors in AML: are we there yet?. Br J Haematol. 2020 Jan;188(1):159-167.

Ghosh A, Politikos I, Perales MA. Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors. *Curr Opin Oncol.* 2017 Nov;29(6):474-483.

Ghosh A, Mailankody S, Giralt SA, Landgren CO, Smith EL, Brentjens RJ. CAR T cell therapy for multiple myeloma: where are we now and where are we headed? *Leuk Lymphoma*. 2018 Sep;59(9):2056-2067

Ghosh A, Holland AM, van den Brink MR. Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers**.** *Immunol Rev.* 2014 Jan;257(1):226-36

Holland AM, Zakrzewski JL, Goldberg GL, **Ghosh A,** van den Brink MR: Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation in mouse and man. *Semin Immunopathol*. 2008 Dec;30(4):479-87

Book Chapters

Ghosh A, Cai S Ch 28. Benign hematology: Hematopoiesis *Pocket Oncology (Pocket Notebook) Second Edition* Ed. Drilon, Postow, Vasan, Carlo Wolters Kluwer Philadelphia. 2018. Print

Ghosh A, Mantha S Ch 28. Benign hematology: Hypercoagulable states *Pocket Oncology (Pocket Notebook) Second Edition* Ed. Drilon, Postow, Vasan, Carlo Wolters Kluwer Philadelphia. 2018. Print

Selected Presentations

Mailankody S, **Ghosh A,** M Staehr,Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial ***(ASH Annual Meeting 2018)***

Ghosh A, Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus CyTOF ***(ASH Annual Meeting 2015)***

Ghosh A, Davila M et al Donor CD19-targeted T cells exert potent graft versus lymphoma activity without GVHD ***(AAI Annual Meeting 2013)***

***Oral presentation, Trainee award**

Ghosh A, Davila M et al CD19-targeted donor T cells exert potent graft-versus-lymphoma activity and attenuated GVHD ***(ASH Annual Meeting 2012)***

***Oral presentation, Abstract achievement award**

Ghosh A, Dogan Y et al Genetic engineering of donor T cells for BMT immunotherapy: Over-expression of TRAIL on donor T cells enhances GVT and suppresses GVHD via elimination of alloreactive T cells and host APC. ***(ASH Annual Meeting 2011)***

***Oral presentation, Abstract achievement award, Highlighted at the ASH press program**

Ghosh A, Holland AM et al Genetic engineering of donor T cells for BMT immunotherapy: Expression of TRAIL and PLZF selectively enhances GVT and abrogates GVHD ***(AACR Annual Meeting 2011)***

***Oral presentation.**

Ghosh A, Holland AM et al Genetic engineering of donor T cells for BMT immunotherapy: Expression of TRAIL and PLZF selectively enhances GVT and abrogates GVHD ***(ASH Annual Meeting 2010)***

***Oral presentation and Travel award**

Ghosh A., Hapke et al**.** Allogeneicity of antigen-presenting cells plays a crucial role for graft-versus-leukaemia effects after adoptive transfer of leukaemia-reactive cytotoxic T-cells ***Bone Marrow Transplantation (EBMT 2007)***

***Oral presentation at the Presidential symposium.**

Other Activities

- Associate Editor: BMC Cancer 2017
- Project leader: Team Checkpoints, SITC MeTIOR program

- Manuscript Review: Blood, Molecular Therapy, New England Journal of Medicine

Certifications

Educational Commission for Foreign Medical Graduates (ECFMG) certification 06/07/2012
American Board of Internal Medicine: Internal Medicine Board certification 2016
American Board of Internal Medicine: Medical Oncology Board certification 2018

Languages Spoken

Native fluency: English, Bengali, Hindi
Working proficiency: German, Kannada

Hobbies

Traveling, Photography.

Biography

Michael L. Cheng, MD is an attending physician at the Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School. Dr. Cheng received his M.D. from the UCLA David Geffen School of Medicine, where he graduated with Alpha Omega Alpha honors. He completed his residency in Internal Medicine at the University of California, San Francisco and his fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center. Dr. Cheng leads clinical and translational research centered on precision oncology for non-small cell lung cancer (NSCLC), with a focus on leveraging plasma and tumor next-generation sequencing (NGS) data to elucidate tumor biology and inform the development of next-generation targeted therapies and immunotherapies. Dr. Cheng strives to provide individualized, compassionate care and continues to be inspired by the tangible and substantial patient benefit driven by research advances.

Harvard Medical School
Curriculum Vitae

Date Prepared:	07/24/20
Name:	Michael L. Cheng
Office Address:	450 Brookline Ave, Dana 1240K, Boston, MA 02215
Home Address:	
Work Phone:	617-632-3468
Work Email:	michael_cheng@dfci.harvard.edu
Work FAX:	617-632-5786
Place of Birth:	California, USA

Education

2008	BA	Molecular Cell Biology	University of California, Berkeley, CA
2012	MD	Medicine	University of California, Los Angeles, CA

Postdoctoral Training

06/12-06/15	Resident	Internal Medicine (Categorical)	University of California, San Francisco, CA
07/15-06/18	Fellow	Medical Oncology	Memorial Sloan Kettering Cancer Center, New York, NY

Faculty Academic Appointments

07/18-present	Instructor	Medicine	Harvard Medical School, Boston, MA

Appointments at Hospitals/Affiliated Institutions

06/12-06/15	Resident	Internal Medicine	University of California, San Francisco
07/15-06/18	Fellow	Medical Oncology	Memorial Sloan Kettering Cancer Center
07/18-present	Physician	Medical Oncology	Brigham and Women's Hospital
07/18-present	Physician	Medical Oncology	Dana-Farber Cancer Institute

Committee Service

Local

2009-2010	Admissions Committee 2009-2010	University of California, Los Angeles David Geffen School of Medicine

Professional Societies

2016-present	American Society of Clinical Oncology (ASCO)
2016-present	American Association for Cancer Research (AACR)
2017-present	International Association for the Study of Lung Cancer (IASLC)

Grant Review Activities

2018-present	Young Investigator and Challenge Award Peer Reviewer	Prostate Cancer Foundation

Editorial Activities

***Ad hoc* Reviewer**

Lung Cancer (Elsevier)

JCO Precision Oncology

British Journal of Cancer

Clinical Cancer Research

Honors and Prizes

2004	Regents' and Chancellor's Scholar	University of California, Berkeley	
2007	Alumni Association Leadership Scholar	University of California, Berkeley	
2008	High Distinction in General Scholarship	University of California, Berkeley	
2008	Phi Beta Kappa	University of California, Berkeley	
2009	Department of Medicine Chiefs' Research Fellowship	University of California, Los Angeles	
2011	Letters of Distinction (six)	University of California, Los Angeles	Awarded for "exemplary performance" during core clerkships
2011	Global Health Program Scholarship	University of California, Los Angeles	
2012	Alpha Omega Alpha	University of California, Los Angeles	
2014	Clinical and Translational Science Institute (CTSI) Resident Research Travel Grant	University of California, Los Angeles	
2017	ASCO Conquer Cancer Foundation Merit Award (2017 Annual Meeting)	American Society of Clinical Oncology	

2017	NIH Clinical Loan Repayment Program Award (National Cancer Institute)	National Institutes of Health

Report of Funded Projects

Current

2017-2020 Mediators of intrinsic sensitivity and acquired resistance to PARP inhibition for the treatment of BRCA-mutant castrate resistant prostate cancer
Prostate Cancer Foundation Young Investigator Award
PI ($225,000 - total direct costs)
This project seeks to correlate BRCA genotypes and genomic measures of HRD with response rate to PARP inhibitors and platinum chemotherapies, and to identify molecular mechanisms of acquired resistance to these therapies.

2019-2023 Pilot study of serial plasma genotyping to guide the adaptive treatment of advanced NSCLC receiving first-line pembrolizumab
ASCO Career Development Award (2020-2023)
PI ($200,000 – total costs)
Dunkin Translational Breakthrough Grant
PI ($150,000 – total costs)
DF/HCC Lung Cancer Program Developmental Research Project Award
PI ($60,000 – total costs)
DFCI Cancer Care Collaborative Research Award
PI ($103,000 – direct costs)
This project seeks to conduct a prospective pilot trial where early plasma response guides adaptive treatment of first-line advanced NSCLC receiving pembrolizumab and study the application of plasma response to clinical care in NSCLC.

2020-2021 Characterization of Siglec ligands in advanced NSCLC treated with PD-(L)1 checkpoint blockade
Palleon Pharmaceuticals Collaboration Research Agreement
PI ($84,164 – total costs)
This project seeks to characterize the expression of Siglec ligands in NSCLC tumor tissue, evaluate serum glycoproteomic signatures, and correlate these findings to clinical outcomes.

Report of Local Teaching and Training

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs):

2018-2019	Fellows' Conference – NSCLC Staging 1st year and other Medical Oncology fellows	Dana-Farber Cancer Institute, Boston, MA One-hr lectures
2019	Fellows' Conference – NTRK Fusions 1st year and other Medical Oncology fellows	Dana-Farber Cancer Institute, Boston, MA One-hr lecture

Clinical Supervisory and Training Responsibilities:

2018-present	Attending Physician (Inpatient Oncology) Resident Physicians and Physician Assistants	DFCI/BWH Boston, MA

Formal Teaching of Peers (e.g., CME and other continuing education courses):

2019	Advancements in First-Line Therapeutics for NSCLC Navigation of Current Treatment Options for Stage IV Non-Squamous NSCLC Potomac Center for Medical Education (supported by Lilly and Merck)	3 Rahway, NJ; Philadelphia, PA; Rockville, MD
2019	Improving Outcomes for Patients with NSCLC in China: New Approaches and Clinical Updates WebMD (supported by AstraZeneca)	1 Shanghai, China

Report of Regional, National and International Invited Teaching and Presentations:

International

2019	IASLC Targeted Therapies Meeting – CSF-1R	Santa Monica, CA
2020	IASLC Targeted Therapies Meeting – ASN 007	Santa Monica, CA

Report of Clinical Activities and Innovations

Current Licensure and Certification

2015	Certification, American Board of Internal Medicine (Internal Medicine)
2017	Certification, American Board of Internal Medicine (Medical Oncology)
2018	Massachusetts Medical License

Practice Activities

2018-present	Ambulatory Care	Medical Oncology, Dana-Farber Cancer Institute	Four half-day sessions per week
2018-present	Inpatient Care	Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital	Approximately two weeks per year

Report of Scholarship

Research investigations

1. **Cheng ML**, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, Wabinga HR, Hiatt RA, Parkin DM, Van Loon K. The incidence of oesophageal cancer in Eastern Africa: Identification of a new geographic hot spot? Cancer Epidemiol 2015; 39: 143-9. PubMed PMID: 25662402; PubMed Central PMCID: PMC4470609
2. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, **Cheng ML**, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB,

Taylor BS, Baselga J. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell 2018 Sep 10;34(3):427-438.e6. PubMed PMID: 30205045

3. Abida W, **Cheng ML**, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Carbone E, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter VE, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol 2019 Apr 1;5(4):471-478. PubMed PMID: 30589920
4. Jonsson P, Bandlamudi C, **Cheng ML**, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS. Tumour lineage shapes BRCA-mediated phenotypes. Nature 2019 Jul;571(7766):576-579. PubMed PMID: 31292550.
5. Postow MA, Chasalow SD, Kuk D, Panageas KS, **Cheng ML**, Yuan J, Wolchok JD. Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma Res 2019 Aug 14. PubMed PMID: 31425479
6. Sands JM, Nguyen T, Shivdasani P, Sacher AG, **Cheng ML**, Alden RS, Jänne PA, Kuo FC, Oxnard GR, Sholl LM. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer. 2019 Dec 16. PubMed PMID: 31855703.
7. Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM*, **Cheng ML***. Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer. Clin Cancer Res 2020 Apr 24. pii: clincanres.3529.2019. doi: 10.1158/1078-0432.CCR-19-3529. [Epub ahead of print]

Other peer-reviewed publications

1. **Cheng ML**, Leibowitz M, Ha E. Coccidioidal endophthalmitis in immunocompetent person, California, USA. Emerg Infect Dis 2012; 18: 1015–6. Pubmed PMID: 22608196; PubMed Central PMCID: PMC3358163.
2. Ryan CJ, **Cheng ML**. Abiraterone acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2013; 14: 91–6. PubMed PMID: 23199349
3. **Cheng ML**, Fong L. Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol 2014; 3: 329. PubMed PMID: 24432249; PubMed Central PMCID: PMC3882875
4. **Cheng ML**, Fong L. Beyond Sipuleucel-T: Immune Approaches to Treating Prostate Cancer. Curr Treat Options Oncol 2014; 15: 115-26. PubMed PMID: 24402184; PubMed Central PMCID: PMC4523381
5. **Cheng ML**, Solit DB. Opportunities and challenges in genomic sequencing for precision cancer care. Ann Intern Med 2018; 168: 221-2. PubMed PMID: 29310131
6. **Cheng ML**, Iyer G. Novel Biomarkers in Bladder Cancer. Urol Oncol. 2018; 36: 115-9. PubMed PMID: 29472156
7. **Cheng ML**, Berger MF, Hyman DM, Solit DB. Clinical tumour sequencing for precision oncology: time for a universal strategy. Nat Rev Cancer. 2018 Sep;18(9):527-528. PubMed PMID: 30030494.
8. **Cheng ML**, Oxnard GR. Does TMB impact the effectiveness of TKIs in EGFR-mutant NSCLC? Clin Cancer Res. 2019 Feb 1;25(3):899-900. PubMed PMID: 30190372

Non-peer reviewed scientific or medical publications/materials in print or other media

- Books/Textbooks for the medical or scientific community

1. **Cheng ML**, Scher HI. Localized Prostate Cancer. In: Pocket Oncology, 2nd edition, Carlo MI and Vasan N, Eds. 2019.

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

1. Audenet F, Donoghue M, Pietzak EJ, Isharwal S, **Cheng ML**, Iyer G, Funt SA, Bajorin DF, Al-Ahmadie HA, Reuter VE, Eng J, Reichel JB, Arcila ME, Tsui DW, Shady M, Berger MF, Bosl GJ, Sheinfeld J, Solit DB, Feldman DR. Genomic comparison of matched primary and metastatic germ cell tumors (GCT). J Clin Oncol 35, 2017 (suppl; abstr 4556). Poster Session (presented as Alternate Presenter), June 2017. ASCO Annual Meeting; Chicago, IL.
2. **Cheng ML**, Shady M, Cipolla CK, Funt SA, Arcila ME, Al-Ahmadie HA, Rosenberg JE, Bajorin DF, Berger MF, Tsui DW, Solit DB, Iyer G. Comparison of somatic mutation profiles from cell free DNA (cfDNA) versus tissue in metastatic urothelial carcinoma (mUC). J Clin Oncol 35, 2017 (suppl; abstr 4533). Poster Session, June 2017. ASCO Annual Meeting; Chicago, IL.
3. **Cheng ML**, Abida W, Rathkopf D, Arcila ME, Barron D, Autio KA, Zehir A, Danila DC, Morris MJ, Gopalan A, Reuter VE, Kantoff PW, Slovin SF, Robson ME, Zhang L, Mandelker D, Tsui DW, Taylor BS, Solit DB, Scher HI. Next-generation sequencing (NGS) of tissue and cell free DNA (cfDNA) to identify somatic and germline alterations in advanced prostate cancer. J Clin Oncol 35, 2017 (suppl; abstr 5010). Poster Discussion Session, June 2017. ASCO Annual Meeting; Chicago, IL.
4. Yang JL, Marass F, Ulz P, Shady M, **Cheng ML**, Kothari P, Somnay S, Shukla N, Modak S, Slotkin E, Kathkopft D, Gopaumar I, Scher HI, Ravazi P, Feldman D, Li B, Chapman P, Rosenberg J, Bajorin D, Berger MF, Seshan VE, Socci ND, Solit DB, Heitzer E, Tsui DWY. Shallow Whole Genome Sequencing of Cell-free DNA to Guide Analysis Strategy in Adult and Pediatric Solid Tumors. Poster presented at: Recent Advances in Circulating DNA & RNA. 10th Circulating Nucleic Acids in Plasma and Serum International Symposium; 2017 Sept 20-22; Montpellier, France.
5. **Cheng ML**, Yang JL, Shady M, Ulz P, Heitzer E, Socci N, Seshan V, Offin M, Stephens D, Makhnin A, Tandon N, Datta S, Gedvilaite E, Arcila ME, Ladanyi M, Chaft JE, Rudin CM, Berger MF, Solit DB, Li BT, Tsui DW. Non-Invasive Tumor Profiling in NSCLC by Targeted and Whole Exome Analysis of Plasma cfDNA. J Thoracic Oncol 12, 2017 (suppl; abstr OA 10.05). Oral Abstract, October 2017. IASLC World Conference on Lung Cancer; Yokohama, Japan. (Selected oral abstract presented by Tsui DW)
6. Jonsson P, **Cheng ML**, Bandlamudi C, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Zehir A, Schultz N, Donoghue MTA, Baselga J, Offit K, Ladanyi M, O'Reilly EM, Scher HI, Stadler ZK, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS. BRCA-mediated tumorigenesis is origin and cell-type dependent. April 2019. AACR Annual Meeting; Atlanta, GA.
7. **Cheng ML**, Lau C, Milan MSD, Supplee JG, Riess JW, Bradbury PA, Paweletz CP, Oxnard GR. Response Assessment Using Plasma Cell-Free DNA (cfDNA) – When Is the Optimal Time to Assess Response? Poster Session, September 2019. IASLC World Conference on Lung Cancer; Barcelona, Spain.

Narrative Report

I am a clinical/translational investigator active in clinical investigation, translational research, patient care, institutional service, and training of students, fellows and physicians. These activities occur at DFCI as well as BWH, and flow mainly through my focus on thoracic malignancies and precision oncology. I dedicate 60% of my time towards clinical and translational research and 40% to patient care, primarily through my outpatient thoracic oncology clinic at DFCI.

My interest in academic oncology began during medical school and residency training, exemplified by an initial first author publication describing elevated esophageal cancer incidence in specific urban populations in Eastern Africa. My research focus coalesced around precision oncology during my fellowship, during which I leveraged large scale next-generation sequencing (NGS) data to elucidate cancer biology, with a special interest towards DNA damage response and repair (DDR) alterations. I was the second author of the largest analysis to characterize the uncommon phenotype of

microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) castrate resistant prostate cancer and demonstrate responses to immune checkpoint blockade, treatments which are ineffective in the overall prostate cancer population. I was the third author and lead clinical author (as the only MD among the first six authors) of an analysis studying the biologic relevance of BRCA mutations across cancer types in greater than 17,000 patients, which demonstrated that tumor lineage strongly dictates BRCA dependence, and these lineage-specific differences in turn define differential sensitivity to PARP inhibition.

I have applied this interest in precision oncology, especially with respect to DDR alterations and novel applications of NGS, towards my focus in thoracic malignancies as a faculty member. I am the co-senior author of the first analysis to demonstrate that deleterious DDR mutations are independently associated with improved clinical outcomes to PD-(L)1 immune checkpoint blockade in patients with non-small cell lung cancer (NSCLC). I am the overall principal investigator of a unique clinical trial which is the first to apply plasma genotyping-based response assessment to prospectively guide adaptive treatment of first-line treatment of NSCLC patients receiving immunotherapy. I have received several grants and awards including the Prostate Cancer Foundation Young Investigator Award and the American Society of Clinical Oncology Career (ASCO) Development Award, both three years in duration. I have presented at national and international meetings, including those held by the American Society of Clinical Oncology (ASCO) and International Association for the Study of Lung Cancer (IASLC).

Mickey Hu, MS, PhD

Dr. Mickey C. Hu has the expertise in antitumor immunity, breast cancer, cancer cell signaling, cancer immunotherapy, cancer metastasis, cell biology, cytotoxic T lymphocytes DNA damage, drug development, FOXO, immune checkpoints, immuno-oncology, immune suppressors, natural killer (NK) cells, ovarian cancer, p53, protein degradation, prostate cancer, reprogramming cancer cell, signaling mechanism, T cells, tumor microenvironment, tumor suppressors, and various cancers. He has served as Principal Investigator and Director of Discovery Oncology at the Panorama Institute of Molecular Medicine, Associate Professor at Stanford University School of Medicine, California.

Mickey C-T. Hu, M.S., Ph.D.

Director in discovery oncology/Principal Investigator - Panorama Institute of Molecular Medicine/Panorama Research Institute - 1230 Bordeaux Drive, Sunnyvale, CA 94089, USA

PROFILE

A self-driven and highly motivated research leader striving for excellent science and innovation with a passion of drug development for improving human health and life quality. Expert in translational oncology and immuno-oncology researches and with 15+ years of independent principal investigator experience in cancer research at Stanford University, etc.

CORE EXPERTISE/PROGRAM

- *Built a research team to develop therapeutic drugs, organized and supervised direct reports.*
- Developing novel therapeutic methods to overcome NK exhaustion, inhibitory networks in the tumor microenvironment (TME), and tumor-infiltration hurdles for establishing NK cell-based therapies (e.g., "off-the-shelf" CAR-NK therapy).
- Developing novel "scFv-split superantigen (SAg)" for cancer immunotherapy to overcome $CD8^+$ T or NK cell exhaustion and boost cytotoxic T or NK cell responses in the TME.
- Developing novel mAbs that selectively block the interaction of the human integrin $\alpha v\beta 8$ with its ligand, latent TGF-β1/-β3 to enhance the antitumor immune response in the TME. Mature TGF-β1/-β3 are major secreted "immune blockers" in the blood.
- Developing novel immunomodulatory drugs to target cellular "immune blockers" (e.g., CBL-B) to promote TAM receptors (TYRO3, AXL, and MER) expressions in cytotoxic T or NK cells in the TME or promoting "off-the-shelf" CAR-NK cells.
- Adult stem cell reprogramming and hormonal therapy for cancer associated lymphedema (and interested in adult stem cell reprogramming for human regenerative medicine).
- Reprogramming cancer stem cells (various cancers) into non-cancerous cells.
- Developing pharmacological drugs or monoclonal antibody (mAb) drugs or Fc- or albumin (ALB)-fusion engineered protein drugs as tumor immunotherapy for treating cancers.

PROFESSIONAL EXPERIENCE

Panorama Institute of Molecular Medicine/Panorama Research Institute

Director and Principal Investigator (equivalent to Professor) 6/2017 – present *Sunnyvale, CA*

- Served as Director and Principal Investigator in discovery oncology
- *Built a research team to develop therapeutic drugs, organized and supervised direct reports.*
- In collaboration with Drs. J. Larrick and B. Yu (PRI) and Dr. R. Jerala, we are developing scFv-split SAg for cancer immunotherapy to overcome $CD8^+$ T or NK cell exhaustion in TME. To solve the problems of conventional antibody–SAg fusion proteins, we have split SAg into two fragments that are individually inactive, until both fragments come into proximity and reassemble into a biologically active form capable of activating cytotoxic T or NK cell responses, and that do not spontaneously reassemble into an active form.
- Targeting metastatic breast cancer and ovarian cancer with novel metastasis-inhibiting drugs.
- Cancer immunotherapy is often negatively regulated by "endogenous immune blockers" in cytotoxic T or NK cells other than immune-checkpoints. Deciphering the key mechanisms by which the "endogenous immune blockers" (e.g., TGF-β, Cbl-b) inhibit cytotoxic T lymphocytes (CTL) or NK cell immune responses against tumors.
- Developing novel therapeutic drugs to target immune blocker to boost CTL or NK cell immune responses against tumors.
- Discovered, first to develop, identified FOXO3 protein which was shown to be essential for pharmacological drug-promoted anti-tumor immunity in tumor microenvironment.

- Developed the FOXO3-based screen for small molecules or biotherapeutics as a drug discovery platform to identify novel anticancer or cancer immunomodulatory drugs.
- Overcoming cancer-associated lymphedema with adult stem cell reprogramming and novel engineered hormonal proteins and/or nanoparticle therapies.
- Managed multiple projects that resulted in patent application filing for cancer therapeutics.

Stanford University Medical Center
Associate Professor (University tenure line) 9/2008 – 6/2017 *Stanford, California*

- Served as Associate Professor in the Division of Gynecologic Oncology
- *Built a research team to develop anticancer drugs, organized and supervised direct reports.*
- Managed a few projects that resulted in patent application filing for cancer therapeutics
- Awarded STTR grant for novel therapies for treating cancer related lymphedema (swelling in an arm or leg caused by a lymphatic system blockage)
- Awarded Avon breast cancer grant for targeting metastatic breast cancer with novel metastasis-inhibiting drugs
- Interested in developing immune receptor blockades by protein or Ab engineering
- Awarded NCI grant for overcoming cancer linked lymphedema with adult stem cell-hormone therapy
- Discovered, first to develop, identified the FOXO3 gene which was shown to be essential for pharmacological drug-mediated tumor suppression
- Discovered, first to develop, identified FOXO3 protein which was shown to be essential for pharmacological drug-induced cancer cell reprogramming
- Developed the FOXO3-based screen for small molecules as a drug discovery platform to identify novel anticancer or immuno-oncology pharmacological drugs
- Works published in Nature Cell Biology 2008, Nature Communications 2012, Scientific Reports 2014, and Oncotarget 2016

University of Texas M.D. Anderson Cancer Center
Assistant Professor (NTRA and tenure-track) 3/1999 – 8/2008 *Houston, Texas*

- Served as Assistant Professor in the Department of Molecular & Cellular Oncology, and the Department of Cancer Biology
- *Built a research team to develop anticancer drugs, organized and supervised direct reports.*
- Discovered, first identified FOXO3 protein which was shown to be a key tumor suppressor
- Discovered, first identified FOXO3 which was shown to be a key regulator in ionizing radiation-induced cancer cell death
- Work published in Cell 2004
- Awarded NCI R01 5-year grant for studying the role of regulation of FOXO3a in tumor suppression
- Awarded DOD USAMRMC Breast Cancer Research grant for targeting breast cancer with a novel tumor-specific drug
- Discovered, first developed a novel tumor-specific neurotropic peptide-toxin for overcoming malignant breast cancer

Amgen Research Center, Amgen Inc.
Principal Investigator 7/1992 – 2/1999 *Thousand Oaks, California*

- Served as Principal Investigator in the Departments of Experimental Hematology and Functional Genomics
- *Built a research team to develop protein drugs, organized and supervised direct reports.*

- Was part of the team that developed a megakaryocyte growth and development factor
- Built the first IgG-Fc fusion engineered proteins, and discovered and first isolated the human HPK1 gene which was shown to be a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade in response to stress.
- Discovered, first demonstrated that JNK kinases regulate p53 tumor suppressor and protein phosphatase X activates c-Rel/NF-κB.
- Discovered, first isolated the FGF-18, a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation, and p38-δ MAPK which was shown to be activated by stress and proinflammatory cytokines.
- Discovered, first demonstrated that the cytoplasmic domain of stem cell antigen CD34 is essential for cytoadhesion signaling in hematopoietic cells.
- Works published in Cell 1994, Genes and Development 1996, Blood 1998, Oncogene 1997 and 1999, Molecular and Cellular Biology 1998, and Journal of Biological Chemistry 1998 and 1999.

Postdoctoral Research Fellow

California Institute of Technology, Division of Biology, Pasadena, CA, Mentor: Dr. **Norman Davidson**, 6/1988 – 5/1989

- Discovered, first developed a combination of de-repression of the *lac* operator-repressor system with positive induction by glucocorticoid and metal ions in mammalian cells
- Work published in Molecular and Cellular Biology 1990

Stanford University Medical Center, Department of Pathology, Stanford, CA, Mentor: Dr. **Irving L. Weissman**, 6/1989 – 7/1992

- Discovered, first made an antibody against the β chain of Peyer's patch homing receptor, integrin α4/β7, first isolated and cloned β7 receptor by expression cloning with β7 antibody
- First documented that the expression of integrin α4/β7 in lymphocytes played a key and essential role in regulating lymphocyte migration and binding to the gut Peyer's patches
- Work published in Proc Natl Acad Sci USA 1992 and Journal of Cell Biology 1991
- Strikingly, this α4/β7 receptor has been highlighted as a novel receptor for HIV entry through the gut (Nature Immunology 2008), and a key target for AIDS therapy.

EDUCATION

Graduate Student/Doctoral Research Scientist

Ph.D. degree: I obtained my Ph.D. degree from ***California Institute of Technology*** in Chemical Biology & Molecular Biology, Mentor: Dr. **Norman Davidson**, 9/1983 – 5/1988, Ph.D. Thesis Title: The inducible *lac* operator-repressor system is functional in mammalian cells.

- Discovered, first developed a novel inducible promoter, a **genetic switch**, in mammalian cells by using the *lac* repressor-operator system
- Works published in Cell 1987, and Gene 1988 and 1991
- First isolated and characterized the mouse skeletal α-actin gene
- Works published in Molecular and Cellular Biology 1986, and Gene 1986

M.S. degree: from National Taiwan University, Biochemical Sciences, 9/1980 – 6/1982, graduation with honor (Mentor: Dr. Yee-Hsiung Chen)

B.S. degree: from National Taiwan University, Chemistry, 9/1974 – 6/1978

Army Chemical School (Taiwan), Nuclear Chemistry & Biology (compulsory military training

and service for two years), 7/1978 – 6/1980

Awards
Graduate Scholarship, California Institute of Technology, 1983-1988
Li-Ming Outstanding Research Award, Los Angeles, 1988
The Herbert Newby McCoy Award, Caltech, 1988
Postdoctoral Research Fellowship, Amgen, Inc., 1988-1989
Leukemia Society of America Postdoctoral Fellowship, 1989-1992
Howard Hughes Medical Institute Postdoctoral Fellowship, 1992-1993

RESEARCH GRANTS

Funded:

Active Research Support:

1. Principal Investigator, Targeting metastatic breast cancer with novel EMT-inhibiting drugs, the 2017 Avon Breast Cancer Crusade Research Program Award, Grant #02-2017-067, 12/01/17-8/31/20
2. Principal Investigator, Stem cell-adrenomedullin therapy for cancer linked lymphedema, NIH/NCI 1R21CA201940-01A1, 09/01/16-07/31/20
3. Principal Investigator, Novel hormonal therapeutics for diabetic impaired wound healing, DOD FY19 Peer Reviewed Medical Research Program Discovery Award, PR192588, 02/01/20-01/31/22 (Recommended For Funding, see an attached letter from DOD)

Pending:

1. Principal Investigator, Development of novel therapeutic approaches for improving resistant hypertension and cardio-myopathy, DOD FY19 Peer Reviewed Medical Research Program Discovery Award, PR192595, 02/01/20-01/31/22 (Recommended As An Alternate)
2. Principal Investigator, Boosting pancreatic cancer immunotherapy by inhibiting killer T cell immune suppressors, NIH/NCI GRANT12883225 (1R03), 05/01/20-04/31/22
3. Principal Investigator, Effective Combination Approaches for Lymphedema, NIH/NCI GRANT12931903 (1R43, SBIR), 07/01/20-06/30/21
4. Principal Investigator, Novel anti-FOLR1 and anti-TROP2 therapies for ovarian cancer, NIH/NCI GRANT12929451 (1R43, SBIR), 07/01/20-06/30/21
5. Principal Investigator, Suppressing kidney cancers by targeting TGF-β1 and -β3 activation for boosting cancer immunotherapy, DOD USAMRMC FY19 Kidney Cancer Research Program Idea Development Award, GRANT12942920, 07/01/20-06/30/22
6. Principal Investigator, Targeting TROP-2 on metastatic breast cancer with novel immunomodulatory drugs for boosting cancer immunotherapy, DOD USAMRMC FY19 Breast Cancer Research Program Breakthrough Award BTA12-2, GRANT12927883, 07/01/20-06/30/23

Completed Research Support:

1. Principal Investigator, Developing innovative therapies against breast and ovarian cancers, the Fini Women's Cancer grant and the Freidenrich Center for Translational Research, Stanford Women's Cancer Center, #1170149, 09/01/14-06/01/17
2. Principal Investigator, Examining combinations of environmental carcinogen exposures in the development of breast cancer, Avon Foundation for Women, Grant# 02-2014-046, 10/01/14-09/30/16.
3. Principal Investigator (dual principal investigators with Dr. S. Hsu), Developing Novel Therapies for Treating Breast Cancer Related Lymphedema, NIH/NCI 1R41CA183335-01, 10/01/14-12/31/15
4. Principal Investigator, Exposure to tobacco smoke and BPA together augments the risk of

developing breast cancer, Avon Foundation for Women, Grant# 02-2013-051, 10/01/13-09/31/14

5. Principal Investigator, The Role of Regulation of FOXO3 in Tumor Suppression, NIH/NCI 7 **R01**CA113859, 02/01/06-12/30/13
6. Principal Investigator, Activation of FOXO tumor suppressor for triple-negative breast cancer therapy, Stanford Cancer Institute (Developmental Cancer Research Award), 09/01/12-08/31/13
7. Mentor, The Ann Schreiber Research Training Programs of Excellence (the Ovarian Cancer Research Fund), Park (PI), Targeting Ovarian Cancer with Combination of Olaparib and Bepridil, 3/1/12-2/28/13
8. Principal Investigator, Roles of BPA and FOXO in DNA damage response in breast cancer development, Avon Foundation for Women, Grant# 02-2010-063, 07/01/10-06/30/12
9. Mentor, The Rivkin Center Scientific Scholar Award by Marsha Rivkin Center, Chung (PI), Targeting Ovarian Cancer with Combination of Olaparib and Trifluoperazine, 4/1/2011-3/31/2012
10. Co-Principal Investigator, Bone Metastasis Factor-1 in Prostate Cancer/Bone Interaction, NIH/NCI 1**R01**CA111479-01A1, Lin (PI), 07/01/05-4/30/10
11. Principal Investigator, Activation of FOXO tumor suppressor for breast cancer therapy and prevention, The Susan G. Komen Breast Cancer Foundation BCTR0504415, 05/01/05-12/31/09
12. Principal Investigator, Targeting malignant breast cancer cells with a tumor-specific neurotropic peptide-toxin, DOD USAMRMC Breast Cancer Research Program Concept Award BC045295, 09/01/05-08/31/08
13. Principal Investigator, FOXO Signaling in DNA Damage and Repair Responses. The Texas Advanced Research Program, ARP grant, 09/01/06-08/30/08
14. Investigator, Targeting Breast Cancer with FOXO Therapy, Development Research Award, P50 CA116199-01 Breast SPORE, Hortobagyi (PI), 06/01/05-51/31/07
15. Co-Investigator, The Functional Analysis of the Coactivator CARM1, NIH/ NIDDK R01 DK62248-01, Bedford (PI), 07/01/02-06/30/07
16. Principal Investigator, Cyclin D1 as a therapeutic target in human breast cancer, The Susan G. Komen Breast Cancer Foundation BCTR0201848, 05/01/03-04/30/06
17. Principal Investigator, Assessing Functional Estrogen Receptors in Primary and Metastatic Breast Cancers in vivo with 99mTc-labeled Estradiol. MDACC Institutional Research Grant, 02/01/03-01/31/04
18. Principal Investigator, The Hormone-Unresponsive Disease of Estrogen Receptor in Breast Cancer, Pharmacia (formerly Monsanto) Research Grant SR00-203-1, 07/01/00-06/30/02
19. Principal Investigator, CCSG Developmental Fund in Breast Cancer, UT MDACC, 06/01/01-05/31/02

PUBLICATIONS

A. Selected Peer-Reviewed Journals: *(56 published, 1 be submitted, and 4 in preparation)*

1. Lin, K.C., Lin, Y.S., and **Hu, M.C.** (1981). Graftcopolymerization of methyl methacrylate onto bamboo using infrared spectroscopic technique as a probe. *Proc. Natl. Sci. Counc.B, ROC* **5**:26-30.
2. Chen, Y.-H., **Hu, M.C.,** and Yang, J.T. (1984). Membrane disintegration and hemolysis of human erythrocytes by snake venom cardiotoxin (a membrane-disruptive polypeptide). *Biochem. Int.* **8**:329-338.
3. Chen, Y.-H., Liou, R.-F., **Hu, M.C.,** Juan, C.-C., and Yang, J.T. (1987). Interaction of snake venom cardiotoxin (a membrane-disruptive polypeptide) with human erythrocytes. *Mol. Cell. Biochem.* **73**:69-76.

4. **Hu, M.C.,** Sharp, S.B., and Davidson, N. (1986). The complete sequence of the mouse skeletal α-actin gene reveals several conserved and inverted repeat sequences outside of the protein-coding region. *Mol. Cell. Biol.* **6**:15-25.
5. **Hu, M.C.** and Davidson, N. (1986). Mapping transcription start points on cloned genomic DNA with T4 DNA polymerase: a porecise and convenient technique. *Gene* **42**:21-29.
6. **Hu, M.C.** and Davidson, N. (1987). The inducible *lac* operator-repressor system is functional in mammalian cells. ***Cell*** **48**:555-566. (Total citation > 245 times)
7. **Hu, M.C.** and Davidson, N. (1988). The inducible *lac* operator-repressor system is functional for control of expression of injected DNA in *Xenopus* oocytes. *Gene* **62**:301-313.
8. **Hu, M.C.** and Davidson, N. (1990). A combination of derepression of the *lac* operator-repressor system with positive induction by glucocorticoid and metal ions provides a high-level-inducible gene expression system based on the human metallothionein-IIA promoter. *Mol. Cell. Biol.* **10**:6141-6151.
9. **Hu, M.C.** and Davidson, N. (1991). Targeting the *Escherichia coli lac* repressor to the mammalian cell nucleus. *Gene* **99**:141-150.
10. Neuhaus, H., **Hu, M.C.,** Hemler, M.E., Takada, Y., Holzmann, B., and Weissman, I.L. (1991). Cloning and expression of cDNAs for the α subunit of the murine lymphocyte-Peyer's patch homing receptor: Homology to the human integrin α4 subunit and other integrins. *J. Cell Biol.* **115**:1149-1158.
11. **Hu, M.C.,** Crowe, D.T., Holzmann, B., and Weissman, I.L. (1992). Cloning and expression of mouse integrin βp(β7): a functional role in Peyer's patch-specific lymphocyte homing. ***Proc. Natl. Acad. Sci. USA*** **89**:8254-8258. (Total citation > 182 times)
12. Bartley, T.D., Bogenberger, J., Hunt, P., Li, Y.S., Lu, H.S., Martin, F., Chang, M.S., Samal, B., Nichol, J.L., Swift, S., Johnson, M.J., Hsu, R.Y., Parker, VP, Suggs, S, Skrine, JD, Merewether, LA, Clogston, C, Hsu, E, Hokom, MM, Hornkohl, A, Choi, E, Pangelinan, M, Sun, Y, Mar, V, Mchinch, J, Simonet, L, Jacobsen, F, Xie, C, Shutter, J, Chute, H, Basu, R, Selander, L., Trollinger, D., Sieu, L., Padilla, D., Trail, G., Elliott, G., Izumi, R., Covey, T., Crouse, J., Garcia, A., Xu, W., Delcastillo, J., Biron, J., Cole, S., **Hu, M.C.**, Pacific, R., Ponting, I., Saris, C., Wen, D., Yung, Y.P., Lin, H., Bosselman, R.A. (1994). Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor *mpl*. ***Cell*** **77**:1117-1124.
13. Hailman, E., Vasselon, T., Kelley, M., Busse, L.A., **Hu, M.C.,** Lichenstein, H.S., Detmers, P.A., and Wright, S.D. (1996). Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. *J. Immunol.* **156**:4384-4390.
14. **Hu, M.C.,*** Qiu, W.R., Wang, X., Meyer, C.F., and Tan, T.-H.* (1996). Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade. ***Genes Dev.*** **10**:2251-2264. [*co-corresponding] (Total citation > 233 times)
15. Wang, W., Zhou, G., **Hu, M.C.,** Yao, Z., and Tan, T.-H. (1997). Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor β (TGF-β)-activated kinase (TAK1), a kinase mediator of TGF-β signal transduction. *J. Biol. Chem.* **272**:22771-22775.
16. **Hu, M.C.,*** Qiu, W.R., and Wang, Y. (1997) JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. *Oncogene* **15**:2277-2287. [*corresponding]
17. **Hu, M.C.,*** and Chien, S.L. (1998). The cytoplasmic domain of stem cell antigen CD34 is essential for cytoadhesion signaling but not sufficient for proliferation signaling. ***Blood*** **91**:1152-1162. [*corresponding]
18. **Hu, M.C.,*** Qiu, W.R., Wang, Y., Hill, D., Ring, B., Scully, S., Bolon, B., DeRose, M., Luethy, R., Simonet, W.S., Arakawa, T. and Danilenko, D. (1998). FGF-18, a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal

proliferation. *Mol. Cell. Biol.* **18**:6063-6074. [*corresponding]
19. **Hu, M.C.,*** and Wang, Y. (1998). IκB kinase-α and -β genes are coexpressed in adult and embryonic tissues but localized to different human chromosomes. *Gene* **222**:31-40.
20. **Hu, M.C.,*** Tang-Oxley, Q., Qiu, W.R., Wang, Y., Mihindukulasuriya, K.K., Afshar R., and Tan, T.-H.* (1998). Protein phosphatase X interacts with c-Rel and stimulates c-Rel/NF-κB activity. *J. Biol. Chem.* **273**:33561-33565. [*corresponding]
21. **Hu, M.C.,*** Wang, Y., Mikhail, A., Qiu, W.R., Tan, T.-H.* (1999). Murine p38-δ mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines. *J. Biol. Chem.* **274**:7095-7102. [*co-corresponding]
22. **Hu, M.C.,*** Wang, Y., and Qiu, W.R. (1999). Human fibroblast growth factor-18 stimulates fibroblast cell proliferation and is mapped to chromosome 14p11. *Oncogene* **18**:2635-2642.
23. **Hu, M.C.,*** Wang, Y., Qiu, W.R., Mikhail, A., Meyer, C.F., and Tan, T.-H.* (1999). Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IκB kinases (IKK-α/β) and IKK-β is a developmentally regulated protein kinase. *Oncogene* **18**:5514-5524. [*co-corresponding]
24. Shih, C-C., **Hu, M.C.,** Hu, J., Medeiros, J., and Forman, S.J. (1999). Long-term *ex vivo* maintenance and expansion of transplantable human hematopoietic stem cells. ***Blood*** **94**:1623-1636.
25. Shih, C-C., **Hu, M.C.,** Hu, J., Weng, Y., Yazaki, P.J., Medeiros, J., and Forman, S.J. (2000). A secreted and LIF-mediated stromal cell-derived activity that promotes ex vivo expansion of human hematopoietic stem cells. ***Blood*** **95**:1957-1966.
26. Shao, R.,* **Hu, M.C.,*** Zhou, B.P., Lin, S-Y., Chiao, P.J., von Lindern, R.H., Spohn, B., and Hung, M.-C. (1999). E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IκB kinases and nuclear factor-κB activities. *J. Biol. Chem.* **274**:21495-21498. [*equal contribution]
27. Zhou, B.P., **Hu, M.C.,** Miller, S., Yu, Z., Xia, W., Lin, S-Y., and Hung, M.-C. (2000). HER-2/*neu* blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway. *J. Biol. Chem.* **275**:8027-8031.
28. Xia, W.,* Lau, Y.K.,* **Hu, M.C.,** Li, L., Johnson, D.A., Sheng, S-J., El-Naggar, A.K., and Hung, M.-C. (2000). High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. *Oncogene* **19**:2398-2403. [*equal contribution]
29. Wen, Y.,* **Hu, M.C.,*** Makino, K., Bartholomeusz, G., Spohn, B., Yan D-H., and Hung, M.-C. (2000). HER-2/*neu* promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. *Cancer Res.* **60**:6841-6845. [*Equal contribution] (Total citation > 506 times)
30. Ling, P., Meyer, C.F., Redmond, L.P., Shui, J.-W., Davis, B., Rich, R.R., **Hu, M.C.,** Wange, R.L., and Tan, T.-H. (2001). Involvement of hematopoietic progenitor kinase 1 in T cell receptor signaling. *J. Biol. Chem.* **276**:18908-18914.
31. **Hu, M.C.,*** Shui, J.-W., Mihindukulasuriya, K.A., and Tan, T.-H.* (2001). Genomic structure of the mouse PP4 Gene: a developmentally regulated protein phosphatase. *Gene* **278**:89-99. [*co-corresponding]
32. Shih, C.C., Weng, Y., Mamelak, A., LeBon, T., **Hu, M.C.,** and Forman, S.J. (2001). Identification of a candidate human neurohematopoietic stem-cell population. ***Blood*** **98**:2412-2422.
33. Zhou, G., Mihindukulasuriya, K.A., MacCorkle-Chosnek, R.A., Van Hooser, A., **Hu, M.C.,** Brinkley, B.R., and Tan, T.-H. (2002). Protein phosphatase 4 is involved in tumor necrosis factor-α-induced activation of c-Jun N-terminal kinase. *J. Biol. Chem.* **277**:6391-6398.

34. Schechter, N.R., Yang, D.J., Azhdarinia, A., Kohanim, S., Wendt III, R., Oh, C-S. **Hu, M.C.**, Yu, D-F., Bryant, J., Ang, K.K., Forster, K.M., Kim, E.E., and Podoloff, D.A. (2003). Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody. *Anti-Cancer Drugs* **14**:49-56.
35. Yadav, N., Lee, J., Kim, J., Shen, J., **Hu, M.C.,** Aldaz, C.M., and Bedford, M.T. (2003). Specific protein methylation defects and gene expression perturbations in CARM1-knockout mice. *Proc. Natl. Acad. Sci. USA* **100**:6464-6468.
36. **Hu, M.C.,*** Lee, D-F., Xia, W., Golfman, L., Ou-Yang, F., Yang, J-Y., Zou, Y., Bao, S., Hanada, N., Saso, H., Kobayashi, R., and Hung, M.-C.* (2004). IκB kinase promotes tumourigenesis through inhibition of Forkhead FOXO3a. ***Cell*** **117**:225-237. [*co-corresponding] (Total citation > **894** times).
    - *Featured in 2004 June Issue of Nature Reviews Cancer Research Highlight "Tumorigenesis: Right place, wrong time".*
    - *Featured in 2004 April Issue of Science STKE Editors' Choice "IKK: Another Path to FOXO inhibition".*
37. Yang, J-Y., Xia, W., and **Hu, M.C.*** (2006). Induction of FOXO3a and Bim expression in response to ionizing radiation. *Int. J. Oncology* 29:643-648. [*corresponding]
38. Kato, M.,Yuan, H., Xu, Z.G., Lanting, L., Li ,S.L., Wang, M., **Hu, M.C.,** Reddy, M.A., and Natarajan, R. (2006). Role of the Akt/FoxO3a pathway in transforming growth factor beta 1-mediated mesangial cell dysfunction. A novel mechanism related to diabetic kidney disease. *J. Am. Soc. Nephrol.* **17**:3325-3335.
39. Shui, J.-W., **Hu, M.C.,** and Tan, T.-H. (2007). Conditional knockout mice reveal an essential role of protein phosphatase 4 in thymocyte development and pre-TCR signaling. *Mol. Cell. Biol.* **27**:79-91.
40. Cheng, C-J., Ye, X-C., Vakar-Lopez, F., Kim, J., Tu, S.-M., Chen, D-T., Navone, N.M., Yu-Lee, L.-Y., Lin, S.-H.,* and **Hu, M.C.*** (2007). Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. *Mol. Cancer Res.* 5:675-684. [*corresponding]
41. Zou, Y., Tsai, W.B., Cheng, C-J., Hsu, C., Chung, Y.M., Li, P.C., Lin, S-H., and **Hu, M.C.*** Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. *Breast Cancer Res.* 2008 Feb 29;10(1):R21. [*corresponding]
42. Tsai, W.B., Chung, Y.M., Takahashi, Y., Xu, Z., and **Hu, M.C.*** (2008). Functional interaction between FOXO3a and ATM regulates DNA damage response. ***Nat. Cell Biol.*** **10**:460-467. [*corresponding] (Total citation > 161 times)
43. Chu, K., Cheng, C-J., Ye, X-C., Lee, Y-C., Zurita A., Chen, D.-T., Yu-Lee, L.-Y., Yeh, E., **Hu, M.C.**, Logothetis, C. J., and Lin, S.-H. (2008). Cadherin-11 promotes the metastasis of cancer cells to bone. *Mol. Cancer Res.* **6**:1259-1267.
44. Lin, S.-H., Cheng, C-J., Lee, Y-C., Ye, X-C., Chen, N., Kim, J., Pasqualini, R., Arap, W., Navone, N.M., Tu, S.-M., **Hu, M.C.**, Yu-Lee, L.-Y., and Logothetis, C.J. (2008). A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. *Oncogene* **27**:5195-5203.
45. Lira, C.B., Chu, K., Lee, Y.C., **Hu, M.C.**, and Lin, S.-H. (2008). Expression of the extracellular domain of OB-cadherin as an Fc fusion protein using bicistronic retroviral expression vector. *Protein Expr. Purif.* **61**:220-226.
46. Tsai, W.B., Zou, Y., Chung, Y.M., Xu, Z., Nakayama, K., Lin, S-H., and **Hu, M.C.*** (2010). Inhibition of FOXO3 tumor suppressor function by βTrCP1 through ubiquitin-mediated degradation in a tumor mouse model. *PLoS ONE* **5**(7):e11171. [*corresponding]
47. Moyal, L., Lerenthal, Y., Gana-Weisz, M., Mass, G., So, S., Wang, S.Y., Eppink, B., Chung, Y.M., Shalev, G., Shema, E., Shkedy, D., Smorodinsky, N.I., van Vliet, N., Kuster, B.,

Mann, M., Ciechanover, A., Dahm-Daphi, J., Kanaar, R., **Hu, M.C.,** Chen, D.J., Oren, M., and Shiloh, Y. (2011). Requirement of ATM-dependent monoubiquitylation of histone H2B for timely repair of DNA double-strand breaks. ***Mol. Cell*** **41**(5):529-542.

48. Segal-Raz, H., Mass, G., Baranes-Bachar, K., Lerenthal, Y., Wang, S.-Y., Chung, Y.M., Ziv-Lehrman, S., Ström, C.E., Helleday, T., **Hu, M.C.,** Chen, D.J., and Shiloh, Y. (2011). ATM-mediated phosphorylation of polynucleotide kinase/phosphatase (PNKP) is required for effective DNA double-strand break repair. *EMBO Rep.* **12**(7):713-719.
49. Levy-Barda, A., Lerenthal, Y., Davis, A.J., Chung, Y.M., Essers, J., Shao, Z., van Vliet, N., Chen, D.J., **Hu, M.C.**, Kanaar, R., Ziv, Y., and Shiloh Y. (2011). Involvement of the nuclear proteasome activator PA28γ in the cellular response to DNA double-strand breaks. *Cell Cycle* **10**(24):4300-4310.
50. Chung, Y.M., Park, S.H., Tsai, W.B., Wang, S.-Y., Ikeda, M.-A., Berek, J.S., Chen, D.J., and **Hu, M.C.*** (2012). FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. ***Nat. Commun.*** **3**:1000. [*corresponding]
51. Zhang, F., Sun, C., Xiang, T., Pandita, T., Huang, Y., **Hu, M.C.**, and Yang, Q. (2014). Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers. *Oncotarget* **5**:3375-3385.
52. Hu, T., Chung, Y.M., Guan, M., Ma, M., Ma, J., Berek, J.S., and **Hu, M.C.*** (2014). Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. *Sci. Rep.* (Nature) **4**:5810 [*corresponding]
53. Park, S.H., Lee, J-H., Berek, J.S., and **Hu, M.C.*** (2014). Anticancer activity of Auranofin against ovarian cancer cells through the activation of FOXO3. *Int. J. Oncol.* **45**: 1691-1698.
54. Chen, M-C., Zhou, B., Yuan, Y-C., Un, F., Hu, S., Chou, C-M., Wu, J., Wang, Y., Liu, X., Smith, D.L., Li, H., Warden, C.D., Su, L., Malkas, L.H., Chung, Y.M., Zhang, K-Q., **Hu, M.C.**, and Yen, Y. (2015). The novel ribonucleotide reductase inhibitor COH29 inhibits DNA repair in vitro. *Mol. Pharmacol.* **87**: 996-1005.
55. Pfeifer, D., Chung, Y.M., and **Hu, M.C.*** (2015). Effects of Low-Dose Bisphenol A on DNA Damage and Proliferation of Breast Cells: The Role of c-Myc. *Environ. Health Perspect.* **123**: 1271-1279. [*corresponding] (*This Journal is #3 in all Public Health Journals*) *@Featured in 2015 December Issue of News/Science Selections. "Examining BPA's Mechanisms of Action: The Role of c-Myc." Environ Health Perspect. 2015 Dec 1;123(12):A304.* (citation > 73 times)
56. Park, S.H., Chung, Y.M., Ma, J., Yang, Q., Berek, J.S., and **Hu, M.C.*** (2016). Pharmacological activation of FOXO3 suppresses triple-negative breast cancer *in vitro* and *in vivo*. *Oncotarget* **7**: 42110-42125 (2016). [*corresponding]

B. Manuscripts Be Submitted or In Preparation:

1. Chung, Y.M., Khan, P.P., Wang, H., Tsai, W.B., Qiao, Y., Yu, B., Larrick, J.W., and **Hu, M.C.*** Enhancing anti-PD-1 efficacy by pharmacological activation of FOXO3 in tumors and recruiting NK or CD8+ T cells. *Commun. Biol. 2020, submitted* [*corresponding]
2. Chung, Y.M., Park, S.H., Ma, J., Berek, J.S., and **Hu, M.C.*** Inhibitions of PARP1 and TOP1 in ovarian tumors suppress tumor drug resistance via FOXO3 activation. (in preparation) [*corresponding]
3. Khan, P.P., Chen, H.H., Ma, J., Chung, Y.M., Yu, B., Larrick, J.W., and **Hu, M.C.*** Novel regenerative therapy for cancer associated lymphedema with the calcitonin receptor-like receptor agonist. (in preparation) [*corresponding]
4. Chung, Y.M., Ma, J., Tsai, W.B., Chen, C.-S., Berek, J.S., and **Hu, M.C.*** Activation of FOXO3 by curcumin, Bortezomib, and OSU-03012 for triple-negative breast cancer therapy. (in preparation) [*corresponding]
5. Chung, Y.M., Zou, Y., Park, S.H., Tsai, W.B., Xu, Z., Berek, J.S., and **Hu, M.C.*** Targeting

ovarian and breast cancer cells with a tumor-specific neurotropic peptide-toxin. (in preparation) [*corresponding]

C. Invited Review Journals and Book Chapters:

1. **Hu, M.C.,** Holzmann, B., Neuhaus, H., and Weissman, I.L. (1991). The Peyer's patch homing receptor: A novel member of the integrin family. In: Cochrane C.G. and Gimbrone Jr., M.A., eds. *Cellular and Molecular Mechanisms of Inflammation: Vascular Adhesion Molecules.* Vol. 2. San Diego: Academic Press, pp. 91-110.
2. **Hu, M.C.,** Siegelman, M.H., Holzmann, B., Crowe, D.T., Neuhaus, H., and Weissman, I.L. (1992). Lymphocyte homing receptors. *Cold Spring Harbor Symp. Quant. Biol.* **57**:291-308.
3. **Hu, M.C.,** Holzmann, B., Crowe, D.T., Neuhaus, H., Weissman, I.L. (1993). The Peyer's patch homing receptor. *Current Topics in Microbiology and Immunology* **184**:125-138.
4. **Hu, M.C.** and Davidson, N. (1993). Mapping transcription start points with T4 DNA polymerase. In: Wu, R., ed. *Methods in Enzymology*: *Recombinant DNA.* Florida: Academic Press, **217**:446-458.
5. Hung, M.-C. and **Hu, M.C.** (2000) Basic science of HER-2/*neu*: a review. *Physicians' Education Resource-HER2 in Onclolgy* **1**:5-8.
6. **Hu, M.C.,** Xia, W., and Hung, M.-C. (2001) Maspin, a potential prognostic marker for human cancers. In: Hendrix, M. J. ed. "Maspin". Georgetown: RG Landes Co., 2001.
7. **Hu, M.C.,** and Hung, M.-C. (2005) Role of IκB kinase in tumorigenesis. *Future Oncology* **1**:67-78.

PATENTS

1. Invention No. S14-454: Hu, M.C., Chung, Y.M., and Berek, J.S. A Small-Molecule Approach for Cancer Immunotherapy. (Stanford University), pending
2. Invention No. S12-202: Hu, M.C., Chung, Y.M., and Berek, J.S. Cancer Therapy with PARP Inhibitors and FOXO3 Activating Small Molecules. (Stanford University), pending

COMMITTEE MEMBERSHIPS

Grant Review Study Sections:

2000 DOD USAMRMC CDMRP, 2000 Breast Cancer Research Program Review Panel: Clinical and Experimental Therapeutics-4

2004 DOD USAMRMC CDMRP, 2004 Breast Cancer Research Program Review Panel: Concept Award

2004 DOD USAMRMC CDMRP, 2004 Prostate Cancer Research Program Review Panel: Clinical and Experimental Therapeutics-2

2004 DOD USAMRMC CDMRP, 2004 Breast Cancer Research Program Review Panel: Pathobiology-3.

2005 DOD USAMRMC CDMRP, 2005 Breast Cancer Research Program Review Panel: Pathobiology-2.

2007 Breast Cancer Campaign, London EC2A 4HT, UK, Ad Hoc Reviewer

2007 Center for Targeted Therapeutics, Neuro Pilot Projects, M. D. Anderson Cancer Center, Ad Hoc Reviewer

2008 DOD USAMRMC CDMRP, 2008 Breast Cancer Research Program Concept Award Review Panel, CET-5

2008 Center for Targeted Therapeutics, Lymphoma/Myeloma, UT-M.D. Anderson Cancer Center, Ad Hoc Reviewer

2009-2010 DOD USAMRMC CDMRP, 2009 and 2010 BCRP Concept Award Review Panel, BCRP IDEA Award PBY-3 Review Panel, and PCRP PRE-PBY-B Review Panel.

2009 NIH RFA OD-09-003 Challenge Grants Panel 10.

2009 NIH Challenge Grants in Health and Science Research (RC1)-hESC Review Panel
2010 Susan G. Komen for the Cure Postdoctoral Fellowship peer review committees
2011 NIH Grant Review Panel, 2011/05 ZRG1 IMM-G (03) (Immunology) M Scientific Review Group (SRG)
2012 DOD USAMRMC CDMRP FY12 BCRP Review Panel: Impact Award
2012-2013 DOD USAMRMC CDMRP FY13 BCRP Review Panel: Training 2-Cell Biology
2013 DOD USAMRMC CDMRP FY13 BCRP Review Panel: Cell and Molecular Biology
2014 DOD USAMRMC CDMRP FY14 BCRP Review Panel: Cell Biology
2015, 2018 DOD CDMRP FY15 BCRP Breakthrough_FL1/2 Award Review Panel: Cell Biology, W81XWH-15-OCRP-IIRA, and W81XWH-18-BCRP-BTA12_IMM-1 review Panel.
2015-2018 NIH Grant, the Cancer Drug Development & Therapeutics (CDDT) study section
2016 NIH Grant, the Special Emphasis Panel 2016/10 ZCA1 SRB-J (O1) S study section
2017 the Cancer Prevention Research Institute of Texas (CPRIT) RES 17.2 C/TCR and CPRIT RES 18.1 C/TCR
2018 DOD BCRP BC18.1 IMM-1, and CPRIT RES 18.2 C/TCR and CPRIT RES 19.1 C/TCR
2019 CPRIT RES 19.2 C/TCR, DOD BCRP_BC19.1 IMM-1, and CPRIT RES 20.1 C/TCR
2020- CPRIT RES 19.2 C/TCR, CPRIT RES 20.1 C/TCR, CPRIT RES 20.2 C/TCR, etc.

Publication Reviewer:

2000-present, Invited journal reviewer for American Journal of Pathology, Cancer Research, Clinical Cancer Research, Oncogene, Journal of Biological Chemistry, Molecular and Cellular Biology, International Journal of Cancer, International Journal of Gynecological Cancer, PLoS One, Oncogene, Oncotarget, Scientific Reports, etc.

Editorial Board:

2015-present **Editorial Board Member** (editor), *Scientific Reports* (Nature Publishing Group)

Committee Member:

2000-2003 Senator of Faculty Senate at UT-M.D. Anderson Cancer Center
2010-2016 The Stanford Cancer Center Scientific Review Committee (SRC) member.

CITIZENSHIP

United States of America

PRESENTATIONS

Presentations at National or International Conferences

2004 The Role of FOXO in Breast Cancer: Pathways to Drug Discovery, Mission Conference, The Susan G. Komen Breast Cancer Foundation, New York, 2004
2006 The Role of FOXO Tumor Suppressor in Breast Cancer, 9th Annual Mission Conference, Susan G. Komen Breast Cancer Foundation, Washington, D.C., 2006
2008 Targeting malignant breast cancer cells with a tumor-specific neurotropic peptide-toxin, The 16th Era of Hope Breast Cancer Meeting Poster, the DOD Breast Cancer Research Program Meeting, Baltimore, Maryland, June 25-28, 2008
2013 Breast cancer, environmental factors, and your health, The 21st Annual National Conference of alpha Kappa Delta Phi Sorority, Santa Clara, California, May 26, 2013
2013 FOXO3 and Out-FOXing Cancer: Pathways to Drug Discovery, Taipei Medical University, Taipei, Taiwan, 5/14/2013 (an invited lecturer)
2014 FOXO3 and out-FOXing cancer: pathways to drug discovery, 19th World Congress on Advances in Oncology 9-11 October, 2014, Athens, Greece (an invited lecturer)

Other Institutions and Local Conferences

2004 Out-FOXing Cancer by FOXO: Pathways to Drug Discovery, Department of Molecular and Cellular Oncology, UT MD Anderson Cancer Center, Houston, Texas, 6/30/2004
2004 The Role of FOXO in Breast Cancer: Pathways to Drug Discovery, GU Medical Oncology Seminar Series, Department of GU Medical Oncology, UT MD Anderson Cancer Center, Department of GU Medical Oncology, Houston, Texas, 11/2/2004
2005 Role of Regulation of FOXO3a in Tumor Suppression, Department of Cancer Biology, MD Anderson Cancer Center, Department of Cancer Biology, Houston, Texas, 3/14/2005
2005 Roles of IKK and FOXO in Cancer: Pathways to Drug Discovery, Division of Johns Hopkins, Nanos, Nanos, Singapore, 4/27/2005
2007 The Role of FOXO3a in Tumor Suppression, Department of Biochemistry & Molecular Biology, UT Medical School, Houston, Texas, 2/21/2007
2007 The Role of FOXO Tumor Suppressor in Breast Cancer: Pathways to Drug Discovery, The Scripps Research Institute, Department of Cancer Biology, Jupiter, Florida, 4/12/2007
2007 The Role of FOXO Tumor Suppressor in Cancer: Pathways to Drug Discovery, Cancer Research Center of Hawaii, Department of Cancer Biology, Honolulu, Hawaii, 7/26/2007
2007 Roles of IKK and FOXO3 in Cancer: Pathways to Drug Discovery, Stanford University, Ob/Gyn and Stem Cell Institute, Stanford, California, 6/26/2007
2007 Role of FOXO Tumor Suppressor in Cancer: Pathways to Drug Discovery, John Hopkins University School of Medicine, Department of Oncology, Baltimore, Maryland, 8/20/2007
2007 The Role of FOXO Tumor Suppressor in Breast Cancer: Pathways to Drug Discovery, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, 10/26/2007
2008 FOXO3 in Tumor Suppression and DNA damage: Pathways to Drug Discovery, Dr. Weissman Montana Symposium 2008, NIAID, NIH, Montana, 7/23/2008
2010 Roles of IKK and FOXO3 in Cancer: Pathways to Drug Discovery, Stanford University, Ob/Gyn Research meeting, Stanford, California, 4/14/2010
2012 FOXO3 and Out-FOXing Cancer: Pathways to Drug Discovery, the Dr. Weissman Montana Symposium 2012, NIAID, NIH, Montana, 9/12/2012
2014 FOXO3 and out-FOXing cancer: pathways to drug discovery, Stanford University, Gynecologic Research Division meeting, Stanford, California, 10/6/2014
2016 Out-FOXing Cancer: Tumor Suppression, Reprogramming, and Immunity, Department of Pharmaceutical Sciences, South Dakota State University, Brookings, SD 57007, 4/11/2016
2016 Multifaceted therapeutic approaches: Tumor reprogramming and immunity, Department of Inflammation and Oncology, Amgen Inc., South San Francisco, CA, 5/25/2016
2016 Out-FOXing Cancer: Tumor Suppression, Reprogramming, and Immunity, Department of Cell Stress Biology, Roswell Park Cancer Institute in Buffalo, New York, 9/7/2016
2017 Out-FOXing cancer: cancer suppression, cancer immunity and reprogramming, Molecular Medicine Research Institute, Sunnyvale, CA 5/17/2017
2017 Boosting cancer immunotherapy with new immuno-pharmacology drugs, The Panorama Institute of Molecular Medicine/Panorama Research Institute, Sunnyvale, CA, 5/30/2017
2017 Out-FOXing cancer: tumor suppression and reprogramming, Taipei Medical University, Center for Cell Therapy and Regeneration Medicine, Taipei, Taiwan 11/16/2017

PROFESSIONAL MEMBERSHIPS

2000-present	American Association for Cancer Research
1999-2008	American Association for the Advancement of Science

Neil Vasan, MD, PhD

Neil Vasan is an Assistant Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. He is a physician-scientist working in the laboratory of Dr. Lewis Cantley (Weill Cornell Medical College) on oncogenic kinases and mechanisms of response to targeted therapies, with a focus on breast cancer. His work has been published in *Nature* and *Science*. He has received the NIH/NCI K08, the Susan G. Komen Career Catalyst Research Award, the ASCO Young Investigator Award, and was named a 2020 AACR NextGen Star. He will be starting his independent laboratory at Columbia University in July 2021.

Updated August 2020

CURRICULUM VITAE

Neil Vasan

New York, NY 11101
Email: vasann@mskcc.org

EDUCATIONAL BACKGROUND

M.D./Ph.D. Yale University School of Medicine, New Haven, CT	2005-2013
A.B./A.M., Chemistry (with Honors), Harvard University, Cambridge, MA	2001-2005

PROFESSIONAL POSITIONS AND EMPLOYMENT

Assistant Attending Physician, Breast Medicine Service Memorial Sloan Kettering Cancer Center, New York, NY	2018-present
Instructor, Department of Medicine, Weill Cornell Medical College, New York, NY	2018-present
Chief Fellow, Memorial Sloan Kettering Cancer Center, New York, NY	2016-2017
Fellow in Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY	2015-2018
Resident in Internal Medicine, Massachusetts General Hospital, Boston, MA	2014-2015
Intern in Internal Medicine, Massachusetts General Hospital, Boston, MA	2013-2014

RESEARCH EXPERIENCE

Postdoctoral Research 2016-present
Mentors: Dr. Lewis Cantley, Dr. Maurizio Scaltriti, and Dr. José Baselga
Weill Cornell Medical Center, Memorial Sloan Kettering Cancer Center
Project: Mechanisms of activation and inhibition of PI3K in breast cancer

Investigator on 60 IRB protocols (40 open, 20 closed) 2018-present
Memorial Sloan Kettering Cancer Center

Dissertation Research with Dr. Karin Reinisch 2007-11
Yale University School of Medicine, Department of Cell Biology
Dissertation title: “Structural studies of the GARP tethering complex”

Research Assistant with Dr. Matthew Shair 2004-05
Harvard University, Department of Chemistry

Research Assistant with Dr. E.J. Corey 2003-04
Harvard University, Department of Chemistry

Summer Research Assistant with Dr. Philippe Baran 2003
The Scripps Research Institute, La Jolla, CA.

Summer Research Assistant with Dr. Raymond Evers 2002
Merck & Co., Inc., Rahway, NJ

FELLOWSHIPS AND GRANTS

NIH/NCI K08 ($1,217,750 over 5 years)	2020-25
NIH/NCI SPORE in Genomic Instability in Breast Cancer, DRP ($250,000 over 5 years)	2020-25
Susan G. Komen Career Catalyst Research (CCR) Grant ($450,000 over 3 years)	2019-22
Innovations in Cancer Informatics Grant ($200,000 over 2 years)	2018-20
ASCO Young Investigator Award ($50,000 over 1 year)	2018-19
Society of MSK Research Grant ($100,000 over 1 year)	2018-19
NIH T32 (CA009207) Investigational Cancer Therapeutics Training Program Grant	2016-18
Society for Translational Oncology Fellows' Forum	2017
AACR Molecular Biology in Clinical Oncology Workshop	2016
NIH F30 (HL097628-01) Predoctoral National Research Service Award (NRSA)	2009-12
NIH Medical Scientist Training Program (MSTP) Fellowship	2006-13

ACADEMIC AND PROFESSIONAL HONORS

AACR NextGen Star	2020
John Mendelsohn Housestaff Teaching Award (MSKCC)	2016

Associate Faculty Member, Faculty of 1000	2010-12
NIH-NHLBI Medical Student Research Fellowship	2006
Merck-Geraldine R. Dodge Foundation Fellowship	2002
Harvard College Scholarship and Dean's List	2001-05
Robert C. Byrd Scholarship	2001-05
National Merit Scholar	2001-02
United States Presidential Scholar (Given to top male high school graduate in WV)	2001
Eagle Scout	2001

PROFESSIONAL ASSOCIATIONS

European Society of Medical Oncology	2019-present
American Association for Cancer Research	2015-present
American Society of Clinical Oncology	2014-present
American Society for Cell Biology	2008-11
American College of Physicians	2005-2013

SERVICE

PI3K Disease Modeling and Drug Targeting Worldwide Zoom Seminar Co-organizer	2020-present
MSKCC Junior Faculty Council member	2019-present
ASCO Membership Advisory Committee Early Career Working Group member	2019-present
ASCO Virtual Mentoring Program	2018-present
ASCO University Review Panel member	2017-2018
AACR Associate Member Council member	2016-2019
ASCO Trainee Council member	2016-2018
Ad-hoc reviewer for *Breast Cancer Research, Cancer, Cell Death and Differentiation Hematology/Oncology and Stem Cell Therapy*	2018
Moderator for *New England Journal of Medicine* Resident 360	2016

PEER-REVIEWED PUBLICATIONS

Gorelick A, Sanchez-Rivera F, Cai Y, Bielski C, Biederstedt E, Jonsson P, Richards A, **Vasan N**, Penson A, Friedman N, Ho YJ, Baslan T, Bandlamudi C, Scaltriti M, Schultz N, Lowe S, Reznik E, Taylor B. Phase and context shape the function of composite oncogenic mutations. *Nature* 2020 582:100-103.

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, **Vasan N**, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Alterations in *PTEN* and *ESR1* promote clinical resistance to alpelisib plus aromatase inhibitors. *Nature Cancer* 2020 1:382-393.

Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, Chandarlapaty S, Rabadan R, Reznik E, Smith ML, Sebra R, Schimmoller F, Wilson TR, Friedman LS, Cantley LC, Scaltriti M*, Baselga J*. Double *PIK3CA* mutations in *cis* increase oncogenicity and sensitivity to PI3Kα inhibitors. *Science* 2019 366:714-723.

This work has been featured in multiple publications:

1) Perspective by Dr. Alex Toker (*Science* 2019, 366:685-686)
2) Online Research Watch in *Cancer Discovery* (DOI: 10.1158/2159-8290.CD-RW2019-172)
3) News in Depth in Cancer Discovery (DOI: 10.1158/2159-8290.CD-ND2020-013)
4) In The Literature in *ESMO Open* (DOI: 10.1136/esmoopen-2020-00680)
5) Genomeweb.com (www.genomeweb.com/cancer/double-mutations-pik3ca-gene-increase-patient-sensitivity-targeted-therapies-study-finds#.Xp79Wy-z2u5)
6) "Your Drug Mileage May Vary: The PIK3CA Double Mutation Story" by Liz Tseng in *Medium* (https://medium.com/pacbio/your-drug-mileage-may-vary-the-pik3ca-double-mutation-story-83f41f6a4f61)

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, **Vasan N**, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S,

Scaltriti M, Reis-Filho JS, Solit DB*, Taylor BS*, Baselga J*. The genomic landscape of endocrine resistant advanced breast cancers. *Cancer Cell* 2018 34:427-438.

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A Targeted Next Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. *Oncologist* 2014 19:453-458.

Vasan N, Hutagalung A, Novick P, and Reinisch KM. Structure of a C-terminal fragment of its Vps53 subunit suggests similarity of the Golgi-associated retrograde protein (GARP) complex to a family of tethering complexes. *PNAS* 2010 107:14176-81.

REVIEW ARTICLES & CASE REPORTS

Vasan N, Hyman DM, and Baselga, J. A view on drug resistance in cancer. *Nature* 2019 575:299-309.

Vasan N, Toska E, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. *Ann Oncol* 2019 30:3-11.

Vasan N, Braghiroli MI, Shoushtari AN, *et al.* An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. *Journal of Gastrointestinal Oncology* 2017 8:596-602.

Vasan N and Dickler MN State-of-the-Art Update: CDK4/6 Inhibitors in ER+ Metastatic Breast Cancer. *AJHO* 2017 13:16-22.

Vasan N, Boyer JL, and Herbst RS. A Ras renaissance: emerging targeted therapies for KRas-mutated non-small cell lung cancer. *Clin Cancer Res* 2014 20:3921-3930.

Vasan N, Saglan O, Killelea BK. Metastatic leiomyosarcoma presenting as bilateral, multifocal breast masses. *BMJ Case Reports* 2012 doi:10.1136/bcr-2012-007188.

BOOK PUBLICATIONS

Vasan N, Carlo M, Drilon A, Postow M. Pocket Oncology, 2nd edition. Lippincott, Williams, & Wilkins, 2018.

Bhushan V, Le T, **Vasan, N**, Tolles J. First Aid for the USMLE Step 1 2010. McGraw-Hill Company, 2010.

Bhushan V, Le T, Grimm L, **Vasan N**. First Aid for the USMLE Step 1 2009. McGraw-Hill Company, 2009.

CONFERENCE PRESENTATIONS

Identifying novel ways to overcome or prevent drug resistance. AACR 2020 Virtual Conference. June 2020. Invited speaker.

Double *PIK3CA* mutations in *cis* enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. AACR 2020 Virtual Conference. June 2020. Invited speaker.

Double *PIK3CA* mutations in *cis* enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. San Antonio Breast Cancer Symposium 2019. San Antonio, TX. December 12, 2019. Poster presentation.

Double *PIK3CA* mutations in *cis* enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. ESMO Breast Cancer 2019. Berlin, Germany. May 2, 2019. Oral presentation.

Double *PIK3CA* mutations in *cis* enhance PI3K oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. AACR Annual Meeting. Atlanta, GA. April 2, 2019. Poster presentation.

Double *PIK3CA* mutations in *cis* enhance PI3K oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer. The Tumour Cell: Plasticity, Progression and Therapy. New York, NY. March 5, 2019. Poster presentation.

Compound *PIK3CA* mutations support a mutational dose response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer. AACR Targeting PI3K/mTOR Signaling. Boston, MA. December 1, 2018. Poster presentation.

On the Shoulders of Giants. American Society of Clinical Oncology. Chicago, IL. June 2, 2017. Invited speaker.

PLATO Foundation 5th Annual Fellows Forum in Breast Oncology. Chicago, IL. June 3, 2016. Invited speaker.

Structure of a C-terminal fragment of its Vps53 subunit suggests similarity of the GARP complex to a family of tethering complexes. American Society for Cell Biology annual meeting, Philadelphia, PA, 2010. Invited speaker.

Structural studies of the GARP tethering complex. American Society for Biochemistry and Molecular Biology Special Symposium on the Secretory and Endocytic Pathways, Tahoe City, CA, 2010. Poster presentation.

Structural studies of the GARP tethering complex (poster). National MD/PhD Student Conference, Keystone, CO, 2010. Poster presentation.

EDUCATIONAL PRESENTATIONS

Advances in Lobular Breast Cancer. New York Metastatic Breast Cancer Conference, New York, NY. October 5, 2019. Invited speaker.

Advances in Hormone Receptor Positive Breast Cancer. Living Beyond Breast Cancer 2019 Conference on Metastatic Breast Cancer, Philadelphia, PA. April 6, 2019. Invited speaker.

Targeting Cell Cycle Progression: The latest advances on CDK4/6 inhibition in metastatic breast cancer. Peninsula Regional Medical Center, Salisbury, MD. February 2, 2018. Invited speaker.

Targeting Cell Cycle Progression: The latest advances on CDK4/6 inhibition in metastatic breast cancer. Maimonides Cancer Center, Brooklyn, NY. January 17, 2018. Invited speaker.

Targeting Cell Cycle Progression: The latest advances on CDK4/6 inhibition in metastatic breast cancer. John Theurer Cancer Center, Hackensack, NJ. January 11, 2018. Invited speaker.

REFERENCES

Lewis Cantley
Meyer Director of the Sandra and Edward Meyer Cancer Center
Professor of Cancer Biology in Medicine
Weill Cornell Medical College
LCantley@med.cornell.edu

José Baselga
Executive Vice-President, Research and Development Oncology
AstraZeneca
Jose.Baselga@astrazeneca.com

Maurizio Scaltriti
Associate Attending Biologist, Department of Pathology, Human Oncology & Pathogenesis Program
Associate Director of Translational Science, Center for Molecular Based Therapy
Memorial Sloan Kettering Cancer Center
scaltrim@mskcc.org

Luis Diaz
Head of the Division of Solid Tumor Oncology
Grayer Family Chair
Memorial Sloan Kettering Cancer Center
LDiaz@mskcc.org

Mark Robson
Chief, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
robsonm@mskcc.org

Walter M. Stadler, MD, FACP
Fred C. Buffett Professor
Depts of Medicine & Surgery
Dean for Clinical Research
Deputy Director, Comprehensive Cancer Center

I am a clinical trialist who has focused on the development of novel therapies and biomarkers in genitourinary cancers. In this context, I have contributed to the development of gemcitabine in bladder cancer, VEGFR and PD1 checkpoint inhibitors in renal cancer, and various hormonal and other targeted therapies in prostate cancer. I have also explored novel trial designs for growth inhibitory agents, considered the necessary clinical characteristics of both molecular and imaging predictive biomarkers, co-authored consensus statements on prostate cancer clinical trial methodology, and am currently addressing novel pharmacologic approaches to mitigating the cost of care and patient financial toxicity. In my current role as Dean for Clinical Research at the University of Chicago, I am responsible for expanding our clinical trials and clinical research activities throughout the enterprise across departments and centers as well as across our clinical network. Working with the Dean for Translational Research/CTSA Director, I seek to enhance infrastructure and support, including informatics support, to provide the tools for faculty to conduct innovative clinical and translational research activities. In this role I have responsibility for all clinical research regulatory, finance and policy for the institution and have a reporting relationship to University level research management.

CURRICULUM VITAE

WALTER M. STADLER, M.D., FACP

Work: University of Chicago Medical Center
Department of Hematology/Oncology
5841 S. Maryland Ave, MC2115
Chicago, IL 60637-1470
Voice: (773)702-4150
Fax: (773)834-0188
e-mail: wstadler@medicine.bsd.uchicago.edu

Academic Appointments:

1994-1995: Instructor, University of Chicago, Section Hematology/Oncology
1995-1996: Clinical Instructor, University of Chicago, Section Hematology/Oncology
1996-1997: Research Associate (Assistant Professor), University of Chicago, Section Hematology/Oncology
1997-2001: Assistant Professor, University of Chicago, Depts. of Medicine and Surgery, Sections of Hematology/Oncology and Urology
2001-2006: Associate Professor, University of Chicago, Depts. of Medicine and Surgery, Sections of Hematology/Oncology and Urology
2006- : Professor, University of Chicago, Depts. Of Medicine and Surgery, Sections of Hematology/Oncology and Urology
2007- : Fred C. Buffett Professor of Medicine
2007-2014: Associate Dean for Clinical Research
8/13-4/19: Section Chief, Section Hematology/Oncology
8/13- : Deputy Director, University of Chicago Comprehensive Cancer Center
4/19 -: Dean for Clinical Research

Academic Training

Undergraduate Education/Experience:

1980-1984: University of Illinois at Champaign/Urbana, B.S. in Chemistry, Summa Cum Laude with highest distinction in curriculum
1983-1984: General Chemistry Teaching Assistant, University of Illinois
1983-1984: Biochemistry Research Assistant, University of Illinois

Medical Education/Experience:

1984-1988: Yale University School of Medicine, M.D.
1984-1986: Undergraduate Tutor, Yale University
1987-1988: Leader of Student Plan Primary Care Clinics, Yale University

1985-1988: Medical Student Advisor
1987: General Medicine Student Rotation, Alaska Indian National Health Service, Bethel, Alaska
1989-1991: Resident Staff Member, AIDS Clinic, Michael Reese Hospital and Medical Center

Post Graduate Education:

1988-1991: Michael Reese Hospital and Medical Center, Resident in Internal Medicine
1990: Instructor, Physical Diagnosis Course for oral surgeons
1990-1991: Volunteer Instructor, Physical Diagnosis Course for 2nd year medical students
1991-1994: University of Chicago, Fellow in Hematology/Oncology

Licensure & Certification:

ABIM Board Certification #135876
Board Certified, General Internal Medicine, 9/91, 5/02, 10/12
Board Certified, Oncology, 11/93, 5/02, 11/13
IL State License: 036-081259

Professional Societies:

American College of Physicians, 1989-
American Association for the Advancement of Science, 1991-
American Federation for Medical Research, 1992-
American Association for Cancer Research, 1991-
American Society of Clinical Oncology, 1995-
American Urological Association, Affiliate Member, 1996-
The Society of Urologic Oncology, Affiliate Member, 1996-
Society for Basic Urologic Research, 1999-2009
Central Society for Clinical Research, 2001-2014
Clinical Research Forum, 2008-2014
Society for Clinical and Translational Science, 2010-

Honors and Awards:

1984: Bronze Tablet, University of Illinois' highest academic award
Phi Beta Kappa Nominee
Nine separate merit scholarships or awards as undergraduate
1991: Alfred Pick Award for Academic Excellence, Michael Reese
1992-1994: Walgreen Fellow
1994: ASCO Young Investigator Award
1996: Cancer Research Foundation, Young Investigator Award
1999: Kidney Cancer Association, Stulberg Clinical Investigator Award
2000: Univ of Chicago Cancer Research Foundation Auxiliary Board annual award
2002: Fellow, American College of Physicians-American Society of Internal Medicine
2005- : Best Doctors in America
2007- : Castle Connolly Medical Ltd, America's Top Doctor's for Cancer

Clinical Service

I am a clinical oncologist focused on the care of patients with genitourinary malignancies. I staff 2 half day clinics per week and attend on the general inpatient oncology services for 6 weeks/year

Scholarship:

Peer-reviewed publications in the primary literature, exclusive of abstracts:

1. **Stadler WM**, Richards JM, Vogelzang NJ. Serum IL-6 level in metastatic renal cell cancer: Correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst 84:1835-1836, 1992

2. **Stadler WM**, Vogelzang NJ, Vokes EE, Charette J, Whitman G. Continuous infusion FUDR with leucovorin and high dose interferon: A phase II study in metastatic renal cell cancer. Cancer Chemother Pharmacol, 31:213-216, 1992

3. **Stadler WM**, Sherman J, Bohlander SK, Roulston D, Rukstalis D, Dreyling M, Olopade OI. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res 54:2060-2063, 1994

4. Yeager T*, **Stadler WM***, Belair C, Olopade OI, Puthenveettil J, Olopade OI, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 55:493-497, 1995(*These authors contributed equally to the manuscript)

5. Olopade OI, Pomykala HF, Hagos F, Sveen L, Espinosa R, Dreyling M, Gursky S, **Stadler WM**, LeBeau MM, Bohlander SK. Construction of a 2.8 megabase YAC contig and cloning of the Methylthioadenosine phosphorylase (MTAP) gene from the tumor suppressor locus on 9p21. Proc Natl Acad Sci USA, 92:6489-6493, 1995

6. **Stadler WM**, Rybak ME, Vogelzang NJ. A phase II study of subcutaneous human recombinant IL-4 in metastatic renal cell cancer. Evidence of biologic and clinical activity. Cancer, 76:1629-1633, 1995

7. **Stadler WM**, Olopade OI. The 9p21 region in bladder cancer cell lines: Large homozygous deletions inactivate the *CDKN2*, *CDKN2B*, and *MTAP* genes Urol Res 24:239-244, 1996

8. Shulman KL, **Stadler WM**, Vogelzang NJ. High dose continuous intravenous infusion interleukin-2 (IL-2) therapy for metastatic renal cell carcinoma, the University of Chicago experience. Urology 47:194-197, 1996

9. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, **Stadler WM**, Thiel RP Hayden CL. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol 156:363-367, 1996

10. Carpinito, GA, **Stadler WM**, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS Thiel RP, Vogelzang NJ, Hayden CL. Urinary nuclear matrix protein (NMP22) as a marker for transitional cell carcinoma of the urinary tract. J Urol 156:1280-1285, 1996

11. Reznikoff CA, Yeager T, Belair CD, Savelieva E, Puthenveettil JA, **Stadler WM**. Elevated p16 in senescent human uroepithelial cells is retained upon E7 but not E6 induced immortalization. Cancer Res. 56:2886-2890, 1996

12. Reeder JE, Morreale JF, O'Connell MJ, **Stadler WM**, Olopade OI, Messing EM, Wheeless LL. Loss of the *CDKN2/p16* locus detected in bladder irrigation specimens by fluorescence in situ hybridization. J Urol 158:1717-1721, 1997

13. **Stadler WM**, Kuzel T, Roth B, Raghavan D, Dorr FA. A phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 15:3394-3398, 1997

14. Yeager TR, DeVries S, Jarrard DF, Kao C, Nakada SY, Moon TD, Bruskewitz R, **Stadler WM**, Meisner LF, Gilchrist KW, Newton MA, Waldman FM, Reznikoff CA. Overcoming cellular senescence in human cancer pathogenesis. Genes Devel 12: 163-174, 1998

15. Rini BI, **Stadler WM**, Spielberger R, Vogelzang NJ. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Renal Cell Cancer: A Phase II Trial. Cancer 82:1352-8, 1998

16. Kirsh EJ, Baunoch DA, **Stadler WM**. Expression of bcl-2 and bcl-X in bladder cancer. J Urol. 159:1348-1353, 1998

17. Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Schumm LP, Brockstein BE, **Stadler WM**, Ratain MJ, Vokes EE. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in advanced renal and colorectal cancer. Clin Cancer Res 4:929-934, 1998

18. **Stadler WM**, Kuzel T, Dumas M, Vogelzang NJ. A multi-center phase II trial of interleukin-2, interferon-α, and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma. J Clin Oncol. 16:1820-1825, 1998

19. Daugherty CK, Ratain MJ, Minami H, Banik DM, Vogelzang NJ, **Stadler WM**, Siegler M. A feasibility study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol: 16:2305-2312, 1998

20. Chekmareva MA, Kadkhodiaian MM, Hollowell CMP, Kim H, Yoshida BA, Luu HH, **Stadler WM**, Rinker-Schaeffer CW. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. Cancer Res. 58:4963-4969, 1998

21. Dubauskas Z, Beck TP, Chmura SJ, Kovar DA, Kadkhodaian MM, Srivastav M, Chung T, **Stadler WM**. Rinker-Schaeffer CW. Activated calphostin C cytotoxicity is independent of p53 status and *in vivo* metastatic potential. Clin Cancer Res. 10:2391-8, 1998

22. **Stadler WM**, Vogelzang NJ, Hoffman PC, Arrieta R, Masters G, Fishkin P, Gibbons J, Lad TE, Vokes EE. CI-980 in Renal Cell and Non-Small Cell Lung Cancer: Multi-Institutional Trials From the University of Chicago Phase II Consortium. Cancer Therapeutics 1:318-320, 1998

23. Chien M, Astumian M, Liebowitz D, Rinker-Schaeffer C, **Stadler WM**. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol 44:81-87, 1999

24. **Stadler WM**, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. A multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 17:2541-2545, 1999

25. Beck TP, Kirsh EJ, Chmura SJ, Kovar DA, Chung T, Rinker-Schaeffer CW, **Stadler WM**. In vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer. Urology 54:573-577, 1999

26. Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, **Stadler WM**, Rinker-Schaeffer CW. MKK4/SEK1, a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 59:5483-5487, 1999

27. **Stadler WM**, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE. Flavopiridol, a novel cyclin dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 18:371-375, 2000

28. Ryan CW, Vogelzang NJ, Dumas MC, Schumm P, Kuzel T, **Stadler WM.** GM-CSF in combination immunotherapy for metastatic renal cell carcinoma: Results of two phase II clinical trials. Cancer, 88:1317-1324, 2000

29. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, **Stadler W.** Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921-1927, 2000

30. Goh BC, Fleming GF, Janish L, Vogelzang NJ, **Stadler WM**, Ratain MJ. Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chem Pharm 45:489-494, 2000

31. Konety BR, Nguyen T-S T, Dhir R, Day RS, Becich MJ, **Stadler WM**, Getzenberg RH. Detection of bladder cancer utilizing BLCA-4, a novel bladder cancer specific nuclear matrix protein. Clin Cancer Res 6:2618-25, 2000

32. Rini BI, Vogelzang NJ, Dumas MC, Wade JL, Taber DA, **Stadler WM**. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419-2426, 2000

33. Chien M, Rinker-Schaeffer C, **Stadler WM**. Normal human uroepithelial response to H_2O_2:G2/M growth arrest underlies senescence-like features. International J Oncol 17: 425-432, 2000

34. Innocenti F, **Stadler WM**, Iyer L, Ramirez J, Vokes EE, Ratain MJ. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res 6:3400-3405, 2000

35. Rini BI, Zimmerman TM, Gajewski TF, **Stadler WM**, Vogelzang NJ. Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J. Urol 165:1208-1209, 2001

36. Rudin DM, Holmlund J, Fleming GF, Mani S, **Stadler WM**, Dorr A, Ratain MJ. A phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-Raf-1, administered by 24-hrour weekly infusion to patients with advanced cancer. Clinical Cancer Res 7:1214-1220, 2001

37. Kim HL, Vander Griend D, Yang X, Benson DA, Dubauskas Z, Yoshida BA, Chekmareva MA, Ichikawa Y, Sokoloff M, Zhan P, Karrison T, Lin A, **Stadler WM**, Ichikawa T, Rubin M, Rinker-Schaeffer CW. MKK4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 61:2833-2837, 2001

38. **Stadler WM**, Steinberg G, Yang X, Hagos F, Turner C, Olopade OI. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluourescent-in-situ-hybridization. Clin Cancer Res 7:1676-1682, 2001

39. Vogelzang NJ, Aklilu M, **Stadler WM**, Dumas MC, Mikulski SM. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs 19:255-260, 2001

40. Mani S, Vogelzang NJ, Bertucci D, **Stadler WM**, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: A potential broadly active regimen for advanced solid tumor malignancies. Cancer 92:1567-1576, 2001

41. Desai A, **Stadler WM**, Vogelzang NJ. Nilutamide: Possible utility as a second-line hormonal agent. Urology 58:1016-1020, 2001

42. George CM, Vogelzang NJ, Rini BI, Geoffroy FJ, Kollipara P, **Stadler WM**. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol 13:116-120, 2002

43. Ryan CW, Vogelzang NJ, Kuzel T, **Stadler WM**. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell cancer. Cancer 94: 2602-2609, 2002

44. Rini BI, Zimmerman T, **Stadler WM**, Gajewski TF, Vogelzang NJ. Allogeneic stem cell transplantation of renal cell cancer after non-myeloablative chemotherapy: Feasibility, engraftment and clinical results J Clin Oncol 20:2017-2024, 2002

45. **Stadler WM,** Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufman D, Moore M. Long term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urologic Oncology 7:153-157, 2002

46. Rini BI, Paintal A, Vogelzang NJ, Gajewski TF*, **Stadler WM***. Flt-3 (Fl) ligand and sequential Fl/Interleukin-2 in metastatic renal carcinoma: Results of two clinical trials. (*these authors contributed equally to the manuscript) J. Immunother 25:269-277, 2002

47. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, **Stadler WM**. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95:1629-1636, 2002

48. Park DK, Ryan CW, Dolan ME, Vogelzang NJ, **Stadler WM**. A phase II trial of temozolomide in patients with metastatic renal cell cancer. Cancer Chem Pharm 50:160-162, 2002

49. Small EJ, Halabi S, Ratain MJ, Rosner G, **Stadler W**, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. A randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of Intergroup 0159 (CALGB 9480). J Clin Oncol 20:3369-3375, 2002

50. Rosner GL, **Stadler WM**, Ratain MJ. The randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-4484, 2002

51. Bennett CL, Schumock GT, Desai AA, Kwaan HC, Raisch D, Newlin, R, **Stadler W**. Thalidomide-associated deep vein thrombosis and pulmonary emboli. Amer J. Med 113:603-606, 2002

52. Cohen EEW, Rosen F, **Stadler WM**, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003

53. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, **Stadler W**, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2679, 2003

54. Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, **Stadler W**, Logan T, Dutcher J, Hudes G, Dorner AJ, Slonim DK, Trepicchio WL, Burczynski ME. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 63:6069-6075, 2003

55. **Stadler WM**, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman TM, Vogelzang NJ. Prognostic Factors for Survival to Gemcitabine Plus 5-FU Based Regimens in Metastatic Renal Cancer. J Urol 170:1141-1145, 2003

56. Vogelzang NJ, Karrison T, **Stadler WM**, Garcia J, Cohn H, Kugler J, Troeger T, Giannone E, Arrieta R, Ratain MJ, Vokes EE. A phase II trial of suramin once monthly x 3: Activity in chemotherapy refractory prostate cancer. Cancer 100:65-71, 2004

57. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, **Stadler WM**. A phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 22:114-119, 2004

58. Yang XJ, Sugimura J, Tretiakova MS, Furge K, Zagaja G, Sokoloff M, Pins M, Bergan R, Grignon DJ, **Stadler WM**, Vogelzang NJ, Teh BT. Gene expression profiling of renal medullary carcinoma – potential clinical relevance Cancer 100:976-985, 2004

59. Atkins M, Hidalgo M, **Stadler WM**, Logan T, Dutcher J, Hudes G, Park Y, Liou S-H, Marshall B, Boni J, Dukart G, Sherman M. Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel mTOR Kinase Inhibitor, in Patients with Advanced Refractory Renal Cell Carcinoma. J Clin Oncol 22:909-918, 2004

60. Small EJ, Halabi S, Dawson NA, **Stadler WM**, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. A phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: Results of CALGB 9583. J Clin Oncol 22:1025-1033, 2004

61. **Stadler WM**, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, Karrison T, Vokes EE. A randomized phase II trial of the antiangiogenic agent SU5416 in hormone refractory prostate cancer. Clin Cancer Res 10:3365-3370, 2004

62. Aklilu A, **Stadler WM**, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF. Depletion of normal B-cells with rituximab as an adjunct to IL2 therapy of renal cell carcinoma and melanoma Ann of Oncol 15:1109-1114, 2004

63. Peterson AC, Swiger S, **Stadler WM**, Medved M, Karczmar G, Gajewski TF. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in melanoma. Clin Cancer Res 10:4048-4054, 2004

64. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TJ, Kindler H, Vokes E, MacEneany P, Mitchell MT, **Stadler WM**. Semi-quantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J. Magn Reson Imaging 20:122-128, 2004

65. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Nicol SJ, **Stadler WM**. A Multi-Institutional Phase II Trial of Gemcitabine Plus Paclitaxel in Patients with Locally Advanced or Metastatic Urothelial Cancer. Urologic Oncology 22:393-397, 2004

66. Amin A, Halabi S, Gelmann EP, **Stadler W**, Vogelzang N, Small E. 9-Nitrocamptothecin as Second Line Chemotherapy for Men with Progressive, Metastatic, Hormone Refractory Prostate Cancer: Results of the CALGB 99901 Urologic Oncology 22:398-403, 2004

67. Ahles TA, Herndon JE 2nd, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, **Stadler W**, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma. Cancer 101:2202-2208, 2004

68. Yang C, Karczmar G, Medved M, **Stadler WM**. Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies. Fundamental concepts and simulations Mag Reson Med 5:1110-1117, 2004

69. Jani AB, Sokoloff M, Shalhav A, **Stadler W**. Androgen Ablation Adjuvant to Post-Prostatectomy Radiotherapy: A Complication-Adjusted Number Needed to Treat (NNT) Analysis. Urology 64:976-981, 2004

70. Artz A, VanBesien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, **Stadler WM**, Vogelzang NJ. Long-term Follow Up of Non-myeloablative Allogeneic Stem Cell Transplantation for Renal Cell Carcinoma: The University of Chicago Experience. Bone Marrow Trnsplnt 35:253-260, 2005

71. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, **Stadler WM**, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the VEGF receptor antagonists SU5416 or SU6668. Clin Cancer Res 11:678-689, 2005

72. Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, **Stadler WM**, Logan T, Dutcher J, Hudes G, Trepicchio WL, Strahs A, Immermann F, Slonim DK, Dorner AJ. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 11:1181-1189, 2005

73. Ryan CW, **Stadler WM**, Vogelzang NJ. A Phase I/II Dose-Escalation Study of Exisulind and Docetaxel in Patients with Hormone-Refractory Prostate Cancer. Brit J Urol 95:963-969, 2005

74. Artz AS, **Stadler W**, Vogelzang N, Zimmerman T, Ryan C. A Phase II Trial Of Sequential Chemotherapy With Docetaxel and Methotrexate Followed By Gemcitabine And Cisplatin For Metastatic Urothelial Cancer. American J of Clinical Oncol 28:109-113, 2005

75. Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K, **Stadler WM**. A Phase II Study of Oxaliplatin in Urothelial Cancer. Urologic Oncology 23:150-154, 2005

76. Desai AA, Schilsky RL, Young A, Janisch L, **Stadler WM**, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ. A Phase I Study of Antisense Oligonucleotide GTI-2040 Given by Continuous Intravenous Infusion in Patients with Advanced Solid Tumors and Lymphoma. Ann Oncol 16: 958-965, 2005

77. **Stadler WM**, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ. Successful Implementation of the Randomized Discontinuation Trial Design: An Application to the Study of the Putative Antiangiogenic Agent Carboxyaminoimidazole (CAI) in Renal Cell Carcinoma - CALGB 69901. J Clin Oncol 23:3726-3732, 2005

78. Yang XJ, Tan M-H, Kim HJ, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayami H, Tan PH, Teh BS, Luan C, Kim W, Tretiakova M, Anema J, Kahnoski R, Nicol T, **Stadler W**, Vogelzang N, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. A molecular classification of papillary renal cancer. Cancer Res 65(13): 5628-37, 2005

79. Davis NB, Ryan CW, **Stadler WM**, Vogelzang NJ. A Phase II Study of Nilutamide in Men with Prostate Cancer Following Failure of Flutamide or Bicalutamide Therapy. BJU International 96:787-90, 2005

80. Kindler HL, Friberg G, Singh DA, Locker GY, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, **Stadler WM**, Vokes EE. A phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 23:8033-8040, 2005

81. Shaheen PE, **Stadler W**, Elson P, Knox J, Winquest E, Bukowski RM. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest New Drugs 23:577-581, 2005

82. Vander Griend DJ, Kocherginsky M, Hickson JA, **Stadler WM**, Lin A, Rinker-Schaeffer CW. The Context-Dependent Activation of the JNK Kinases JNKK1/MKK4 and MKK7 Suppresses Metastatic Colonization. Cancer Res, 65:10984-10991, 2005

83. Lara PN, **Stadler WM**, Longmate J, Quinn DI, Wexler J, Van Loan M, Meyers FJ, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. Markers of bone metabolism predict survival in hormone refractory prostate cancer patients with skeletal metastases. Clin Cancer Res 12:1556-1563,2006

84. Polite BN, Desai AA, Manchen B, **Stadler WM**. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: Results of a single Institution Phase II trial. Clin Genitourin Cancer 4:275-280, 2006

85. Ratain MJ, Eisen T, **Stadler WM**, Flaherty KT, Kaye SB, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. A Phase II, Placebo-Controlled, Randomized Discontinuation Trial of Sorafenib in Patients with Metastatic Renal Cell Carcinoma. J Clin Oncol 24:2505-2512, 2006

86. Rini BI, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T, **Stadler WM**, McCarthy PL, Linker CA, Small EJ. CALGB 90003: Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: An intergroup phase II study. Biology of Blood and Marrow Transplantation 12:778-785, 2006

87. Peterson, AC, Harlin H, Karrison T, Knost JA, Kugler JW, Lester E, Vogelzang N, Vokes E, Gajewski TF, **Stadler WM**. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs 24:141-149, 2006

88. **Stadler WM**, Margolin L, Ferber S, McCulloch W, Thompson J. A phase II study of depsipeptide (FK228, FR901228, NSC630176) in refractory metastatic renal cell cancer. Clin Genitourin Cancer 5:57-60, 2006

89. **Stadler WM**, Halabi S, Rini BI, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ. A Phase II Study of Gemcitabine and Capecitabine in Metastatic Renal Cancer: A Report of Cancer and Leukemia Group B Protocol 90008. Cancer 107:1273-1279, 2006

90. Jin JJ, Lehmann J, Taxy J, Huo D, Stöckle M, Steinberg G, **Stadler WM**. Phase II trial of adjuvant gemcitabine plus cisplatin with amifostine cytoprotection in patients with locally advanced bladder cancer. Clin Genitourinary Cancer 5:150-154, 2006

91. Lacouture ME, Desai A, Soltani K, Rosic VP, Laumann AE, Ratain MJ, **Stadler WM**. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multi-targeted tyrosine kinase inhibitor. Clinical Experimental Derm 31:783-785, 2006

92. Furge KA, Kort EJ, Yang XJ, **Stadler WM**, Kim H, Teh BT. Gene expression profiling in kidney cancer:Combining differential expression and chromosomal and pathway analyses. Clin Genitourinary Ca 5:227-231, 2006

93. Escudier B, Eisen T, **Stadler WM**, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai A, Rolland F, Demkow T, Hutson T, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. Sorafenib in Advanced Clear-Cell Renal Cell Carcinoma. N. Engl J Med 356:125-134, 2007

94. Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak D, **Stadler WM**, Rodin M. Comprehensive geriatric assessment for identifying disability in older prostate cancer patients receiving androgen ablation. Cancer 109:802-810, 2007

95. Gomez-Abuin G, Winquist E, **Stadler WM**, Pond G, Degendorfer P, Wright J, Moore MJ. A Phase 2 Study of PS-341 (Bortezomib) in Advanced or Metastatic Urothelial Cancer. A trial of the Princess Margaret Hospital and University of Chicago Phase II consortia. Invest. New Drug 25:181-185, 2007

96. Posadas EM, Undevia S, Manchen E, Colevas AD, Karrison T, Vokes EE, **Stadler WM**. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Bio Ther 6:490-493 PMID: 17457044, 2007

97. Ryan CW, Huo D, Bylow K, Demers LM, **Stadler WM**, Henderson TO, Vogelzang NJ. Suppression of bone density loss and bone turnover in hormone-sensitive prostate cancer patients receiving zoledronic acid. British J Urol 100:70-75, 2007

98. Ryan CJ, **Stadler WM**, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine, in patients with hormone refractory prostate cancer. Invest New Drugs 25:445-51, 2007

99. Lotan TL, Lyons M, Huo D, Taxy J, Brendler C, Foster B, **Stadler WM**, Rinker-Schaeffer C. Upregulation of MKK4, MKK6 and MKK7 During Prostate Cancer Progression: An Important Role for SAPK Signaling in Prostatic Neoplasia. J Pathol 212:386-94, 2007

100. Yang C, Karczmar G, **Stadler WM**. A multiple reference tissue method for contrast agent arterial input function estimation. Magn Reson Med 58:1266-1275, 2007 [PMID: 17969061]

101. Karrison TG, Maitland ML, **Stadler WM**, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small cell lung cancer. J Natl Cancer Inst 99:1455-1461, 2007

102. **Stadler WM**, Desai AA, Quinn DI, Bukowski R, Poiesz B, Kardinal CG, Lewis N, Makalinao A, Murray P, Torti FM. A Phase I/II Study of GTI-2040 and Capecitabine in Patients with Renal Cell Carcinoma. Cancer Chemother Pharm 61:689-694, 2008 [PMID: 17569043]

103. Flaig TW, Tangen CM, Hussain MHA, **Stadler WM**, Raghavan D, Crawford ED, Glode LM. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 26:1532-1536, 2008

104. Lassiter LK, Tummala MK, Hussain MH, O'Shaughnessy J, **Stadler WM**, Petrylak DP, Lerner S, Henry D, Carducci MA. Phase II, Open Label Study of Oral Piritrexim in Patients with Advanced Carcinoma of the Urothelium Who Have Failed Standard Chemotherapy. Clin Genitourin Cancer 6:31-35, 2008

105. Lee RT, Beekman KE, Hussain M, Davis NB, Clark JI, Thomas SP, Nichols KF, **Stadler WM**. A University of Chicago Consortium Phase II trial of SB-715992 in Advanced Renal Cell Cancer. Clin Genitourin Cancer 6:21-24, 2008

106. Jonasch E, **Stadler W**, Bukowski R, Hayes T, Varadhachary A, Malik R, Figlin R, Srinivas S. Phase Two Trial of Talactoferrin in Previously Treated Patients with Metastatic Renal Cell Carcinoma. Cancer 113:72-77, 2008 (DOI: 10.1002/cncr.23519)

107. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, **Stadler WM**, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ. Antitumor Activity and Biomarker Analysis of Sunitinib in Patients with Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. J Clin Oncol 26:3743-3748, 2008 (PMID: 18669461)

108. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, **Stadler WM**, Vokes EE, Fleming GF. Efficacy and Safety of Bevacizumab Plus Erlotinib for Patients with Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: A Trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110:45-55, 2008

109. Bylow KA, Dale W, Mustian K, **Stadler WM**, Rodin M, Hall W, Lachs M, Mohile SG. Falls and Physical Performance Deficits in Older Prostate Cancer Patients Undergoing Androgen Deprivation Therapy. Urology 72:422-427, 2008

110. Salama J, Chmura S, Mehta N, Yenice K, **Stadler W**, Vokes E, Haraf D, Hellman S, Weichselbaum R. An Initial Report of a Radiation Dose Escalation Trial in Patients with One to Five Sites of Metastatic Disease. Clin Cancer Res 14:5255-5259, 2008 (PMID: 18698045)

111. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, **Stadler WM**. A dynamic contrast-enhanced MRI pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572-4578, 2008 (PMID: 18824708)

112. Rini BI, Halabi S, Rosenberg JE, **Stadler WM**, Vaena DA, Ou S-S, Archer L, Atkins JN, Picus J, Tanguay S, Dutcher J, Small EJ. Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of CALGB 90206. J Clin Oncol 26:5422-5428, 2008 (PMID: 18936475)

113. Knight D, Peterson AC, Rini BI, Harlin H, Gajewski TF*, **Stadler WM**. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. The Prostate 69:142-148, 2009; PMID: 18942640) (*contributed equally)

114. Gofrit ON, **Stadler WM**, Zorn KC, Lin S, Silvestre J, Shalhav AL, Zagaja GP, Steinberg GD. Adjuvant chemotherapy in lymph node positive bladder cancer. Urol Oncol 27:160-164, 2009 (PMID: 18440835)

115. Bylow KA, Atkins MB, Posadas EM, **Stadler WM**, McDermott DF. Trial of Carboplatin and Taxol in Papillary Renal Cell Carcinoma. Clin Genitourinary Ca 7:39-42, 2009

116. Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakova M, Saddiqui J, Pienta KJ, **Stadler WM**, Rinker-Schaeffer C, Salgia R. FYN is overexpressed in human prostate cancer. BJU Intl 103:171-7, 2009 (PMID: 18990162)

117. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, **Stadler WM**, Knowles HL, Bedrosian C, Ratain MJ. A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus (AP23573) an mTOR Inhibitor, in Patients with Advanced Malignancies. Clin Cancer Res 15:1428-34, 2009 (PMID: 19228743)

118. Yang C, Karczmar GS, Medved M, Oto A, Zamora M, **Stadler WM**. Reproducibility Assessment of a Multiple Reference Tissue Method for Quantitative DCE-MRI Analysis. Magn Reson Med 61:851-859, 2009 (PMID: 19185002)

119. Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, **Stadler WM**. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: A prospective cohort study J Clin Oncol 27:1557-1563, 2009 (PMID: 19255325)

120. Dreicer R, **Stadler WM**, Ahman R, Whiteside T, Bizouarne N, Acres B, Limacher J-M, Squiban P, Pantuck A. MVA-MUC1-IL2 Vaccine Immunotherapy (TG4010) in Patients with Prostate Cancer with Biochemical Failure. Invest New Drugs 27:379-386, 2009 (PMID: 18931824)

121. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, **Stadler W**, Gandara DR. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: A California Cancer Consortium study. Anticancer Drugs 20:179-184, 2009 (PMID: 19396016)

122. Vaughn DJ, Srinivas S, **Stadler WM**, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, deWit E, Pautret V, George C. Vinflunine in platinum pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study. Cancer 115:4110-4117, 2009 [PMID: 19536904]

123. Escudier B, Eisen T, **Stadler WM**, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III TARGET Study. J Clin Oncol 27:3312-3318, 2009 [PMID: 19451442]

124. Rini BI, Wilding G, Hudes G, **Stadler WM**, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462-4468, 2009 [PMID: 19652060]

125. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, **Stadler WM**, Elliott WJ, Ratain MJ. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 15:6250-6257, 2009 [PMID: 19773379]

126. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, **Stadler WM**. A randomized phase I study of testosterone replacement for patients with low risk castrate resistant prostate cancer Eur Urol 56:97-104, 2009 [PMID: 19282098]

127. Bradley D, Rathkopf D, Dunn R, **Stadler WM**, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and Interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase II Consortium. Cancer 115:5541-5549, 2009 [PMID: 19711464]

128. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AHA, Patterson S, Riggs CE Jr, Higano C, **Stadler WM**, McCulloch W, Dearnaley D, Parker C, de Bono JS. Phase II, two-stage, single arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration resistant prostate cancer. Ann Oncol 21:109-113, 2010 [PMID: 19608618]

129. Liauw SL, **Stadler WM**, Correa D, Weichselbaum RR, Jani AB. Dose escalated radiation therapy for high risk prostate cancer: Outcomes in the modern era with short term androgen deprivation therapy. International Journal of Radiation Oncology, Biology, Physics 77:125-130, 2010 [PMID: 19695789]

130. **Stadler WM,** Figlin RA, McDermott DF, Dutcher JP, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Pendergrass KB, Logie KW, Trent D, Xia C, Cupit L, Bukowski RM. Safety and efficacy results of the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access program in North America. Cancer. 116:1272-1280, 2010 [PMID: 20082451]

131. O'Donnell PH, Jensen A, Posadas EM, Bridge JA, Yeldandi AV, Yang XJ, **Stadler WM**, Al-Ahmadie H. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol 7:110-114, 2010 [PMID: 20145663]

132. Rini BI, Halabi S, Rosenberg JE, **Stadler WM**, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28:2137-2143, 2010 [PMID: 20368558]

133. Yang C, **Stadler WM**, Karczmar GS, Milosevic M, Yeung I, Haider MA. Comparison of quantitative parameters in cervix cancer measured by dynamic contrast enhanced MRI and CT. Magnetic Resonance in Medicine 63:1601-1609, 2010 [PMID 20512864]

134. Chung EK, Posadas EM, Kasza K, Karrison T, Manchen E, Hahn OM, **Stadler WM**. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Amer J Clin Oncol 34:150-154, 2011 [PMID: 20395787]

135. Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, **Stadler WM.** Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. (Originally withdrawn from Epub by permission from authors and publisher so that it could be published in first edition of the Journal of Geriatric Oncology). Transferred publication to Journal of Geriatric Oncology 1:13-19, 2010; reprinted in Critical Reviews of Hematology/Oncology 75:152-9, 2010

136. Twardowski P, **Stadler WM**, Frankel P, Lara PN, Ruel C, Chatta G, Heath EI, Quinn DI, Gandara DR. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer-a California Cancer Consortium trial. Urology 76:923-926, 2010 [PMID: 20646741]

137. Bukowski RM, **Stadler WM**, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program Oncology 78:340-347, 2010 [PMID: 20733337]

138. Lin HK,* Zheng S,* Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M , **Stadler W**, Datar RH, Tai Y-C, Cote RJ. Portable filter-based microdevice for detection and characterization of circulating tumor cells Clin Cancer Res 16:5011-5018, 2010 [DOI 10.1158/1078-0432.CCR-10-1105] [PMID 20876796]

139. Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T, Dahi F, Shalhav AL, Karczmar G, **Stadler WM**. Differentiation of central gland prostate cancer from benign prostatic hyperplasia using Diffusion weighted and dynamic contrast enhanced MR imaging. Radiology 257:715-723, 2010 [PMID 20843992]

140. Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, **Stadler WM**, Vokes EE. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs 30:382-386, 2012 (ePub ahead of print 2010) [PMID: 20803052]

141. O'Donnell PH, Undevia SD, **Stadler WM**, Karrison TM, Nicholas MK, Janisch L, Ratain MJ. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs, 30:604-610, 2012 (ePub ahead of print 2010) [PMID: 20839028]

142. Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, **Stadler WM**, Small EJ; for Cancer and Leukemia Group B. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006 Cancer 117:526-33, 2011 [PMID: 20862750]

143. Bylow K, Hemmerich J, Mohile SG, **Stadler WM**, Sajid S, Dale W. Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. Urology 77:934-940, 2011 [PMID: 21269665]

144. Hahn NM, **Stadler WM**, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ. A phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma - Hoosier Oncology Group GU 04-75 J Clin Oncol 29:1525-1530, 2011 [PMID: 21422406]

145. Schöffski P, Garcia JA, **Stadler WM**, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner K, Anderson A, Zhu M, Kabbinavar F. A phase 2 study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma British J Urol Int 108:679-686, 2011 [PMID: 21156020]

146. Trask PC, Bushmakin AG, Cappelleri JC, Tarazi J, Rosbrook B, Bycott P, Kim S, **Stadler WM**, Rini B. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Surviv 5:255-262, 2011 [PMID: 21476015]

147. Cohen EEW, Sharma MR, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming GF, **Stadler WM**, Ratain MJ. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies Eur J Cancer 47:1484-1489, 2011 [PMID: 21439817]

148. Chen JL, Li J, **Stadler WM**, Lussier YA. Protein-Network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence J Amer Med Infor Assoc 18:392-402, 2011 [PMID21672909]

149. **Stadler WM**, Lerner SP, Groshen S, Stein JP, Shi S-R, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L, Hall C, Skinner DG, Cote RJ. A phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin Oncol 29:3443-3449, 2011. [PMID:21810677]

150. Sharma MR, Wroblewski K, Polite BN, Knost JA, Kozloff MF, Modi S, Sleckman BG, Taber D, Vokes EE, **Stadler WM**, Kindler HL. Dasatinib in previously treated metastatic colorectal cancer: A phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs, 30:1211-1215, 2012 (ePub ahead of print 2011). [PMID:21552992]

151. Pili R, Häggman, M, **Stadler W.M**, Gingrich J, Assikis V, Björk A, Nordle Ö, Forsberg G, Carducci MA, Armstrong A.J. Phase II Randomized double blind placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 29:4022-4028, 2011 [PMID: 21931019]

152. Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, **Stadler WM**, Conzen SD. Serum/glucocorticoid Regulated Kinase 1 Expression as a Potential Biomarker for Androgen Pathway Activation in Prostate Cancer. The Prostate 72(2):157-64, 2012. [PMID:21563193]

153. Ward JE, Karrison T, Chatta G, Hussain M, Shevrin, D, Szmulewitz RZ, O'Donnell PH, **Stadler WM**, Posadas EM. A randomized phase II stud of pazopanib in castrate-sensitive prostate cancer: A University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer and Prostatic Diseases, 15:87-92, 2012 (ePub ahead of print 2011) [PMID: 22006050]

154. Oh WK, Galsky MD, **Stadler WM**, Srinivas S, Chu F, Bubley GJ, Goddard J, Dunbar J, Ross RW. Multicenter phase 2 trial of the Hsp-90 inhibitor, IPI-504 (retaspimycin hydrochloride), in patients with castration-resistant prostate cancer. Urology 78:626-630, 2011. [PMID:21762967]

155. Kayhan A, Yang C, Lakadamyalı H, Agrawal G, Karzmar G, **Stadler WM**, Oto A. Dynamic contrast-enhanced magnetic resonance imaging findings of bone metastases in patients with prostate cancer. World J Radiology 3:1-00, 2011, [PMID 22229077]

156. Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar G, **Stadler WM**. Diffusion weighted and dynamic contrast enhanced MR imaging of prostate cancer: Correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 197:1382-90, 2011 [PMID:22109293]

157. Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, **Stadler WM**, Ratain MJ. Resampling phase III data to assess phase II trial designs and endpoints in renal cancer. Clin Cancer Res 18:2309-2315, 2012 [PMID:22287601]

158. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, **Stadler WM**, Morris M, Kantoff P, Monk P, Kaplan E, Vogelzang NJ, Small EJ. A randomized double-blind placebo controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration resistant prostate cancer. J Clin Oncol 30(13):1534-40, 2012 [PMID: 22454414]

159. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, **Stadler WM**, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012; 118(11):2962-70, 2012 [PMID:22020702]

160. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA, Quinn DI, Koczywas M, Brahmer J, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, **Stadler WM**, Vokes EE. Multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30(20):2509-15, 2012 [PMID:22665541]

161. Karrison T, Ratain M, **Stadler WM**, Rosner G. Estimation of progression-free survival for all treated patients in the randomized discontinuation trial design. The American Statistician 66:155-162, 2012 [http://dx.doi.org/10.1080/00031305.2012.720900]

162. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, **Stadler WM**, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 78:76-80, 2012 [PMID: 22831987]

163. Ranck MC, Golden DW, Corbin KS, Hasselle MD, Liauw SL, **Stadler WM**, Hahn OM, Weichselbaum RR, Salama JK. Stereotactic Body Radiotherapy for the Treatment of Oligometastatic Renal Cell Carcinoma. Am J Clin Oncol. 3:589-95, 2013 [PMID: 22868242]

164. Liauw S, Pitroda S, Eggener S, **Stadler WM**, Vannier M, Oto A. Evaluation of the Prostate Bed for Local Recurrence after Radical Prostatectomy using Endorectal MRI. Int Journal of Rad Oncol Biol Physics. 85:378-84, 2013 [PMID: 22717242]

165. Haney CR, Fan X, Markiewicz E, Mustafi D, Karczmar GS, **Stadler WM**. Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI – Comparing pixel-by-pixel with region of interest analysis. Technol Cancer Res Treat. 12(1):71-8, 2013 [PMID: 22905809]

166. Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, **Stadler WM**, Watson S, Eggener S. Magnetic Resonance Imaging-Guided Focal Laser Ablation for Prostate Cancer: Phase I Trial Radiology. 267:932-940, 2013 [PMID: 23440319]

167. Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong Y-N, Ko Y-J, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TB, **Stadler WM**, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled prospective phase II trials. Eur Urol. 63:717-23, 2013 [PMID: 23206856]

168. Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, **Stadler WM**, Karrison TG, Ratain MJ, Bies RR. Estimation of renal cell carcinoma treatment effects from disease progression modeling of placebo data. Clin Pharmacol Ther 93:345-351, 2013 [PMID: 23443753]

169. Rini BI, Garrett M, Dutcher JP, Rixe O, Wilding G, **Stadler WM**, Pithavala YK, Kim S, Tarazi J, Motzer RJ. Axitinib in metastatic renal cell carcinoma: Results of a pharmacokinetic and pharmacodynamic analysis J Clin Pharmacol. 53:491-504, 2013 [PMID: 23553560]

170. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, **Stadler WM**, Morris M, Kantoff P, Monk JP, Carducci M, Small EJ. The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance) Cancer 119(20):3636-43, 2013 [PMID: 23913744]

171. Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Rathmell WK, McDermott DF, **Stadler WM.** FDG-PET as a Predictive Biomarker for Therapy With Everolimus in Metastatic Renal Cell Cancer (mRCC). Cancer Medicine 2:545-52, 2013 [PMID: 24156027]

172. Armstrong AJ, Häggman M, **Stadler WM**, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle Ö, Forsberg G, Carducci MA, Pili R. Long-term survival and biomarker correlates of Tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res 19:6891-6901, 2013 [PMID 24255071]

173. Halabi S, Rini B, Escudier B, Archer LE, **Stadler WM**, Small EJ. Progression-free survival as an intermediate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer 120:52-60, 2014 [PMID: 24347384]

174. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy P, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, **Stadler WM**, Larson RA, Stock W, Odenike O. Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myeloid Leukemia (AML): A University of Chicago Phase II Consortium trial. Clin Cancer Res 20: 490, 2014 [PMID: 24178622]

175. Dreicer R, MacLean D, Suri A, **Stadler WM**, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. Phase 1/2 trial of orteronel (TAK-700) – an investigational 17,20-lyase inhibitor – in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 20: 1335-1344, 2014 [PMID: 24418642]

176. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, **Stadler W**, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202. J Clin Oncol. 32:1143-50, 2014 [PMID: 24590644]

177. Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu AQ, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, **Stadler WM**, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, di Lorenzo G, Sternberg CN, Mehta AN, Sonpavde G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 113:E137-43, 2014. [PMID:24219029]

178. Grivas PD, Daignault S, Tagawa ST, Nanus DM, **Stadler WM**, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 120(5):692-701, 2014 [PMID: 24249435]

179. **Stadler WM**, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin C-C, Mahoney J, Modi S, Lee P, Ernstoff MS, Su W-C, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci M. An Open-Label, Single-Arm Phase II Trial of the Polo-Like Kinase Inhibitor Volasertib (BI 6727) in Patients With Locally Advanced or Metastatic Urothelial Cancer 120:976-82, 2014 [PMID: 24339028]

180. Garcia JA, Hudes GR, Choueiri TK, **Stadler WM**, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y, Schwartz JD, Thompson JA. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer 120:1647-55, 2014 [PMID: 24577874]

181. VanderWeele DJ, Brown CD, Taxy JB, Gillard M, Hatcher DM, Tom WR, **Stadler WM**, White KP. Low-grade prostate cancer diverges early from high grade and metastatic disease. Cancer Sci. 105(8):1079-85, 2014 [PMID:24890684]

182. Lerario AM, Worden FP, Ramm CA, Hasseltine EA, **Stadler WM**, Else T, Shah MH, Agamah E, Rao K, Hammer GD. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer 5(4):232-9, 2014 [PMID: 24849545]

183. Armstrong AJ, Kaboteh R, Carducci MA, Damber J-E, **Stadler WM**, Hansen M, Edenbrandt L, Forsberg F, Nordle Ö, Pili R, Morris MJ. Assessment of bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer Urologic Oncology. 32(8):1308-16, 2014 [PMID: 25240761]

184. Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, **Stadler WM**, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer 50(18):3145-52, 2014 [PMID:25457633]

185. Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile A, **Stadler WM**, Vander Griend DJ, Szmulewitz RZ. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med 26;12(1):313, 2014 [PMID: 25424879]

186. von Rundstedt FC, Mata DA, Groshen S, Stein JP, Skinner DG, **Stadler WM**, Cote RJ, Kryvenko ON, Godoy G, Lerner SP. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 116:44-49, 2015 [PMID:25413313]

187. Mata DA, Groshen S, Von Rundstedt FC, Skinner DG, **Stadler WM**, Cote RJ, Stein JP, Lerner SP. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 111:923-8, 2015 [PMID: 25873574]

188. Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, **Stadler WM**, Schuetze SM. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 26(7):1459-64, 2015 [PMID: 25858498]

189. Chen Y, Rini BI, Motzer RJ, Dutcher JP, Rixe O, Wilding G, **Stadler WM**, Tarazi1 J, Garrett M, Pithavala YK. Effect of renal impairment on the pharmacokinetics and safety of axitinib. Targeted Oncology (online ahead of press), DOI: 10.1007/s11523-015-0389-2; 2015 [PMID: 26400730]

190. Catenacci DVT, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman1 B, Lenz H-J, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Vannier M, Wang X, **Stadler WM**, de Sauvage FJ, Kindler HL. A Randomized Phase Ib/II Study of Gemcitabine and Placebo/Vismodegib, a Hedgehog Pathway Inhibitor, in Patients with Metastatic Pancreatic Cancer. J Clin Oncol 33(36):4284-92. doi: 10.1200/JCO.2015.62.8719, 2015 [PMID: 26527777]

191. Stein MN, Hussain M, **Stadler WM**, Liu G, Tereshchenko IV, Goodin S, Jeyamohan C, Kaufman HL, Mehnert J, DiPaola RS. A Phase II Study of AT-101 to Overcome Bcl-2 Mediated Resistance to Androgen Deprivation Therapy in Patients with Newly Diagnosed Castration Sensitive Metastatic Prostate Cancer. Clin Genitourinary Ca 14(1):22-7. doi: 10.1016/j.clgc.2015.09.010, 2016 [PMID: 26476589]

192. Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JI III, Shen J, Gururajan M, Sievert M, **Stadler WM**. A phase 2 study of saracatinib (AZD0530) as a metastasis inhibitor in advanced metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. The Prostate 76(3):286-93. doi: 10.1002/pros.23119, 2016 [PMID: 26493492]

193. Owonikoko TK, Hussain A, **Stadler WM**, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, Cohen LJ. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemo Pharm 77(1):155-62. doi: 10.1007/s00280-015-2909-2, 2016 [PMID: 26576779]

194. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, and the **Grading Committee**. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Path 40(2):244-52. doi:10.1097/PAS.0000000000000530, 2016 [PMID: 26492179]

195. Armstrong AJ, Halabi S, Eisen T, Broderick S, **Stadler WM**, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cel carcinoma (ASPEN): a multicenter, open-label, randomized phase 2 trial. Lancet Oncol 17:378-88. doi: 10.1016/S1470-2045(15)00515-X, 2016 [PMID: 26794930]

196. Scher HI, Morris MJ, **Stadler WM**, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D Stein MN, Rathkopf DE, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin M-E, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations from the Prostate Cancer Clinical Trials Working Group (PCWG3) J Clin Oncol 34:1402-18, doi: 10.1200/JCO.2015.64.2702, 2016 [PMID: 26903579]

197. Sweis RF, Spranger S, Bao R, Paner GP, **Stadler WM**, Steinberg G, Gajewski TF. Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res; 4: 563–8, 2016 doi: 10.1158/2326-6066.CIR-15-0274 [PMID: 27197067]

198. Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL 3rd, Karrison T, **Stadler WM**, Nakamura Y, O'Donnell PH. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 34:2165-2171, 2016 [PMID: 27044931]

199. Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, **Stadler WM**, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen LJ, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 22: 5461–71, 2016 [PMID: 27169994]

200. O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, **Stadler WM**, Bajorin DF. Clinical Evaluation of Cisplatin Sensitivity Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourinary Cancer 14:511–517 2016 [PMID: 27150640]

201. Heery CR, Madan RA, Stein MN, **Stadler WM**, DiPaola RS, Rauckhorst M, Steinberg SM, Marté JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL. Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget.7:69014-69023, 2016 [PMID: 27486817]

202. Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O''Donnell PH, Fishkin P, Karrison T, **Stadler WM**. Dynamic contrast enhanced-magnetic resonance imaging as a pharmacodynamic biomarker for pazopanib in metastatic renal carcinoma. Clin Genitourinary Ca 15:207-212, 2017 doi: 10.1016/j.clgc.2016.08.011 PMID: [27634566]

203. McKillip RP, Borden BA, Galecki P, Ham SA, Patrick-Miller L, Hall JP, Hussain S, Danahey K, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, **Stadler WM**, Ratain MJ, Meltzer DO, O'Donnell PH. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2016 [Epub ahead of print] doi: 10.1002/cpt.586 [PMID: 27981566]

204. O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, Klammer C, Hussain S, Siegler M, Sorrentino MJ, Davis AM, Sacro YA, Nanda R, Polonsky TS, Koyner JL, Burnet DL, Lipstreuer K, Rubin DT, Mulcahy C, Strek ME, Harper W, Cifu AS, Polite B, Patrick-Miller L, Yeo KJ, Leung EK, Volchenboum SL, Altman RB, Olopade OI, **Stadler WM**, Meltzer DO, Ratain MJ. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 102(5):859-869, 2017 doi: 10.1002/cpt.709 [PMID: 28398598]

205. Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin J, Cohen KS, Knost JA, **Stadler WM**, Doyle A, Karrison T, Gordon L, Evens AM. University of Chicago Phase II Consortium Trial of Selumetinib (MEKi) Demonstrates Low Tolerability and Efficacy in Relapsed DLBCL Br J Haematol., 181:264-267, 2018. doi: 10.1111/bjh.14544. [PMID: 28419407]

206. Dorff TB, Longmate JA, Pal SK, **Stadler WM**, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN Jr. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer 123:4566-4573, 2017 doi: 10.1002/cncr.30942. [PMID: 28832978]

207. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, **Stadler W**, Carducci M, Coomes R, DiPaola RS.Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 387:2008-16, 2016. doi: 10.1016/S0140-6736(16)00559-6. PMID: 26969090.

208. Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, **Stadler WM,** Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 16:213-218, 2018. doi: 10.1016/j.clgc.2017.11.004. PMID: 29289519

209. Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, **Stadler WM**, Feng FY, Chinnaiyan AM. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 36:991-999, 2018. doi: 10.1200/JCO.2017.75.7310. PMID: 29261439

210. Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, **Stadler WM**, Ratain MJ. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36(14):1389-1395, 2018. doi: 10.1200/JCO.2017.76.4381. PMID: 29590007

211. Danzig MR, Mallin K, McKiernan JM, **Stadler WM**, Sridhar SS, Morgan TM, Bochner BH, Lee CT. Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. Cancer. 124(12):2507-2514, 2018 doi: 10.1002/cncr.31372. PMID: 29624636

212. Wellmann R, Borden BA, Danahey K, Nanda R, Polite BN, **Stadler WM**, Ratain MJ, O'Donnell PH. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 124(14):3052-3065. 2018. doi: 10.1002/cncr.31382. PMID: 29742281

213. Jelinek MJ, Lee SM, Wyche Okpareke A, Wing C, Koyner JL, Murray PT, **Stadler WM**, O' Donnell PH. Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase-Associated Lipocalin and Cystatin C. Clin Transl Sci. 11(4):420-427, 2018. doi: 10.1111/cts.12547. PMID: 29691991. PMID: 30083962

214. Monk P, Liu G, **Stadler WM**, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 Oct;36(5):919-926. doi: 10.1007/s10637-018-0630-9. Epub 2018 Aug 7.

215. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, **Stadler WM**, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Oct 5. PMID: 29867230

216. Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, **Stadler WM**, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00060. Epub 2018 Aug 16. PMID: 30761386

217. Borden BA, Galecki P, Wellmann R, Danahey K, Lee SM, Patrick-Miller L, Sorrentino MJ, Nanda R, Koyner JL, Polonsky TS, **Stadler WM**, Mulcahy C, Kavitt RT, Ratain MJ, Meltzer DO, O'Donnell PH. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics. 2019 Feb;29(2):31-38. doi: 10.1097/FPC.0000000000000362. PMID: 30531377

218. Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, **Stadler WM**, Karmali R, Venugopal P, Rapoport AP, Smith SM.Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 Feb 1. doi: 10.1002/cncr.31877. PMID: 30707764

219. Borden BA, Lee SM, Danahey K, Galecki P, Patrick-Miller L, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, **Stadler WM,** Kavitt RT, Meltzer DO, Ratain MJ, O'Donnell PH. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 Feb 11. doi: 10.1038/s41397-019-0076-2. PMID: 30713337

220. Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, **Stadler WM**, Schuetze SM. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2019 Aug 1;30(8):1405. doi: 10.1093/annonc/mdy557. PMID: 30726873

221. Labbate C, Hatogai K, Werntz R, **Stadler WM**, Steinberg GD, Eggener S, Sweis RF. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 Mar 11;7(1):66. doi: 10.1186/s40425-019-0546-8. PMID: 30857555

222. Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, **Stadler WM**, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9. PMID: 31079938

223. Sagar V, Vatapalli R, Lysy B, Pamarthy S, Anker JF, Rodriguez Y, Han H, Unno K, **Stadler WM**, Catalona WJ, Hussain M, Gill PS, Abdulkadir SA. EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells. Cell Death Dis. 2019 Oct 22;10(11):801. doi: 10.1038/s41419-019-2042-y. PMID: 31641103

224. Atkins MB, Rini BI, Motzer RJ, Powles T, McDermott DF, Suarez C, Bracarda S, **Stadler WM**, Donskov F, Gurney H, Oudard S, Uemura M, Lam ET, Grüllich C, Quach C, Carroll S, Ding B, Zhu Q, Piault-Louis E, Schiff C, Escudier B. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clin Cancer Res. 26: 2506-2514. doi: 10.1158/1078-0432.CCR-19-2838. PMID: 32127394.

225. Kochanny SE, Worden FP, Adkins DR, Lim DW, Bauman JE, Wagner SA, Brisson RJ, Karrison TG, **Stadler WM**, Vokes EE, Seiwert TY. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 Feb 19. doi: 10.1002/cncr.32762. [Epub ahead of print]. PMID: 32073648

226. Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, Wade JL, Sleckman BG, Anderson D, Brisson RJ, Karrison T, **Stadler WM**, Vokes EE. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 126:3237-3243, 2020 May 4. doi: 10.1002/cncr.32929. PMID: 32365226

Book chapters, reviews, letters, and editorials (* = peer reviewed).

1. *__Stadler W__, Vogelzang N. Human Renal Cancer Carcinogenesis - A Review of Recent Advances. Ann Oncol 4:451-462, 1993

2. __Stadler W__, Vogelzang N. Renal Cancer. Chapter in Handbook of Chemotherapy in Clinical Oncology, 2nd ed., Armand JP, Cvitkovic E, Droz JP, Khoury S, eds. pp 540-543. Scientific Communication International Ltd, 1993.

3. *__Stadler WM__. Molecular events in the initiation and progression of bladder cancer (Review) Int J Onc 3:549-557, 1993

4. Vogelzang NJ, __Stadler W__, Rukstalis D. Cure of bladder cancer: Need for multidisciplinary efforts [editorial] J Urol 151:605-606, 1994

5. __Stadler WM__, Vogelzang NJ. Low dose interleukin-2 therapy in the treatment of metastatic renal cell carcinoma. Sem Oncol. 22: 67-73,1995

6. __Stadler WM__, Elwell CM, Jones WG. Overview on penile cancer in Comprehensive Textbook of Genitourinary Oncology, Vogelzang NJ, Scardino P, Shipley B, Coffey D, eds. Williams and Wilkins, 1996

7. __Stadler WM__,. Chemotherapy for penile cancer in Comprehensive Textbook of Genitourinary Oncology, Vogelzang NJ, Scardino P, Shipley B, Coffey D, eds. Williams and Wilkins, 1996

8. __Stadler WM__, Kuzel TM, Raghavan D, Levine E, Vogelzang NJ, Roth B, Dorr FA. The use of gemcitabine in metastatic bladder cancer. Eur J Cancer 33, Suppl 1: S23-S26, 1997

9. Fagbemi S, __Stadler WM__. Advanced bladder cancer: New molecules and regimens in Adjuvant Treatment In Urological Cancer. Abi-Aad A, deKernion JB eds. Parthenon Publishing Group NY, NY, 1997

10. Fagbemi SO, __Stadler WM__. New chemotherapy regimens for advanced bladder cancer. Semin Urol Oncol 16:23-29, 1998

11. *Yoshida BA, Chekmareva MA, Wharam JF, Kadkhodaian M, __Stadler W__, Boyer A, Watabe K, Nelson JB, Rinker-Schaeffer CW. Prostate cancer metastasis-suppressor genes: A current perspective. In Vivo 12: 49-58, 1998

12. * Vogelzang NJ, __Stadler WM__. Kidney Cancer. Lancet 352:1691-1696, 1998

13. __Stadler WM__, Vogelzang NJ. Metastatic Renal Cell Cancer - Back to the drawing board. New Engl J Med (letter) 339:849, 1998

14. *Vogelzang NJ, **Stadler WM**. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology 53:243-50, 1999

15. **Stadler WM**, Brendler CB. The biology of bladder cancer in Bladder Cancer: Biology, Diagnosis and Management, Syrigos KN, Skinner D, eds. Oxford University Press, New York, 1999, pp141-156

16. **Stadler WM**. Genitourinary malignancies: Bladder, urethral, and penile cancers. Oncologic Therapies, Vokes EE, Golomb HM eds. Springer-Verlag, 829-846, 1999

17. **Stadler WM**. Drug development of noncytoxic agents: Some further thoughts. CALGB Newsletter, 1999

18. Bigelow KR, Spiotto MT, **Stadler WM**. Antiangiogenic agents and strategies, in Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical Management, Bukowski RM, Novick A, eds Humana Press Inc, Totowa, NJ, 2000

19. ***Stadler WM**, Ratain MJ. Development of Target-based anti-neoplastic agents. Invest New Drugs 18:7-16, 2000

20. **Stadler WM**, Roth BJ. Bladder Cancer: Chemotherapy for metastatic disease, in Comprehensive Textbook of Genitourinary Oncology, 2nd edition, Vogelzang NJ, Scardino P, Shipley B, Coffey D, eds. pp 513-524, Williams and Wilkins, 2000

21. **Stadler WM**. Chemotherapy for penile cancer, in Comprehensive Textbook of Genitourinary Oncology, 2nd edition, Vogelzang NJ, Scardino P, Shipley B, Coffey D, eds. pp 1070-1072, Williams and Wilkins, 2000

22. **Stadler WM**. Renal cancer immunotherapy: A ray of hope or regression to the mean? [editorial] Cancer Investigation 18,490-491, 2000

23. Tenent T, Rinker-Schaeffer CW, **Stadler WM**. Angiogenesis Inhibitors, Current Oncology Reports 2:11-16, 2000

24. **Stadler WM**. Fluorodeoxyuridine in Outline of Oncology Therapeutics, Ratain MJ, Tempero M, Skosey C eds. WB Saunders, p43, 2001

25. Cohen EEW, **Stadler WM**. Treatment of metastatic urothelial cancer in the post-MVAC era. World Journal of Urology 19:126-132, 2001

26. Ryan CW, Vogelzang NJ, **Stadler WM**. Rationale for docetaxel and exisulind for hormone refractory prostate cancer Advances in Prostate Cancer 5:5-7, 2001

27. Ratain MJ, **Stadler WM**. Clinical Trial Designs for Cytostatic Agents: New Approaches Are Needed (letter) J Clin Oncol 19:3154, 2001

28. George C, **Stadler WM**, Vogelzang NJ. Primary neoplasms of the kidney and renal pelvis. In Schier RW (ed), Diseases of the Kidney (7th edition) Philadelphia: Lippincott Williams and Wilkins, 2001

29. Ryan CW, **Stadler WM**, Vogelzang NJ. Docetaxel and exisulind in hormone refractory prostate cancer. Seminars in Oncol 28 (Supp15):56-61, 2001

30. **Stadler, WM**. New trial designs to assess antitumor and antiproliferative agents in prostate cancer. Invest New Drugs 20:201-208, 2002

31. **Stadler WM**. Gemcitabine doublets in advanced urothelial cancer. Seminars in Oncol 29, Supp 3:15-19, 2002

32. Davis NB, **Stadler WM**. Genitourinary malignancies: Bladder, urethral, and penile cancers. Oncologic Therapies, 2nd edition, Vokes EE, Golomb HM eds. Springer-Verlag, Berlin, Heidelberg, New York. 2002 pp521-530

33. George C, **Stadler WM.** Genitourinary malignancies: Testicular cancer. Oncologic Therapies, 2nd edition, Vokes EE, Golomb HM eds. Springer-Verlag, Berlin, Heidelberg, New York. 2002 pp499-512

34. *Kauffman EC, Robinson VL, **Stadler WM**, Sokoloff MH, Rinker-Schaeffer CW. Metastasis Suppression: The Evolving Role of Metastasis Suppressor Genes in Regulating Cancer Cell Growth at the Secondary Site. J Urol 169:1122-1133, 2003

35. **Stadler WM**, Lerner SP. Perioperative Chemotherapy in Locally Advanced Bladder Cancer: The End of A Beginning. Lancet 361:1922-1923, 2003

36. *Winquist E, Vincent M, **Stadler W**. Acute Bilateral Abducens Paralysis Due to Oxaliplatin J Natl Cancer Inst 95:488-489, 2003

37. **Stadler WM**, Wilding G. Angiogenesis inhibitors in genitourinary cancer. Crit Rev in Oncol Hem 46 (Suppl 1):41-47, 2003

38. George CM, **Stadler WM**. The role of systemic chemotherapy in the treatment of kidney cancer. In Kidney Cancer, Figlin RA ed. Kluwer Academic Publishers, [Cancer Treat Res.116:173-182] Norwell, MA, 2003

39. **Stadler W**. Developing drugs that do not cause tumor regression. Clinical Advances in Hematology and Oncology, 1:652-653, 2003

40. **Stadler WM**, Cote R, Lerner S, Stein J, Groshen S. Phase II trial assessing 3 cycles of MVAC in organ-confined bladder cancer with p53. Oncology Times 26:4, 2004 (letter)

41. **Stadler WM**. New growth factor inhibitors crack the code at cellular level to shut down signal transduction pathways. Kidney Ca J 1:7-10, 2004

42. **Stadler WM**. Current approaches to advanced kidney cancer. in ASCO Educational Book, 2004, American Society Clinical Oncology, Alexandria, VA, 2004, pp258-264

43. *Berger JC, Vander Griend D, **Stadler WM**, Rinker-Schaeffer C. Metastasis suppressor genes: signal transduction, crosstalk and the potential for modulating the behavior of metastatic cells. Anticancer Drugs 15:559-568, 2004

44. **Stadler WM**. Therapeutic options for variant renal cancer: A true orphan disease. Clin Cancer Res 10:6393s-6396s, 2004

45. Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MG, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, **Stadler WM**, Teh BT, Yang JC, King L. Innovations and Challenges in Renal Cancer: Consensus Statement. Clin Cancer Res 10:6277s-6281s, 2004

46. **Stadler WM.** Cytotoxic chemotherapy for metastatic renal cell carcinoma. Urologe A. Suppl 2, S145, 2004

47. Desai AA, **Stadler WM**. Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents. Curr Oncol Rep 7:114-122, 2005

48. **Stadler WM**. Chapter 30: Genitourinary Cancer in Cancer: Principles and Practice of Oncology Review, G. Govinden ed, Lippincott, Williams, and Wilkens, Philadelphia, PA, 2005

49. *Mohile SG, **Stadler WM**. Is advanced age an adverse prognostic factor for treatment with platinum-based combination therapy for metastatic urothelial cancer? Nature, Clin Pract Oncol 2:392-393, 2005

50. **Stadler WM**, Michaelis L, Ratain MJ. Randomized phase II trials and PSA in prostate cancer: Much ado about nothing? (letter) J. Clin. Oncol 23:8124-8125, 2005

51. **Stadler WM**. Targeted therapies for the treatment of advanced renal cell carcinoma. Cancer 104:2323-2333, 2005

52. Jin JJ, Boyar M, Petrylak DP, **Stadler WM**. Adjuvant chemotherapy for invasive bladder cancer, in Bladder Cancer, Stein JP, Sternberg C, Schoenberg MP eds, Taylor and Francis Medical, Abingdon, UK, 2005

53. **Stadler WM**. Chemotherapy and Other Approaches in the Management of Metastatic Renal Cell Carcinoma in Comprehensive Textbook of Genitourinary Oncology, 3rd edition, Vogelzang NJ, Scardino P, Shipley B, Debruyne F.M.J, Linehan WM eds. Lippincott, Williams, and Wilkens pp796-805, Philadelphia, PA, 2006

54. **Stadler WM**. New targets, therapies, and toxicities: Lessons to be learned. (editorial) J Clin Oncol 24:4-5, 2006

55. Sternberg C, Donat SM, Bellmunt J, Millikan RE, **Stadler W**, DeMulder P,Sherif A, Von der Maase H, Tsukamoto T, Soloway M. Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy and metastatic cancer. In Bladder Tumors, Soloway M, Carmack A, Khoury S, eds. Health Publication Ltd, 2006 (ISBN 0-9546956-4-X)

56. Small EJ, Halabi S, Kantoff P, D'Amico A, **Stadler W**, Kelley WK, Mohler J, Bajorin D, Vogelzang NJ. Activities and Accomplishments of the CALGB Genitourinary (GU) Committee Clin Cancer Res, 12(11 pt 2):3596s-3600s, 2006

57. ***Stadler WM**. Development of growth inhibitory agents in urologic and other malignancies. British J Urol. 98:497-502, 2006

58. **Stadler W.** New therapeutic options for renal cell carcinoma. Clin Adv in Hematalogy Oncology 4: 429-430, 2006

59. *Hahn O, **Stadler WM**. Sorafenib. Curr Opinion Oncol. 18:615-621, 2006

60. **Stadler WM**, Bro W. Physicians, patients, industry, and regulators: An unholy but necessary alliance for cancer clinical trials. Kidney Ca Journal 4:4, 2006

61. ***Stadler WM**. Fuzzy thinking on biomarkers. Urologic Oncology, 25:97-100, 2007

62. ***Stadler WM**. Chromosomes, Hypoxia, Angiogenesis, and Trial Design, a brief history of renal cancer drug development. Clin Cancer Res, 13:1630-1633, 2007

63. *Furge KA, Tan MH, Dykema K, Kort E, **Stadler W**, Yao X, Zhou M, Teh BT. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene 26:1346-1350, 2007

64. *Knight DA, **Stadler WM**. Prognostic factors in localized renal cell cancer. Brit J Urol 99:1212-1216, 2007

65. ***Stadler WM**. The randomized discontinuation trial: A phase II design to assess growth inhibitory agents. Molec. Cancer Therap. 6:1180-1185, 2007

66. Hahn O, **Stadler WM**. Renal cell carcinoma in Molecular Targeting in Oncology, Antman K, Kaufman HL, Wadler S, eds. Humana Press, Totowa, NJ, 2007 (ISBN13: 978-1-58829-577-4)

67. *Szmulewitz R, **Stadler W**. A new standard of care for metastatic renal-cell carcinoma? Practice Point Commentary Nature, Clinical Practice Oncology 4:458-459, 2007

68. *Bylow K, Mohile SG, **Stadler WM**, Dale W. Does androgen deprivation therapy accelerate the development of frailty in older men with prostate cancer? A conceptual review. Cancer 2604-2613 PMID: 17960609, 2007

69. **Stadler, WM.** Commentary on Margel, et al., Serum tumor markers may predict overall and disease-specific survival in patients with clinically organ-confined invasive bladder cancer. J Urol 178:2300-2301, PMID: 17936826, 2007.

70. *Bradley DA, Dunn R, Nanus D, **Stadler W**, Dreicer R, Rosenberg J, Smith DC, Hussain M. Randomized Blinded Phase II Trial of Maintenance Sunitinib versus Placebo Post Chemotherapy for Patients with Advanced Urothelial Carcinoma: Scientific Rational and Study Design. Clinical Genitourinary Ca 5:460-463, 2007

71. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, **Stadler WM**, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: Revolution or evolution? Eur J Cancer. 44:8-11 PMID: 17981025, 2008

72. Jin JO, **Stadler WM**. Chemotherapy for metastatic clear cell renal cell cancer, in Clinical Management of Renal Tumors, Bukowski R, Novick A (eds).Humana Press, Chapt 24, pp385-397 ISBN: 978-1-58829-251-3, 2008

73. **Stadler WM**. Cytotoxic chemotherapy for metastatic renal cell cancer in Renal Cell Cancer, Rosette J, van Poppel H, Sternberg C. Springer-Verlag, London, ISBN: 978-1-84628-385-7, 2008

74. Jin JO, Boyar M, Petrylak DP, **Stadler WM**. Adjuvant chemotherapy for invasive bladder cancer in Treatment and Management of Bladder Cancer, Lerner S, Schoenberg M, Sternberg C eds. Informa Healthcare, London, UK, ISBN-10: 0-415-46217-7 (ISBN-13: 978-0-415-46217-4), 2008

75. Rathmell WK, **Stadler WM**, Rini BI. Rational strategies for the choice of therapy for patients with metastatic kidney cancer. in American Society of Clinical Oncology Educational Book., Govindan R (ed) (ISSN 1548-8748). ASCO, Alexandria VA, pp 192-199 2008

76. **Stadler WM**. Beyond RECIST: Meaningful and acceptable endpoints in phase II trials. American Society of Clinical Oncology Educational Book, Govindan R (ed) (ISSN 1548-8748). ASCO, Alexandria VA, pp 89-94, 2008

77. **Stadler, WM.** Commentary on Tannir, et al, A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180:872, PMID: 18635199, 2008.

78. Milowsky MI, **Stadler WM**, Bajorin DF. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Intl 102:1339-1344, 2008. doi: 10.1111/j.1464-410X.2008.07980.x

79. *O'Donnell PH, **Stadler WM**. The role of chemotherapy in upper tract urothelial carcinoma. Advances in Urology vol. 2009, Article ID 419028, 4 pages, 2009. doi:10.1155/2009/419028

80. *Chung E, **Stadler WM**. VEGF pathway targeted therapy as initial systemic treatment of renal cancer. Clin Genitourinary Cancer 6:S22-S28, 2008

81. **Stadler WM.** Deconstructing the design of phase II trials: Why we need to look anew at appropriate endpoints. (guest editor) Kidney Ca J 6:181, 2008

82. ***Stadler WM.** VEGF and mTOR pathway targeted therapy and beyond in renal cancer. Clinical and Translational Oncology 11 (Extraord. 2):37-40, 2009

83. **Stadler WM.** Effective therapy for metastatic renal cancer, whither to now? (editorial). J Clin Oncol 27:3573-4, 2009 [PMID: 19487371]

84. **Stadler WM**. Chapter 21: Genitourinary Cancer in Cancer: Principles and Practice of Oncology Review, 2nd Edition, G. Govinden ed, Lippincott, Williams, and Wilkens, Philadelphia, PA, 2010

85. ***Stadler WM.** Other paradigms: The randomized discontinuation trial design. Cancer J 15:431-434, 2009 [PMID: 19826364]

86. **Stadler WM.** Prognosis and prediction in a Facebook world. Cancer 115:5368-5370, 2009 [PMID: 19658183]

87. *Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz A, Koehler M, Ratain M, Shankar LK, **Stadler WM**, True LD, Gravell A, Grever MR. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 16:1745-1755, 2010 [PMID: 20215558]

88. ***Stadler WM**, Phillips G, George DJ, Halabi S, Small E. Bevacizumab and Everolimus in renal cancer: A rational way forward. J. Clin Oncol 28:e692-3, 2010 [PMID: 20940194]

89. Ward JE, **Stadler WM**. Pazopanib in Renal Cell Carcinoma. Clin Cancer Res 16:1-5, 2010 [PMID: 21059813]

90. Emerging Cancer Therapeutics: Renal Cancer. **Stadler WM**, guest editor. Demos Medical Publishing, New York, NY, 2011

91. *Sharma MR, **Stadler WM**, Ratain MJ. Randomized phase II trials: A long-term investment with promising returns. J Natl Cancer Inst 103:1093-1100, 2011 [PMID 217-9274]

92. *Nabhan C, Parsons B, Touloukian EZ, **Stadler WM**. Novel approaches and future directions in castration-resistant prostate cancer Ann of Oncol 22:1948-1957, 2011 [PMID: 21252057]

93. *Lussier Y, **Stadler WM**, Chen J. Advantages of genomic complexity: Bioinformatics opportunities in microRNA cancer signatures. JAMIA 19:156-60, 2012 [PMID: 22101905]

94. **Stadler WM**. Chapter 21: Genitourinary Cancer in Cancer: Principles and Practice of Oncology Review, 3rd edition, G. Govinden ed, Lippincott, Williams, and Wilkens, Philadelphia, PA 2012

95. *O'Donnell PH, **Stadler WM**. Pharmacogenomics in Early Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II? Clin Cancer Res 18:2809–16, 2012 [PMID: 22427349]

96. **Stadler, WM**. Renal cancer therapeutics: now what? Oncology (Williston Park). 301:304, 2012 [PMID: 22545315]

97. *Geynisman DM, Szmulewitz RZ, **Stadler WM**. A Trial Postmortem: Challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer. Eur Urol 62:864-6, 2013 [PMID: 22939385]

98. *Sternberg CN, Sonpavde G, **Stadler WM**, Bajorin D, Dreicer R, George D, Milowsky M, Theodorescu D, Vaughn D, Galsky M, Quinn D. Chemotherapy for metastatic transitional cell carcinoma of the urothelium. International Committee Urologic Diseases (ICUD) recommendations Eur Urol 63:58-66, 2013 [PMID: 22917984]

99. *Michaelson MD, **Stadler WM.** Predictive markers in advanced renal cell carcinoma**.** Semin Oncol. 40:459-64, 2013 [PMID: 23972709]

100. ***Stadler WM**. Maturing of Renal Cancer Therapeutics. J Clin Oncol 32:722-4, 2014 [PMID:24516015]

101. Halabi S, Rini BI, Escudier B, **Stadler WM**, Small EJ. Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. (epub ahead of print), 2015 [PMID: 25677867]

102. Vanderweele DJ, **Stadler WM**. The time for molecular phenotyping of prostate cancer is now. Current Controversies in Hematology & Oncology in C*linical Advances in Hematology & Oncology. Vol 13, Issue 9, September 2015*

103. Geynisman DM, **Stadler WM**. Variant Renal Carcinoma Histologies: Therapeutic Considerations, *in* Kidney Cancer, Principles and Practice (Lara P, Jonasch E, eds). Springer, 2015 [ISBN 978-3-319-17903-2]

104. *Rini BI, McKiernan JM, Chang SS, Choueiri, TK, Kenney PA, Landman J, Leibovich BC, Tickoo SK, Vikram R, Zhou M, **Stadler WM**. Kidney. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: pages 739-748

105. *McKiernan JM, Hansel DE, Bochner BH, Efstathiou JA, Konety BR, Lee CT, Plimack ER, Reuter VE, Sridhar S, Vikram R, **Stadler WM**. Renal Pelvis and Ureter. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: pages 749-755

106. *Hansel DE, Bochner BH, Efstathiou JA, Konety BR, Lee CT, McKiernan JM, Plimack ER, Reuter VE, Sridhar S, Vikram R, **Stadler WM**. Urinary Bladder. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: pages 757-765

107. *Hansel DE, Reuter VE, Bochner BH, Efstathiou JA, Konety BR, Lee CT, Plimack ER, Sridhar S, **Stadler WM,** Vikram R, McKiernan JM. Urethra. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: pages 767-776

108. *Drazer MW, **Stadler WM**. The role of testosterone in the treatment of castration-resistant prostate cancer. Cancer J. 22:330-333, 2016 [PMID: 27749326]

109. *Paner GP, **Stadler WM**, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. (17)31064-3. 2018. doi: 10.1016/j.eururo.2017.12.018. PMID: 29325693

110. Szmulewitz RZ, **Stadler WM**, Ratain MJ. Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. J Clin Oncol. 2018 Sep 6:JCO2018793190. doi: 10.1200/JCO.2018.79.3190. PMID: 30188785

111. Szmulewitz RZ, Karrison T, **Stadler WM**, Ratain MJ. Low-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 Sep 6:JCO2018793018. doi: 10.1200/JCO.2018.79.3018. [Epub ahead of print]. PMID: 30188785

112. *Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, **Stadler WM**, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10. PMID: 30968729

113. *Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, **Stadler WM**, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00060. Epub 2018 Aug 16. PMID: 30761386

114. **Stadler WM**. Management of Urothelial Bladder Cancer: Predicting the Future. J Oncol Pract. 2019 Aug;15(8):429-430. doi: 10.1200/JOP.19.00419. PMID: 31404513

115. **Stadler WM**. No interest, no conflict. Cancer. 2020 Jun 4. doi: 10.1002/cncr.32995. Online ahead of print. PMID: 32497250

116. Heiss B, **Stadler WM**. The billion-dollar scrotal cosmesis solution: LHRH analogues, androgen suppression, and adherence. The Cancer Letter, Issue 31, 7/31/20

Abstracts/Scientific Presentations

italics = oral presentation
* = Presented

1. **Stadler W**. The nature of the electron transfer reactions between putidaredoxin and P-450-CAM. Thesis submitted in partial fulfillment for degree of B.S. in Chemistry, 1983

2. *Unger B, Fisher M, **Stadler W**, et al. Expression and characterization of cytochrome P-450-CAM in E. Coli. Abstract, annual meeting, American Society of Biological Chemistry, 1984

3. **Stadler W**. Oncogenes, Differentiation, and Cancer. Review for Boehringer-Ingelheim 100 Year Anniversary Pharmacology Essay Contest, 1985

4. **Stadler W**. Characterization of and myc expression in a HL-60 mutant resistant to DMSO induced differentiation. Thesis submitted in partial fulfillment for degree of M.D., 1988

5. **Stadler W**, Charette J, Whitman G, Vogelzang NJ. A phase II study of 5 day continuous infusion FUDR, leucovorin, and high dose interferon-α2b in metastatic renal cancer. Proc Amer Soc Clin Oncol 11:698, 1992

6. **Stadler W**, Charette J, Whitman G, Vogelzang NJ. Modulation of FUDR by leucovorin and high dose interferon-α2b is not effective in treating metastatic renal carcinoma. Clinical Res 40:425A, 1992

7. ***Stadler WM**, Sherman J, Diaz MO, Olopade O. Chromosome 9p deletions in bladder cancer. Proc Amer Assoc Cancer Res 34:539, 1993

8. **Stadler WM**, Vogelzang NJ, Ratain MJ, Mick R, Richards JM. Physician bias in the entry of patients with metastatic renal cell cancer in phase I trials. Proc Amer Soc Clin Oncol 12:249, 1993

9. ***Stadler W**, Vogelzang N, Ryback ME. A Phase II study of IL-4 in metastatic renal cell cancer (RCC). Proc Soc Surg Onc, 1994

10. ***Stadler WM**, Rukstalis D, Srivastave S, Muul JW. Loss of heterozygosity (LOH) on the 9p chromosomal arm in testicular cancer. Proc Soc Basic Urol Res, 1994

11. *Dreyling MH, **Stadler W**, Hagos F, Olopade OI, Diaz MO, Rowley JD, LeBeau MM, Bohlander SK. Flourescent in situ hybridization to interphase nuclei - Detection of deletions of the interferon gene cluster. Proc Amer Assoc Cancer Res. 35:3612, 1994

12. ***Stadler WM**, Bohlander SK, Diaz MO, Rowley JD, Olopade OI. Transfection of a yeast artificial chromosome spanning the interferon and methylthioadenosine phosphorylase loci on 9p21-22. Proc Amer Assoc Cancer Res. 35:3610, 1994.

13. ***Stadler WM**, Bohlander SK, Diaz MO, Olopade OI. Homozygous deletions in bladder cancer in the region of the 9p21-22 tumor suppressor gene. Proc Amer Soc Clin Oncol. 13:126, 1994

14. **Stadler WM**, Karius D, Rybak ME, Vogelzang NJ. Recombinant human IL-4 in renal cell carcinoma: Evidence of biologic activity without clinical response. Proc Amer Soc Clin Oncol. 13:247, 1994

15. *Nicholas MK, **Stadler WM**, Olopade O. Detection of loss of allelic heterozygosity on human chromosome 9p in gliomas. Proc Am Neurol Assoc, 1994

16. *+**Stadler WM** and Olopade OI, Yeager T, Reznikoff C. Role of p16 and p15 deletions in bladder cancer (BC). Proc. Amer. Urol. Assoc. 153:718, 1995

17. *Goldfischer ER, Rinker-Schaeffer CW, Rukstalis DB, **Stadler W**. Loss of heterozygosity (LOH) on the 9p chromosomal arm in testicular cancer. Proc. Amer. Urol. Assoc., 153:332, 1995

18. **Olopade OI, Gursky S, Pomykala H, Hagos F, Sveen L, Dreyling M, **Stadler WM** and Bohlander S. Identification of candidate tumor suppressor genes (TSG) on chromosome band 9p21-22. Proc. Amer. Assoc. Cancer Res., 36:859, 1995*

19. *__Stadler WM__, Olopade OI, Yeager T, Reznikoff C. p16 and p15 in human papillomavirus type 16 E6 and E7 immortalized urothelium and bladder cancer. Proc. Amer. Assoc. Cancer Res., 36:194, 1995

20. *__Stadler WM__, Siegel R, Hayden CL. NMP22, a nuclear matrix protein, in the urine of patients with cancer. Proc Amer Assoc of Cancer Res, 36:147, 1995

21. *McKay S, **Stadler WM,** Ryback ME, Vogelzang NJ. Subcutaneous granulocyte-macrophage colony stimulating factor (GM-CSF) with or without oral pentoxyfilline in the treatment of patients with metastatic renal cell carcinoma. Proc Amer Soc Clin Oncol, 14:640,1995

22. *__Stadler W__, Kuzel T, Raghavan D, Levine E, Vogelzang N, Dorr FA. A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma. Proc Amer Soc Clin Oncol, 14:638, 1995

23. *Shulman K, **Stadler W**, Vogelzang NJ. High dose continuous IV infusion Interleukin-2 therapy for metastatic renal cell carcinoma, The University of Chicago experience. Proc Amer Soc Clin Oncol, 14:636, 1995

24. Wharam JF, Ferrency SL, Smith RC, Chekmareva MA, **Stadler WM**, Rinker-Schaeffer CW. Identification and Characterization of Candidate Prostate Cancer Metastasis-Suppressor Genes on Human Chromosome 17p12-q21.1. Society of Basic Urology Research Meeting, Chapel Hill, NC, 1995

25. *Kuzel T, **Stadler W**, Raghavan D, Levine E, Vogelzang N, Roth B, Dorr A. Gemcitabine in the treatment of patients with advanced transitional cell carcinoma: A phase II study. Eur J Cancer 31A, Supp 5:1152, 1996

26. Brockstein B, Vogelzang N, Schilsky R, **Stadler W**, Hoehne C, Siortino D, Gibbons J, Anseri R, Garcia J, Ratain M, Vokes E. Pyrazine diazohyroxide: Lack of efficacy in phase II studies of colorectal and renal carcinoma. 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Ann Onc 7 (supp 1): 487, 1996

27. *__*Stadler WM*__*, *Talabay K, Vogelzang NJ. Interleukin-2, interferon-alpha, and cis-retinoic acid: an effective outpatient regimen for metastatic renal cell carcinoma. Proc Amer Soc Clin Oncol 15:602 1996*

28. *Daugherty C,Lyman K, Minami H, Cooper N, Mick R, Vogelzang N, **Stadler W**, Siegler M, Ratain MJ. A feasibility study of informed consent and medical decision-making employing an interactive patient choice design in phase I trials. Proc Amer Soc Clin Oncol 15:352, 1996

29. Sciortino DF, Gibbons J, Gabrys GT, Brockstein B, Vogelzang N, Schilsy R, Ansari R, **Stadler W**, Hoehne C, Garcia J, Ratain M, Vokes E. Pyrazine diazohydroxide: A pharmacodynamic analysis during phase II investigations of metastatic colorectal and renal cell carcinomas. Proc Amer Soc Clin Oncol. 15:386, 1996

30. *Yeager T, Belair CD, Puthenveettil JA, Savelieva EI, **Stadler WM**, Reznikoff CA. Differentiation, senescence, and immortalization of normal human uroepithelial cells in vitro. New England Association for Cancer Research Scientific Symposium.

31. **Reznikoff CA, Belair CD, Yeager TR, Puthenveettil JA, Savelieva E, __*Stadler WM*__. Differentiation, senescence, and immortalization of normal human uroepithelial cells in vitro. 1st, International Bladder Symposium, 1996*

32. **__*Stadler WM*__*, *Yeager T, Belair C, Savelieva L, Puthenveettil J, Reznikoff CA. Senescence and immortalization of human uroepithelial cells: the role(s) of 9p21 loss of heterozygosity and p16 loss. Proc Amer Assoc Cancer Res 37:49, 1996*

33. *Wharam JF, Chekmareva MA, Smith RC, **Stadler WM**, and Rinker-Schaeffer CW. Identification of candidate prostate cancer metastasis-suppressor genes on human chromosome 17p12-q21. Proc Amer Assoc Cancer Res 37:582, 1996

34. **Stadler WM**, Kuzel TM, Ragahavan D, Roth B, Vogelzang NJ, Levine EL and Dorr FA. A phase II study of gemcitabine in bladder cancer. Ann Oncol 7:(supp 5):272, 1996

35. *Kirsh EJ, Baunoch DA, Stadler, WM. Expression of Bcl-2 and Bcl-x in bladder cancer: Correlation with stage, survival, pRb1 and p53 status. J Urol 157: (supplement), 42, 1997

36. **Stadler WM**, Murphy B, Kaufman D, Raghavan D, Voi M. Phase II trial of gemcitabine (gem) plus cisplatin (cddp) in metastatic urothelial cancer (uc). Proc Amer Soc Clin Oncol. 16:1152, 1997

37. **Stadler WM**, Lestingi T, Kuzel T,.Haraf D,.Thompson C, Vogelzang NJ. Phase II trial of selective radiotherapy (rt), granulocyte-macrophage colony stimulating factor (gm-csf) and interleukin-2 (il2) in metastatic renal cell carcinoma (rcc). Proc Amer Soc Clin Oncol. 16:1232, 1997

38. Sobecks RM, **Stadler WM**, Daugherty CK, Ratain MJ, Vogelzang NJ. Vinorelbine and paclitaxel in relapsed metastatic bladder carcinoma. Proc Amer Soc Clin Oncol. 16:1230, 1997

39. Brockstein B, Vogelzang NJ, Kugler J, **Stadler WM**, Vukov A, Dumas M, Klepsch A, Fasanmade A, Ratain MJ, Vokes E. A phase II study of trimethylcolchicinic acid methyl ether d-tartrate in patients with hormone refractory prostate cancer. Proc Amer Soc Clin Oncol. 16:1174, 1997

40. *Vogelzang NJ, **Stadler WM**. Gemcitabine: A new chemotherapeutic agent for the treatment of metastatic bladder cancer in Benign and Malignant Diseases of the Bladder and Prostate Gland, Proceedings from the 3rd annual Advances in Urology Meeting, Dearborn, MI, 10/31/97

41. *+Chien M, Atumian M, **Stadler WM**. Cell cycle and cytotoxicity effects of flavopiridol (FP), a novel cyclin dependent kinase inhibitor, in bladder cancer. Proceedings of 2nd World Congress on Urological Research, 1997

42. ***Stadler W**. Gemcitabine in bladder cancer. Cancer Invest 16 (Suppl 1):10-11, 1998

43. ***Stadler W**, Astumian M, Chien M. Senescence-like growth arrest without $p16^{INK4A}$ expression in normal human urothelial cells exposed to hydrogen peroxide. Bladder Cancer: New Concepts in Biology and Therapy., 1998

44. *Chien M, Astumian M, **Stadler WM**. Normal human urothelial cell response to H_2O_2: senescence-like growth arrest without $p16^{INK4A}$ expression. Proc Amer Assoc Cancer Res, 39:1762, 1998

45. *Mani S, Gordon G, Vogelzang N, Bertucci D, Schilsky R, **Stadler W**, Ratain M. A phase I trial of continuous infusion 5-Fluorouracil and weekly gemcitabine: Updated results of an active combination for renal cell, pancreatic, hepatocellular, and colon carcinoma. 10th NCI-EORTC syposium on new drugs in cancer therapy

46. ***Stadler WM**, Liebowitz DN, Vogelzang NJ, Amato R, Sosman J, Taber D, Vokes E. A Phase II Study of 72 Hour Continuous Infusion (CI) Flavopiridol (FP) in Metastatic Renal Cell Carcinoma (RCC) 10th NCI-EORTC syposium on new drugs in cancer therapy

47. **Turner CD, Steinberg GD, Olopade O, Hagos F, **Stadler WM**. The use of fluorescence in situ hybridization to detect genetic alterations in superficial bladder cancer: A potential marker for early intervention. Univ of Chicago Dept. Of Surgery Charles Huggins Symposium, 1998*

48. ***Stadler WM**, Yeager T, Olopade OI, Reznikoff CA. Bladder cancer: chromosome 9 deletions, ink4a inactivation, and escape from cellular senescence. Univ of Chicago Dept. Of Surgery Charles Huggins Symposium, 1998*

49. ***Stadler WM**, Shapiro CL, Sosmann J, Clark J, Vogelzang NJ, Kuzel T. A multi-institutional study of the angiogenesis inhibitor tnp-470 in metastatic renal cell carcinoma (rcc). Proc Amer Soc Clin Oncol 17: 1192, 1998*

50. *Kaufman D, **Stadler W**, Carducci M, Raghavan D, Murphy B, Aisner J., Kuzel T, John W, Voi M.. Gemcitabine (gem) plus cisplatin (cddp) in metastatic transitional cell carcinoma (tcc): final results of a phase II study. Proc Amer Soc Clin Oncol 17: 1235, 1998

51. Fishkin P, **Stadler WM**, Gibbons J, Vogelzang NJ, Vokes EE. A University of Chicago phase II consortium study (UCPC) of CI-980 in patients (pts) with metastatic renal cell carcinoma (rcc). Proc Amer Soc Clin Oncol 17: 1275, 1998

52. Cataland S, Kuzel T, Vogelzang NJ, **Stadler WM**. A phase II trial of radiation (rt) and outpatient subcutaneous Il-2 plus GM-CSF in patients (pts) with metastatic renal cell cancer (rcc). Proc Amer Soc Clin Oncol 17: 1262, 1998

53. Dumas MC, **Stadler W**, Mikulski S., Vogelzang NJ. Phase II clinical trial of intravenous onconase (onc) in patients (pts) with metastatic renal cell carcinoma (rcc). Proc Amer Soc Clin Oncol 17: 1272, 1998

54. Gordon GS, Mani S, Vogelzang NJ, Bertucci D, Schilsky RL, **Stadler WM**, Ratain MJ. A phase I study of weekly gemcitabine (g) and prolonged continuous infusion (ci) 5-fluorouracil (5FU) with activity in renal cell carcinoma (rcc). Proc Amer Soc Clin Oncol 17: 1280, 1998

55. *Yeager TR, Reznikoff CA, Jarrard DF, Nakada SY, Moon TD, Bruskewitz R, **Stadler WM**, Meisner LF, Gilchrist KW, Newton MA, DeVries S, Waldman FM. Overcoming cellular senescence in human cancer pathogenesis. J Urol 159 (supplement): 1102, 1998

56. *Ryan CW, Vogelzang NJ, Dumas MC, **Stadler WM**. A phase II trial of outpatient subcutaneous GM-CSF, interleukin-2, and interferon-alpha plus oral cis-retinoic acid in patients with metastatic renal cell cancer. Amer Fed Med Res, Midwest Section, 1998

57. *Chien M, Rinker-Schaeffer C, **Stadler WM**. Hydrogen peroxide mediated human urothelial cell growth inhibition and decreased proliferative potential without senescence. Proc. Amer. Assoc. Cancer Res. 40: 1772, 1999

58. *Hollowell CMP, Zaucha MM, Jaeger EB, Roach J, **Stadler WM**, Zimmer SG, and Rinker-Schaeffer C. Activated matrix metalloproteinase 2 (MMP-2) activity is required for the development of dunning AT6.1-Tßgal rat prostate cancer lung metastases. Proc. Amer. Assoc. Cancer Res. 40: 4673, 1999

59. *+Yoshida BA, Dubauskas Z, Chekmareva MA, Zaucha MM, Christiano AP, **Stadler WM**, and Rinker-Schaeffer C. Identification and characterization of candidate prostate cancer metastasis-suppressor genes encoded on human chromosome 17. Proc. Amer. Assoc. Cancer Res. 40: 701, 1999

60. *Holmlund JT, Rudin CM, Mani S, Fleming GF, **Stadler W**, Kunkel K, Kwoh TJ, Geary R, Dorr A, Ratain MJ. Phase I trial of ISIS 5132/ODN 698A, a 20-mer phosphorothioate antisense oligonucleotide inhibitor of c-raf kinase, administered by a 24-hr weekly intravenous infusion to patients with advanced cancer. Proc Amer Soc Clin Oncol 18:605, 1999

61. *Ryan CW, Vogelzang NJ, Dumas MC, **Stadler WM**. A phase II trial of gemcitabine ad 5-FU with IL2 and interferon-alfa in patients with metastatic renal cell cancer. Proc Amer Soc Clin Oncol 18:1264, 1999

62. Bertucci D, Mani S, Vogelzang NJ, **Stadler WM**, Ratain MJ. Phase I trial of continuous infusion 5-fluorouracil and weekly gemcitabine: Updated results. Proc Amer Soc Clin Oncol 18:782, 1999

63. *+**tadler WM**, Dumas M, Flickinger S, Wade J, Vokes EE, Vogelzang NJ. Gemcitabine and 5-fluorouracil in metastatic renal carcinoma: a University of Chicago phase II consortium study. Proc Amer Soc Clin Oncol 18:1277, 1999

64. *Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, **Stadler WM**. GM-CSF in combination immunotherapy for metastatic renal cell carcinoma. Proleukin Second International Congresss, 6/99

65. *Yoshida BA, Chekmareva MA, Dubauskas Z, Rubin MA, Yang X, **Stadler W**, Rinker-Schaeffer CW. MKK4/SEK1, a putative prostate cancer metastasis-suppressor gene regulates micrometastatic growth. Proc. Amer. Assoc. Cancer Res. 41:4536, 2000

66. *Innocenti F, **Stadler WM**, Iyer L, Vokes EE, Ratain MJ. Flavopiridol-induced diarrhea is related to the systemic metabolism of flavopiridol to its glucuronide. Proc Amer Soc Clinc Oncol 19:694, 2000

67. *Garcia JC, Vogelzang NJ, Cohn HC, **Stadler WM**, Kugler JW, Troeger T, Giannone E, Arrieta RL, Ratain MJ, Vokes EE. Monthly bolus suramin in hormone refractory prostate cancer: A study from the University of Chicago Phase II Network. Proc Amer Soc Clinc Oncol 19:1332, 2000

68. *Kaufman DS, **Stadler WM**, Carducci MA, Kuzel T, Todd MB, Raghavan D, Reznikoff G, Cohen J, Smith C, Woodley S, Murphy BA, Nicol SJ. Gemcitabine and paclitaxel every two weeks: A muticenter phase II trial in locally advanced or metastatic urothelial cancer. Proc Amer Soc Clinc Oncol 19:1341, 2000

69. **Stadler WM**, Steinberg GS, Vogelzang NJ. Low rate of patient enrollment in an adjuvant study of gemcitabine, cisplatin, and amifostine for high risk localized urothelial cancer. Proc Amer Soc Clinc Oncol 19:1409, 2000

70. Cohn HC, Picus J, Kuzel TM, **Stadler WM**, Simonich WL, Crispen R, Vogelzang NJ. Strontium-89, mitoxantrone, and hydrocortisone in hormone refractory prostate cancer: Final results of a phase I-II study. Proc Amer Soc Clinc Oncol 19:1478, 2000

71. Dumas MC, Ryan CW, Dolan ME, Vogelzang NJ, **Stadler WM**. A phase II trial of oral temozolomide with measurement of tumor O6-Alkylguanine-DNA Alkyltransferase activity in patients with metastatic renal cell cancer. Proc Amer Soc Clinc Oncol 19:1479, 2000

72. Ryan CW, **Stadler WM**, Vogelzang NJ. Docetaxel plus exisulind in hormone-refractory prostate cancer. CapCure meeting 2000

73. *Rini BI, Gavin D, Vogelzang NJ, Bosman J, Gjewski TF, **Stadler WM**. Circulating $CD11c^{+}/CD83^{+}$ mature dendritic cells in vivo following sequential Flt3 ligand and Interleukin-2 administration in renal carcinoma patients. Proc Amer Soc Hematology, Abst #1960, 2000

74. *Rini BI, Zimmerman TM, Gajewski TF, **Stadler WM**, Vogelzang NJ. Allogeneic stem cell transplantation of metastatic renal cell cancer (rcc) after non-myeloablative chemotherapy: engraftment rates, toxicity and initial clinical results. Proc Amer Soc Clin Oncol 20:719, 2001

75. ***Stadler WM**, Heimann R, Karczmar G, Gajewski T, Kindler H, MacEneany P, Zamora M, Medved M, Vokes EE. Clinical evaluation of tumor angiogenesis markers in metastatic cancer. Proc Amer Soc Clin Oncol 20:382, 2001

76. *Kindler HL, Vogelzang NJ, Chien K, **Stadler WM**, Karczmar G, Heimann R, Vokes EE. SU5416 in malignant mesothelioma: A University of Chicago phase II consortium study. Proc Amer Soc Clin Oncol 20:1359, 2001

77. Eng C, Kindler HL, **Stadler WM**, Karczmar G, Heimann R, Wade JL III, Nattam S, Agamah E, Vokes EE. SU5416 in advanced colorectal cancer (crc): A University of Chicago phase II consortium study. Proc Amer Soc Clin Oncol 20:2215, 2001

78. Desai AA, Vogelzang NJ, Rini B, Ryan C, Rodriguez M, **Stadler WM**. A phase II trial of weekly intravenous gemcitabine with prolonged continuous infusion 5-fluorouracil and oral thalidomide in patients with metastatic renal cell cancer. Proc Amer Soc Clin Oncol 20:2448, 2001

79. Rodriguez M, Geroge CM, Vogelzang NJ, Rini BI, **Stadler WM**. A phase II trial of weekly intravenous gemcitabine and cisplatin with prolonged continuous infusion 5-fluorouracil in patients with metastatic renal cell carcinoma. Proc Amer Soc Clin Oncol 20:2450, 2001

80. *Gajewski TF, Flickinger S, Heimann R, Karczmar G, Rini B, Dragovich T, **Stadler WM**. Phase II study of the anti-angiogenic Flk-1 tyrosine kinase inhibitor SU5416 in melanoma: Initial results Proc Amer Soc Clin Oncol 20:1436, 2001

81. Hu HS, Rini BI, Zimmerman TM, Gajewski TF, **Stadler WM**, Vogelzang NJ. Non-Myeloablative Allogeneic Stem Cell Transplantation for Mestastatic Renal Cell Carcinoma: the University of Chicago Experience. Society for Biologic Therapy, 10/01

82. ***Stadler WM**, Rosner G, Small E, Ratain MJ. Feasibility of the randomized discontinuation clinical trial design for assessing cytostatic drug activity. Proc AACR-NCI-EORTC Intl Conf Mol Targets Cancer Ther:377, 2001

83. *Kindler HL, Vogelzang NJ, Chien K, **Stadler WM**, Karczmar G, Heimann R, Vokes EE. A phase II study of SU5416 in malignant mesothelioma. Proc AACR-NCI-EORTC Intl Conf Mol Targets Cancer Ther:42, 2001

84. *Atkins MB, Hidalgo M, **Stadler W**, Logan T, Dutcher J, Hudes G, Park Y, Marshall B, Boni, J, Dukart G. A randomized, double-blind, phase II study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc Amer Soc Clin Oncol 21: 36, 2002

85. **Hu HS, Rini BI, Zimmerman M, Gajewski TF, **Stadler WM,** Vogelzang NJ. Allogeneic stem cell transplantation for metastatic renal cell cancer after non-myeloablative chemotherapy: updated results from the University of Chicago. Proc Amer Soc Clin Oncol 21:718, 2002*

86. *George CM, Huo D, Vogelzang NJ, Rini BI, Ryan CW, Desai AA, **Stadler WM**. Pooled analysis of advanced renal cell carcinoma patients treated with gemcitabine and 5-fluorouracil. Proc Amer Soc Clin Oncol 21: 762

87. *Kaufman DS, Carducci MA, Kuzel T, Todd MB, Raghavan D, Oh WK, Smith MR, Nicol SJ, **Stadler WM**. Gemcitabine and paclitaxel every two weeks: a completed multicenter phase II trial in locally advanced or metastatic urothelial cancer. Proc Amer Soc Clin Oncol 21:767, 2002

88. *Ryan CW, Schumm PL, Hansen M, Huo D, **Stadler WM**, Olive-Henderson T, Vogelzang NJ. Early bone mineral density loss in patients undergoing androgen ablation. Proc Amer Soc Clin Oncol 21: 1534, 2002

89. Aklilu M, Kindler HL, Gajewski TF, Vogelzang NJ. Vokes EE, **Stadler WM**. Toxicities of the antiangiogenic agent SU5416 in phase II studies. Proc Amer Soc Clin Oncol 21:1921, 2002

90. Pruitt-Scott DE, Ryan CW, **Stadler WM**, Vogelzang NJ. Exisulind plus docetaxel for hormone refractory prostate cancer. Proc Amer Soc Clin Oncol 21:2460, 2002

91. *Medved M, MacEneany P, Karczmar G, Kindler H, Gajewski T, Vokes E, O'Connor E, **Stadler W**. Contrast Agent Dynamics as an Early Marker of Antiangiogenic Agent Action. Tenth Scientific Meeting and Exhibition of ISMRM, Honolulu, HI, May 2002

92. *Ryan CW, Schumm P, Hansen M, Huo D, **Stadler WM**, Henderson T, Vogelzang NJ. Early bone mineral density loss in prostate cancer patients undergoing androgen deprivation. Oncology 17 (Supp 3):31, 2003

93. *Gustin DM, Winegarden J, Haraf D, Stenson K., Dekker A, **Stadler W**, Vokes E. Phase I study of bevacizumab, fluorouracil, hydroxyurea and radiotherapy for patients with poor prognosis head and neck cancer. Proc Amer Assoc Cancer Res 44:5357, 2003

94. *Davis DW, Xiong HQ, **Stadler W**, Herbst RS, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers in tumor biopsies from phase I/II Studies with VEGF receptor tyrosine kinase inhibitors. Proc Amer Assoc Cancer Res 44:4022, 2003

95. *Tennant TR, Zaucha M, Hollowell CMP, Jaeger EB, Raviv S, **Stadler W**, Rinker-Schaeffer C. Matrix metalloproteinase 2 in the Dunning model – a novel upregulation in metastasis. Proc Amer Assoc Cancer Res 44:4240, 2003

96. *VanderGriend DJ, Yoshida B, **Stadler W**, Lin A, Rinker-Schaeffer C. MKK4 suppresses metastasis by activating the JNK/SAPK stress activated signaling pathway. Proc Amer Assoc Cancer Res 44:5903, 2003

97. *Janisch LA, Desai A, **Stadler W**, Vogelzang N, Ratain M, Young AH, Wright JA, Schilsky R. Phase I study of GTI-2040 given by continuous intravenous infusion in patients with advanced malignancies. Proc Amer Soc Clin Oncol 22:819, 2003

98. *Peterson AC, Swiger S, **Stadler W**, Karczmar G, Gajewski T. Phase II study of the Flk-1 TK inhibitor SU5416 in patients with advanced melanoma. Proc Amer Soc Clin Oncol 22:2863, 2003

99. *Aklilu M, George CM, **Stadler WM**, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M Gajewski TF. Depletion of normal B cells with rituximab as an adjunct to IL2 therapy for renal cell carcinoma (RCC) and melanoma. Proc Amer Soc Clin Oncol 22:688, 2003

100. *Hidalgo M, Atkins MB, **Stadler WM**, Logan T, Dutcher JP, Hudes G, Marshall B, Liou S-H, Dukart G. A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma: Prognostic factor analysis. Proc Amer Soc Clin Oncol 22:804, 2003

101. *Kindler HL, Ansari R, Lester E, Locker G, Nattam S, **Stadler WM**, Wade-Oliver K, Vokes EE. Bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. Proc Amer Soc Clin Oncol 22:1037, 2003

102. *Davis NB, Taber DA, Ansari RH, Ryan CW, Vokes EE, Vogelzang NJ, **Stadler WM**. A phase II trial of PS-341 in patients with renal cell cancer. Proc Amer Soc Clin Oncol 22:1551, 2003

103. *Moore MJ, Winquist E, Vokes EE, Hirte H, Hoving K, **Stadler WM**. Phase II study of oxaliplatin in patients with inoperable, locally advanced or metastatic transitional cell carcinoma of the urothelial tract who have received prior chemotherapy. Proc Amer Soc Clin Oncol 22:1638, 2003

104. *Artz AS, **Stadler WM**, Vogelzange NJ, Zimmerman TM, Ryan CW. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic transitional cell carcinoma of the bladder. Proc Amer Soc Clin Oncol 22:1664, 2003

105. *Cohen EEW, Stenson K, Gustin DM, Lamont E, Mauer AM, Blair E. **Stadler WM**, Dekker A, Mallon W, Vokes EE. A phase II study of 250 mg gefitinib monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck. Proc Amer Soc Clin Oncol 22:2021, 2003

106. **Stadler WM*, *Rosner G, Rini B, Hollis D, Small E, Ratain MJ. Successful implementation of the randomized discontinuation trial design with the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma. Proc Amer Soc Clin Oncol 22:773, 2003*

107. **Ratain MJ, O 'Dwyer P, Stadler W, Kaye S, Xiong H, Eisen T, Patnaik A, Smith M, Flaherty KT, Kindler H, Lee RJ, Lewis J, Schwartz B. A phase II study of BAY 43-9006 using the randomized discontinuation design in patients with advanced refractory cancer. 2nd International Symposium on Signal Transduction Modulators in Cancer Therapy (NDDO), 10-25-03 (http://www.nddo.org/files/pdf/STM-2003%20Sci%20Prog.pdf)*

108. **Ratain MJ, Stadler WM, Smith M, Kindler H, O'Dwyer PJ, Flaherty KT, Kaye S, Xiong H, Eisen T, Patnaik A, Lee RJ, Lewis J, Schwartz B. A phase II study of BAY 43-9006 using the randomized discontinuation design in patients with advanced refractory cancer. Clin Cancer Res 9:6265s (abstract)*

109. **Kindler HL, Friberg G, Stadler WM, Singh D, Locker G, Nattam S, Kozloff M, Kaaza K, Dachman A, Vokes EE. Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: Interim results of a phase II trial from the University of Chicago Phase II Consortium ASCO 2004 Gastrointestinal Cancers Symposium, Abstract 86*

110. *Artz AS, VanBesien K, Zimmerman T, Gajewski TF, Rini BI, Hu S, **Stadler WM**, Vogelzang NJ. Long-term Follow Up after Non-myeloablative Allogeneic Stem Cell Transplantation for Renal Cell Carcinoma: The University of Chicago Experience. "Tandem BMT Meeting" Fl 2/04

111. *Davis DW, Xiong HQ, Herbst RS, Abbruzzese JL, Heymach JV, Demetri GD, **Stadler W**, McConkey DJ. Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668. Proc Amer Assoc Cancer Res 45:3988 (abstract), 2004

112. *Lara PN, Longmate J, **Stadler W**, Quinn DI, Twardowski P, Martel CI, Vogelzang NJ, Vokes EE, Doroshow JH, Gandara DR. Angiogenesis inhibition in metastatic hormone refractory prostate cancer: A randomized phase II trial of two doses f the matrix metalloproteinase inhibitor BMS-275291. Proc Amer Soc Clin Oncol 22:417 (abst 4647), 2004

113. *Kindler HI, Friberg G, **Stadler WM**, Singh DA, Locker G, Nattam S, Kozloff M, Kasza K, Vokes EE. Bevacizumab plus gemcitabine in patients with advanced pancreatic cancer: updated results of a multi-center phase II trial. Proc Amer Soc Clin Oncol 22:314 (abst 4009), 2004

114. **Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial. Proc Amer Soc Clin Oncol 22:381 (abst 4501), 2004*

115. **Stadler WM*, *Halabi S, Ernstoff MS, Barrier R, Davila E, Picus J, Small EJ. A phase II study of gemcitabine and capecitabine in patients with metastatic renal cell cancer: A report of Cancer and Leukemia Group B #90008. Proc Amer Soc Clin Oncol 22:384 (abst 4515), 2004*

116. *Peterson AC, Harlin H, Karrison T, Knost JA, Kugler JW, Vogelzang NJ, Vokes EE, Gajewski TF, **Stadler WM**. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin in patients with renal cell carcinoma. Proc Amer Soc Clin Oncol 22:407 (abst 4608), 2004

117. *Villano JL, Husain AN, **Stadler WM**, Hanson LL, Vogelzang NJ, Kindler HL. A phase II trial of imatinib mesylate in patients with malignant mesothelioma. Proc Amer Soc Clin Oncol 23:663 (abst 7200), 2004

118. Davis NB, Ryan CW, **Stadler WM**, Vogelzang NJ, A phase II study of nilutamide in men with prostate cancer following failure of flutamide or bicalutamide therapy. Proc Amer Soc Clin Oncol 2:422 (abst 4669), 2004

119. +Ryan CW, Huo D, Hanson M, **Stadler WM**, Vogelzang NJ. Effect of zoledronic acid versus placebo on bone mineral density in androgen-deprived prostate cancer patients with and without bone metastases. Proc Amer Soc Clin Oncol 22:445 (abst 4760), 2004

120. Gupta S, Bylsma F, Dignam J, Kuball K, **Stadler W**, Rodin M. Prevalence of functional impairment among prostate cancer patients determined by comprehensive geriatric assessment: Baseline data for a prospective study of androgen ablation and quality of life. Proc Amer Soc Clin Oncol 23:777 (abst 8210), 2004

121. *Desai AA, Janisch L, Berk L, Knowles HL, Rivera VM, Kindler HL, **Stadler WM**, Bedrosian CL, Ratain MJ. A phase I trial of weekly (wkly) AP23573, a novel mTOR inhibitor, in patients (pts) with advanced or refractory malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Eur J Cancer Supp 2:117 (abst 390)

122. *Desai AA, Bukowski R, Murray P, Poiesz B, Quinn D, Saltzman M, **Stadler WM,** Wright J, Young A, Torti FM. Interim evaluation of a multi-institution phase I/II study of antisense oligonucleotide GTI-2040 (G) and capecitabine (C) in patients with metastatic renal cell carcinoma (mRCC). Eur J Cancer Supp 2:136 (abst 457)

123. ***Stadler WM**. Cytotoxic chemotherapy for metastatic renal cell carcinoma. Der Urologe 43:S145-S146, 2004

124. *Gupta S, Lacy M, Kuball K, Nader T, **Stadler W**, Rodin M. Pre-treatment cognitive functioning of older prostate cancer patients: Baseline data from a prospective study of androgen ablation and health status. Proc ASCO 2005 Prostate Cancer Symposium, p106 (abst 144), 2005

125. *Ryan CW, Huo D, **Stadler WM**, McWhorter LT, Vogelzang NJ. Sustained suppression of bone turnover in androgen-deprived prostate cancer patients receiving infrequent infusions of zoledronic acid. Proc ASCO 2005 Prostate Cancer Symposium, p107 (abst 147), 2005

126. **Dreicer R, Ahman R, Pantuck A, **Stadler WM**, Bizouarne N, Acres B, Limacher J-M, Squiban P. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) in patients with prostate cancer with biochemical failure. Proc ASCO 2005 Prostate Cancer Symposium, p159 (abst 249), 2005*

127. *Ryan C, **Stadler WM**, Roth B, Dong R-P, Puchalski T, Koehler M, Small E. Safety and tolerability of AZD2171, a highly potent VEGFR inhibitor, in patients with advanced prostate adenocarcinoma. Proc ASCO 2005 Prostate Cancer Symposium, p161 (abst 253), 2005

128. *Lyon MB, **Stadler WM**, Orveito MA, Vander Griend DJ, Brendler CB, Steinberg GD, Kocherginsky M, Keller ET, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4 (MKK4) and Raf kinase inhibitory protein (RKIP) expression in prostate cancer: Role in biochemical failure after radical prostatectomy and metastatic lesions. Proc Amer Assoc Cancer Res 46:5591 (abstract), 2005

129. Polite BN, Desai AA, Peterson A, Manchen E, **Stadler WM**. A Phase II Study of Imatinib Mesylate (IM) and Interferon-Alpha (IFNA) in Metastatic Renal Cell Carcinoma (RCC) Proc Amer Soc Clin Oncol 23:425s (abstract 4689), 2005-04-28

130. Jin JO, Lehmann J, Stockle M, Steinberg G, Stadler W. Phase II trial of adjuvant gemcitabine plus cisplatin with amifostine cytoprotection in patients with locally advanced bladder cancer. Proc Amer Soc Clin Oncol 23:426s (abstract 4695), 2005

131. *Ryan C, **Stadler WM**, Roth B, Puchalski T, Koehler M, Small E. Safety and tolerability of AZD2171, a highly potent VEGFR inhibitor, in patients with advanced prostate adenocarcinoma Proc Amer Soc Clin Oncol 23:204s (abstract 3049), 2005

132. **Stadler WM**, Swerdloff JN, Margolin K, McCulloch B, Thompson J. A phase II study of depsipeptide in patients with metastatic renal cell cancer. Proc Amer Soc Clin Oncol 23:420s (abstract 4669), 2005

133. *Ratain MJ, Eisen T, **Stadler WM**, Flaherty KT, Gore M, Desai A, Patnaik A, Xiong H, Schwartz B, O'Dwyer P. Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) Proc Amer Soc Clin Oncol 23:388s (abstract 4544), 2005

134. *Lara PN, Longmate J, **Stadler W**, van Loan M, Wexler J, Quinn DI, Twardowski P, Vokes EE, Gandara DR. Markers of bone metabolism predict survival in hormone refractory prostate cancer: Results from a randomised California Cancer Consoritum and University of Chicago trial. Proc Amer Soc Clin Oncol 23:395s (abstract 4569), 2005

135. Sridhar SS, **Stadler W**, Se L, Hedley D, Pond G, Wright J, Vokes E, Thomas S, Moore M. Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital Phase II Consortium. Proc Amer Soc Clin Oncol 23:422s (abstract 4677), 2005

136. **Dreicer R, Ahman R, Pantuck A, **Stadler WM**, Bizouarne N, Acres B, Derbij A, Limacher J-M, Squiban P. Vaccine immunotherapy with MVA-Muc1-IL2 (TG4010) in prostate cancer patients with biochemical failure. Proc Amer Soc Clin Oncol 23:382s (abstract 4518), 2005*

137. **Escudier B, Szczylik C, Eisen T. **Stadler WM**, Schwartz B, Shan M, Bukowski RM. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor BAY 43-9006 (sorafenib) in patients with advanced renal cell carcinoma (RCC) Proc Amer Soc Clin Oncol 23:380s (abstract LBA4510), 2005*

138. **Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, Janne P, Guterz TL, **Stadler WM**, Vokes EE. A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (gc) plus bevacizumab (b) or placebo (p) in patients (pts) with malignant mesothelioma (mm). Proc Amer Soc Clin Oncol 23:625s (abstract 7019), 2005*

139. Gupta S, Lacy M, Kuball K, **Stadler W**, Rodin M. Pre-treatment cognitive functioning of older prostate cancer patients: Baseline data from a prospective study of androgen ablation and health status. Proc Amer Soc Clin Oncol 23:772s (abstract 8175), 2005

140. *Ryan C, **Stadler WM**, Roth B, Puchalski T, Morris C, Small E. Phase I evaluation of AZD2171, a highly potent VEGFR tyrosine kinase inhibitor, in patients with advanced prostate adenocarcinoma Proc AACR-EORTC, abstract A4, pg 55, 2005

141. **Escudier B, Szczylik C, Eisen T, Oudard S, **Stadler W.M.**, Schwartz B, Shan M, Bukowski R.M. Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. European Journal of Cancer Supplements 3:226 (abst 794), 2005*

142. *Ryan C, **Stadler WM**, Roth B, Puchalski T, Morris C, Small E. Phase I evaluation of AZD2171, a highly potent VEGFR tyrosine kinase inhibitor, in patients with advanced prostate adenocarcinoma Proc ASCO Prostate Ca Symposium, Abstract 261, 2006

143. *Bylow KA, Mohile SG, **Stadler WM**, Rodin MR. Functional and Physical Impairment in Older Prostate Cancer (PC) Patients on Androgen Deprivation Therapy (ADT) Proc ASCO Prostate Ca Symposium, Abstract 193, 2006

144. *Molife R, Patterson S, Riggs C, Higano C, **Stadler WM**, Dearnaley D, Parker C, McCulloch W, Shalaurov A, de Bono J. Phase II study of FK228(depsipeptide) in patients with metastatic hormone refractory prostate cancer. Proc ASCO Prostate Ca Symposium, Abstract 217, 2006

145. *Dale W., Bylow K, Hemmerich J, **Stadler W**. The impact of patient anxiety on the timing of ADT initiation after rising PSA: Preliminary findings. Proc ASCO Prostate Ca Symposium, Abstract 209, 2006

146. *Yang C, Wolf GL, Karczmar GS, **Stadler WM**. Improved T1 estimation with spoiled gradient recall echo (SPGR) images using a modified variable flip angle method. Proceedings ISMRM, Abstract 2499, 2006

147. **Yang C, **Stadler WM**, Medved M, Karczmar GS. Tumor Arterial Input Function (AIF) estimation in DCE-MRI studies using a multiple reference tissue method: preliminary experience. Proceedings ISMRM, Abstract 384, 2006*

148. *Dale W, Hemmerich J, Bylow K, **Stadler W.** Does patient anxiety influence the timing of androgen deprivation therapy initiation after prostate specific antigen starts rising? Proc Society for Medical Decision Making, 2006 (www.smdm.org)

149. *Maitland ML, Moshier KK, Imperial J, Kasza KE, Karrison T, Elliott W, Undevia SD, **Stadler W**, Desai AA, Ratain MJ. Blood pressure as a biomarker for sorafenib, an inhibitor of the vascular endothelial growth factor signaling pathway. J Clin Oncol 24:87s (abst 2035), 2006

150. *Undevia SD, Janisch L, **Stadler WM**, Wittemer SM, Ratain MJ. A phase I and pharmacokinetic study of continuous infusion EMD 121974, an antiangiogenic $\alpha v\beta 3$ and $\alpha v\beta 5$ integrin antagonist, in patients with advanced solid malignancy. J Clin Oncol 24:133s (abst 3052), 2006

151. **Teh BT, Yang XJ, Tan M, Kim HL, **Stadler W**, Vogelzang NG, Amato R, Figlin R, Belldegrun A, Rogers CG. Gene expression profiling identifies two distinct papillary renal cell carcinoma subgroups of contrasting prognosis. J Clin Oncol 24:217s (abst 4503), 2006*

152. **Rini BI, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, **Stadler WM**, Margolin K, Hutson TE, Baum CM. Efficacy and safety of sunitinib malate in bevacizumab refractory metastatic renal cell carcinoma. J Clin Oncol 24:222S (abst 4522), 2006*

153. **Eisen T, Bukowski RM, Staehler M, Szcylik c, Oudard S, **Stadler WM**, Schwartz B, Simantov R Shan M, Escudier B. Randomized phase III trial of sorafenib in advanced renal cell carcinoma: Impact of crossover on survival. J Clin Oncol 24:223S (abst 4524), 2006*

154. *Gao X, Reddy P, Dhanda R, Gondek K, Yeh YC, **Stadler WM**, Jonasch E. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. J Clin Oncol 24:242S (abst 4604), 2006

155. *Srinivas, **Stadler WM**, Bukowski R, Figlin R, Hayes T, Yankee EW, Jonasch E. Talactoferrin alfa may prolong progression-free survival in advanced renal carcinoma patients. J Clin Oncol 24:241S (abst 4600), 2006

156. Mays TA, Sarantopoulos J, Tolcher A, Lwy I, Preston G, Levy E, Oslund MD, Manchen E, Kelly A, **Stadler WM**. MDX-070, a human anti-PSMA antibody, administered as either a single dose or as multiple doses to patients with hormone-refractory prostate cancer. J Clin Oncol 24:640S (abst 14549), 2006

157. Molife R, Patterson S, Riggs C, HIgano C, **Stadler WM**, Dearnaley D, Parker C, McCulloch W, Shalaurov A, De-Bono JS. Phase II study of FD228 in patients with hormone refractory prostate cancer. J Clin Oncol 24:641S (abst114554), 2006

158. +Posadas EM, Undevia S, Colevas AD, Manchen E, Vokes EE, **Stadler WM**. A phase II study of ixabepilone in metastatic renal cell carcinoma. J Clin Oncol 24:648S (abst 14646), 2006

159. **Rini BI, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, **Stadler WM**, Margolin K, Hutson TE, Baum CM. Phase II study of sunitinib malate in bevacizumab refractory renal cell cancer. Ann Oncol 17 (supp 9):ix144 (abstract 438O), 2006*

160. *Molife R, Dearnaley D, Parker C, Patterson S, Riggs C, Higano C, Stadler WM, McCulloch W, Shalorauv A, deBono J. Phase II study of FK228 in patients with metastatic prostate cancer. Ann Oncol 17 (supp 9):ix149 (abstract 456P), 2006

161. Yang C, Haider MA, Karczmar GS, Milosevec M, Yeung I, **Stadler WM**. Comparison of tumor permeability measured by dynamic contrast enhanced CT and MRI (DCE-CT, DCE-MRI) analyzed with a novel Arterial Input Function (AIF) estimation method. RSNA 92nd Annual Meeting, Chicago, USA, 2006

162. *Ahmed F, Hemmerich J, Bylow K, **Stadler W**, Dale W. Variance in physician attitudes toward androgen therapy initiation for rising PSA for asymptomatic recurrent prostate cancer. Proc Prostate Cancer Symposium of Amer. Soc. Clin. Oncology, abstract 195, 2007

163. *Dale W, Hemmerich J, Bylow K, **Stadler W**. Does patient anxiety influence the likelihood of starting androgen deprivation therapy when the PSA starts rising? Proc Prostate Cancer Symposium of Amer. Soc. Clin. Oncology, abstract 211, 2007

164. *Lotan TL, Lyons M, Huo D, Brendler C, Rinker-Schaeffer C, **Stadler WM**. Upregulation of MKK4, MKK6 and MKK7 During Prostate Cancer Progression. US and Canadian Association of Pathology meeting San Diego, 2007

165. **Bukowski RM, Figlin R, **Stadler W**. Safety analysis of the Advanced Renal Cell Carcinoma Study, an expanded access program. Eur Urology, 6:237(abst 858), 2007*

166. **Eisen T, Bukowski R, Staehler M, Szcylik C, Oudard S, Stadler W, Simantov R, Shan M, Escudier B. Randomized phase III trial of sorafenib in advanced renal cell carcinoma: Impact of crossover on survival. Eur Urology, 6:237(abst 857), 2007*

167. **Tuazon ED, Groshen SG, Lerner SP, **Stadler W**, Stein JP, Cote RJ. Patinet randomization factors in the p53 targeted therapy trial in bladder cancer. J Urol 177:192 (abstract 576), 2007*

168. *Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen B, Mitchell M, Ratain M, **Stadler WM**. Dynamic contrast enhanced MRI: a pharmacodynamic study of sorafenib in metastatic renal cell carcinoma: results of randomized, phase II trial. J Clin Oncol 25(18S):149s (abstract number 3545), 2007

169. *Cripe L, McGuire W, Wertheim M, Eisenberg P, **Stadler W**, Paquette R, Logan T, Zimmerman T, Matei D, Matulonis U. Integrated report of the phase 2 experience with XL999 administered IV to patients with NSCLC, renal cell CA, metastatic colorectal CA, recurrent ovarian CA, acute myelogenous leaukemia, and multiple myeloma. J Clin Oncol 25(18S):160s (abstract number 3591), 2007

170. *Wallace JA, Locker G, Nattam S, Kasza K, Wade-Oliver K, **Stadler WM**, Vokes EE, Kindler HL. Sorafenib plus gemcitabine for advanced pancreatic cancer: A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 25(18S):224s (abstract number 4608), 2007

171. **Knox JJ, Figlin RA, **Stadler WM**, McDermott DF, Gabrail N, Miller WH Jr, Hainsworth J, Ryan CW Cupit L, Bukowski RM on behalf of the ARCCS Investigators. The advanced renal cell carcinoma sorafenib expanded access trial in North America: Safety and efficacy. J Clin Oncol 25(18S):237s (abstract number 5011), 2007*

172. **Bukowski RM, Eisen T, Szczylik C, **Stadler WM**, Simantov R, Shan M, Elting J, Pena C, Escudier B. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol 25(18S):240s (abstract number 5023), 2007*

173. *Rini BI, Wilding GT, Hudes G, **Stadler WM**, Kim S, Tarazi JC, Bycott PW, Liau KF, Dutcher JP. Axitinib (AG-013736) in patients with metastatic renal cell cancer refractory to sorafenib. J Clin Oncol 25(18S):242s (abstract number 5032), 2007

174. *Geroge DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, **Stadler WM**, Margolin K, Hutson TE, Rini BI. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma: Updated results and analysis of circulating biomarkers. J Clin Oncol 25(18S):243s (abstract number 5035), 2007

175. ***Stadler WM**, Figlin RA, Ernstoff MS,Curti B, Pendergrass K, Srinivas S, Canfield V, Weissman C, Poulin-Costello, Bukowski RM. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients with non-clear cell renal cell carcinoma. J Clin Oncol 25(18S):243s (abstract number 5036), 2007

176. *Drabkin HA, Figlin RA, Stadler WM, Hutson TE, Hajdenberg J, Chu L, Trent D, Campos LT, Kelly F, Bukowski RM. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients with prior bevacizumab treatment. J Clin Oncol 25(18S):245s (abstract number 5041), 2007

177. *Ryan CW, Bukowski RM, Figlin RA, Knox JJ, Hutson TE, Dutcher JP, George J, Kirshner J, Humphrey J, **Stadler WM**. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: Long term outcomes in first-line patients. J Clin Oncol 25(18S):258s (abstract number 5096), 2007

178. *Hussain M, Dunn R, Rathkopf D, **Stadler W**, Wilding G, Smith DC, Bradley D, Cooney KA, Zweibel J, Scher H. Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer patients: A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862). J Clin Oncol 25(18S):267s (abstract number 5132), 2007

179. *Nimeiri HS, Faoro L, Oza AM, Morgan RJ, Gandara D, Janamanchi V, Salgia R. **Stadler WM**, Vokes EE, Fleming GF. Molecular correlates (EGFR status) and plasma VEGF levels associated with a phase II study of bevacizumab plus erlotinib for patients with recurrent ovarian cancer and fallopian tube cancer. J Clin Oncol 25(18S):287s (abstract number 5554), 2007

180. **Karrison T, Kindler HL, Gandara DR, Lu C, Gueterz TL, Nichols K, Chen H, **Stadler WM**, Vokes EE. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 25(18S):391s (abstract number 7526), 2007*

181. Henderson CA, Bukowski RM, **Stadler WM**, Dutcher JP, Kindwall-Keller T, Hotte SJ, Logie K, Baltz B, Wilson K, Figlin RA. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: Subset analysis of patients with brain metastases. J Clin Oncol 25(18S):650s (abstract number 15506), 2007

182. Gofrit ON, **Stadler WM**, Zorn KC, Silvestre J, Shalhav AK, Zagaja GP, Steinberg GD. Adjuvant chemotherapy in lymph node positive bladder cancer. J Clin Oncol 25(18S):652s (abstract number 15526), 2007

183. Beekman KW, Dunn R, Colevas D, Davis N, Clark J, Agamah E, Thomas S, Nichols K, Redman B, **Stadler W**. University of Chicago Consortium phase II study of ispinesib (SB-715992) in patients with advanced renal cell carcinoma. J Clin Oncol 25(18S):655s (abstract number 15573), 2007

184. Hemmerich JA, Ahmed F, Bylow K, **Stadler W**, Dale W. Variance in physician attitudes toward androgen deprivation therapy initiation for biochemical cancer recurrence. J Clin Oncol 25(18S):660s (abstract number 15626), 2007

185. *Rini B, Wilding G, Hudes G, **Stadler WM**, Kim S, Tarazi J, Bycott P, Liau K, Dutcher J. Axitinib (AG013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib. European Journal of Cancer Supplements, 5:300 (abst 4507), 2007

186. *Hutson TE, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, **Stadler WM**, Margolin K, Rini BI. A phase 2 trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. European Journal of Cancer Supplements, 5:301 (abst 4510), 2007

187. *George C, Vaughn DJ, Petrylak D, Srinivas S, Pili R, **Stadler W**, De Marco S, Smith DC, Nason S, De Wit E. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). European Journal of Cancer Supplements, 5:309 (abst 4534), 2007

188. *Maitland ML, Kasza KE, Moshier K, Sit L, **Stadler WM**, Undevia SD, Elliott WJ, Karrison T, Ratain MJ. Clinical investigation of sorafenib pharmacokinetics and pharmacodynamic biomarkers. Proceedings AACR-EORTC Symposium Molecular Targets and Therapeutics; p74 (abstract A27), 2007

189. **Knox JJ, Figlin RA, **Stadler WM**, Henderson CA, Drabkin HA, McDermott DF, Gabrail N, Miller H, Hainsworth J, Ryan CW, Cupit L, Bukowski RM, on behalf of the ARCCS Investigators. Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access program in North America. Proc 1st European Multidisciplinary Meeting on Urological Cancers. Abs P149, 2007*

190. *Bukowski R, Heng D, Eisen T, Szczylik, C, **Stadler WM**, Simantov R, Shan M, Elting J, Pena C, Bernard B. Phase III Trial of Sorafenib in Advanced RCC: Survival and Biomarker Results. Proc 1st European Multidisciplinary Meeting on Urological Cancers. Abs O5, 2007

191. *Szmulewitz RZ, Posadas EM, Manchen B, Knight D, **Stadler WM**. Phase I study of testosterone for the treatment of hormone refractory prostate cancer. Proc Genitourinary Cancers Symposium, Abs 201, 2008

192. *Bradley DA, Dunn R, Rathkopf D, **Stadler WM**, Wilding G, Smith DC, Pili R, Scher H, Keller ET, Hussain M. Vorinostat in hormone refractory prostate cancer: Trial results and IL6 analysis. Proc Genitourinary Cancers Symposium, Abs 211, 2008

193. *Vauhn DJ, Srinias S, Petrylak DP, Pili R, **Stadler W**, Sternberg C, Smith DC, Nason S, George C, DeWit E. Vinflunine in patients with platinum-refractory transitional cell carcinoma of the urothelium: Results of a large phase II study. Proc Genitourinary Cancers Symposium, Abs 316, 2008

194. **Rini BI, Halabi S, Rosenberg JE, **Stadler WM**, Vaena D, Ou S, Taylor J, Tanguay S, Dutcher J, Small EJ. A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Proc Genitourinary Cancers Symposium, Abs 350, 2008*

195. *Wondergem B, Zhang Z, Tan M-H, Kim HL, Rogers CG, Kahnoski RJ, **Stadler W**, Nicol D, Kanayama H, Belldegrun A, Teh BT. Overexpression of PTTG1 in clear cell renal cell carcinoma is correlated to high nuclear grade, tumor stage, and poor patient survival. Proc Amer Assoc Cancer Res, abst 1791, 2008

196. *Zhang Z, Tan M-H, Kim HL, Rogers CG, Anema J, **Stadler W**, Nicol D, Kanayama H, Belldegrun A, Teh BT. HIF2alpha rather than HIF1alpha predicts poor prognosis in clear cell RCC. Proc Amer Assoc Cancer Res, abst 1818, 2008

197. *Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Kasza K, Tretiakova M, **Stadler WM**, Salgia R. FYN, a SRC family member, is highly expressed, functional and is a novel molecular target in prostate cancer. Proc Amer Assoc Cancer Res, abst 4112, 2008

198. *O'Donnell PH, Zhang W, **Stadler WM**, Dolan ME. Inter-ethnic genetic determinants of platinum chemotherapy toxicity susceptibility using an unbiased genome-wide approach. Proc Amer Assoc Cancer Res, abst 5820, 2008

199. *Lee RT, Qato D, **Stadler WM**, Lindau ST. Older cancer patients use of biologically based complementary and alternative medicine (CAM) and the prevalence of CAM-medication interactions: A national population based study in the United States. J Invest Med 56:612 (abst 11), 2008

200. **Katz MH, Gofrit OF, Zorn KC, Bernstein AJ, Eng MK, Acharya SS, **Stadler WM**, Shalhav AL, Zagaja GP, Steinberg GD. Adjuvant chemotherapy in lymph node positive bladder cancer improves survival. J. Urol 179:582 (abst 1701), 2008*

201. **Kindler HL, Gangadhar T, Karrison T, Hochster HS, Moore MJ, Micetich K, Sun W, Catenacci DV, **Stadler WM**, Vokes EE. Final analysis of a randomized phase II study of bevacizumab and gemcitabine plus cetuximab or erlotinib in patients with advanced pancreatic cancer. J Clin Oncol 26:213S (abstr 4502), 2008*

202. *Bukowski RM, **Stadler WM**, Figlin RA, Knox JJ, Gabrail N, McDermott DF, Cupit L, Miller WH, Hainsworth JD, Ryan CW. Safety and efficacy of sorafenib in elderly patients ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access program in North America. J Clin Oncol 26:213S (abstr 5045), 2008

203. *Dutcher JP, Wilding G, Hudes GR, **Stadler WM**, Kim S, Tarazi JC, Rosbrook B, Rini BI. Sequential Axitinib therapy of patients with metastatic clear cell renal cell cancer refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol 26:213S (abstr 5127), 2008

204. **Lee RT, Qato D, Curlin F, **Stadler WM**, Lindau ST. Older cancer survivors' use of biologically based complementary and alternative medicine: A national population-based study in the United States. J Clin Oncol 26:213S (abstr 9508), 2008*

205. **Wiebe L, Kasza KE, Maki RG, D'Adamo, DR, Chow WA, Wade JL, Agamah E, **Stadler WM**, Vokes EE, Kindler HL. Activity of sorafenib in patients with imatinib and sunitinib resistant gastrointestinal stromal tumors: A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 26:213S (abstr 10502), 2008*

206. *Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, **Stadler W**. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence: a prospective cohort study. Society for Medical Decision Making Annual Meeting, 2008.

207. *Rixe O, Dutcher JP, Motzer RJ, Wilding G, **Stadler WM**, Kim S, Tarazi J, Rosbrook B, Rini B. Association between diastolic blood pressure (dbp) ≥90 mmhg and efficacy in patients (pts) with metastatic renal cell carcinoma receiving axitinib. European Society of Medical Oncology 33rd Congress, Stockholm, 9/12-9/16/08; abstract 587PD

208. *Dutcher JP, Rixe O, Motzer RJ, Wilding G, **Stadler WM**, Kim S, Tarazi J, Rosbrook B, Rini B. Levothyroxin treatment of hypothyroidism and axitinib (AG-013736) efficacy in patients (pts) with metastatic renal cell carcinoma. European Society of Medical Oncology 33rd Congress, Stockholm, 9/12-9/16/08; abstract 900P

209. *Bukowski RM, Wood LS, Knox JJ, **Stadler WM**, Figlin RA. The incidence and severity of hand-foot skin reaction: a subset analysis from the advanced renal cell carcinoma sorafenib expanded access program in North America. European Society of Medical Oncology 33rd Congress, Stockholm, 9/12-9/16/08; abstract 904P

210. *Oto A, Kulkarni K, Yang C, Karczmar G, **Stadler W.** Evaluation of dynamic contrast-enhanced MRI for detection of bone metastasis in patients with prostate cancer. Proc Amer Roentg Ray Society, 4/26 – 5/1/08, Boston MA

211. *Bylow K, Hemmerich J, Mohile S, **Stadler WM**, Dale W. Abnormal physical performance and frailty in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy. Amer Geriatric Society Annual Meeting; (abstract 598390), 2009

212. *Lee RT, Hemmerich J, Kwon N, Mullaney M, Bylow K, **Stadler WM**, Curlin F, Dale W. Does anxiety about prostate cancer lead to increased lifestyle modifications including complementary and alternative medicine among patients with biochemical recurrence? Proc ASCO Genitourinary Cancers Symposium, abstract 70, ISBN 978-1-932312-70-6, 2009

213. *Oh WK, **Stadler WM**, Srinivas S, Chu F, Bubley G, Quigley M, Goddard J, Dunbar J, Grayzel D, Ross RW. A single arm phase II trial of IPI-504 in patients with castration resistant prostate cancer. Proc ASCO Genitourinary Cancers Symposium, abstract 219, ISBN 978-1-932312-70-6, 2009

214. *Chung EK, Posadas EM, Karrison T, Manchen E, Michalak L, Hahn OM, **Stadler WM**. A phase II trial of gemcitabine, capecitabine and bevacizumab in patients with metastatic renal cell carcinoma. Proc ASCO Genitourinary Cancers Symposium, abstract 332, ISBN 978-1-932312-70-6, 2009

215. *Lerner SP, Stein JP, **Stadler W**, Groshen S, Tuazon E, Skinner DG, Raghavan D, Esrig D, Steinberg GD, Klotz LH, Hall C, Cote RJ. Variability in surgical Quality in a randomized clinical trial of adjuvant chemotherapy following radical cystectomy and pelvic lymphadenectomy. J Urol 181 (supplement):1747, 2009

216. *Williams A, Lin H, Zheng S, Szmulewitz R, **Stadler W**, Scher H, Fleisher M, Liu J, Nie S, Hawes D, Groshen S, Datar R, Tai Y-C, Cote R. Development of a membrane microfilter device for capture and characterization of circulating tumor cells in blood. Proc Ann Meeting Amer Assoc Cancer Res, abst 2608, 2009

217. *Chung EK, Daniel SS, **Stadler WM**, Kocherginsky M, Al-Ahmadie H, Conzen SD. Expression of serum/glucocorticoid regulated kinase 1(SGK1) in untreated and anti-androgen treated prostate cancer. Proc Ann Meeting Amer Assoc Cancer Res, abst 2719, 2009

218. ***Stadler WM**, Lerner SP, Groshen S, Stein JP, Skinner DG, Raghavan D, Steinberg GD, Wood D, Klotz LH, Hall MC, Cote R. Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined node-negative urothelial bladder cancer (UBC). J Clin Oncol 27:15s, 2009 (suppl; abstr 5017)*

219. Twardowski P, **Stadler WM**, Frankel P, Lara PN, Ruel C, Chatta G, Heath EI, Quinn DI, Gandara DR. Phase II study of aflibercept (VEGF-Trap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: A California Cancer Consortium trial. J Clin Oncol 27, 2009 (suppl; abstr e16030)

220. *Bradley D, Daignault S, Smith DC, Nanus D, Tagawa S, **Stadler WM**, Garcia J, Dreicer R, Al-Hawary M, Hussain M. Maintenance sunitinib postchemotherapy (CT) in patients (pts) with advanced urothelial carcinoma (UC): A randomized placebo controlled phase II trial. J Clin Oncol 27:15s, 2009 (suppl; abstr 5073)

221. **Hahn NM, **Stadler WM**, Zon RT, Waterhouse DM, Picus J, Nattam SR, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ. A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475. J Clin Oncol 27:15s, 2009 (suppl; abstr 5018)*

222. **Rini BI, Halabi S, Rosenberg J, **Stadler WM**, Vaena DA, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 27:18s, 2009 (suppl; abstr LBA5019)*

223. Chung EK, Posadas EM, Kasza K, Karrison T, Manchen E, Michalak L, Hahn OM, **Stadler WM**. A phase II trial of gemcitabine(G), capecitabine (C), and bevacizumab (B) in patients (pts) with metastatic renal cell carcinoma (RCC). J Clin Oncol 27, 2009 (suppl; abstr e16072)

224. *Rixe O, Dutcher J, Motzer R, Wilding G, **Stadler WM**, Garrett M, Pithavala Y, Kim S, Tarazi J, Rini BI. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). J Clin Oncol 27:15s, 2009 (suppl; abstr 5045)

225. Bylow KA, Hemmerich J, Mohile S, **Stadler W**, Dale W. Abnormal physical performance and frailty in older men with biochemical recurrence of prostate cancer (PCa) on androgen deprivation therapy (ADT). J Clin Oncol 27, 2009 (suppl; abstr e20578).

226. *Bukowski R, Eisen T.E. **Stadler W.M.**, Szczylik C.S., Oudard O.S., Siebels M.S., Negrier S.N., Anderson S.A., Shan M.S., Escudier B.E. Efficacy and safety of sorafenib in patients with advanced clear-cell renal-cell carcinoma (RCC) with bone metastases: results from the phase III target study. European Journal of Cancer Supplements, 7:432, 2009

227. *Quinn D.I., Aparicio A.M., Tsao-Wei D.D., Groshen S., Synold T., **Stadler W.M.**, Massopust K., Gandara D., Lara P.N., Newman E. Phase II study of eribulin (Halichondrin B analogue, E7389) in patients with advanced urothelial cancer (AUC) - California Cancer Consortium led NCI/CTEP-sponsored trial. European Journal of Cancer Supplements, Vol 7:442, 2009

228. *Garcia J.A., Hudes G., Choueiri T.K., **Stadler W.M.**, Wood L., Bhatia S., Youssoufian H., Rowinsky E.K, Schwartz J.D., Thompson J.A. Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12-0605/NCT00515697). European Journal of Cancer Supplements, Vol 7:425, 2009

229. *Kabbinavar F., Garcia J.A., **Stadler W.M.**, Gil T., Jonasch E., Tagawa S.T., Smitt M., Yang X., Oliner K., Schof P. Efficacy and safety of AMG 102 in patients with advanced renal cell carcinoma (RCC) European Journal of Cancer Supplements, Vol 7:425, 2009

230. *Dreicer R, Agus DB, MacVicar GR, MacLean D, Zhang T, **Stadler WM**. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: A phase I/II open label study. Proc Genitourinary Cancer Symposium, Abst 103, 2010

231. *Garcia JA, Hudes GR, Choueiri TK, **Stadler WM**, Wood LS, Bhatia S, Youssoufian H, Rowinsky EK, SChwarts JD, Thompson JA. Phase II study of IMC-1121B in patients with metastatic renal cancer following VEGFR-2 tyrosine kinase inhibitor therapy. Proc Genitourinary Cancer Symposium, Abst 326, 2010

232. *Harzstark AL, Halabi, S, **Stadler WM**, Vaena DA, Atkins JN Picus J, Czaykowski P, Dutcher JP, Rini BI, Small EJ. Hypertension is associated with clinical outcome for patients with metastatic renal cell carcinoma treated with interferon and bevacizumab on CALGB 90206. Proc Genitourinary Cancer Symposium, Abst 351, 2010

233. *Halabi S, Rini BI, **Stadler WM**, Archer L, Small EJ. Evaluation of progression free survival as a predictor of overall survival in patients with metastatic renal carcinoma. Proc Genitourinary Cancer Symposium, Abst 385, 2010

234. *Bylow K, Hemmerich J, Mohile S, **Stadler W,** Dale W. Does Hormone Therapy for Prostate Cancer Cause Obese Fraility? American Geriatrics Society Ann Meeting, Poster B6, 2010

235. *Trask PC, Bushmakin AG, Cappelleri JC, Tarazi JC, Rosbrook B, Bycott PW, Kim S, **Stadler WM**, Rini BI. Can patient-reported kidney cancer-specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma? J Clin Oncol 28 (15S): 1636 (abstract), 2010

236. *Kwon N, Lee RT, Ray M, Szmulewitz RZ, Von Roenn JH, **Stadler WM**, Curlin FC. The incidence of potential medication interactions including herbs and supplements among breast and prostate cancer patients during and after systemic anticancer therapy. J Clin Oncol 28 (15S): 9028 (abstract), 2010

237. *Sharma M, Karrison T, Maitland ML, **Stadler WM**, Ratain MJ. VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints. J Clin Oncol 28 (15S): 2520 (abstract), 2010

238. *Synold TW, Tsao-Wei DD, Quinn DI, Groshen SG, Aparicio A, Twardowski P, **Stadler WM**, Gandara DR, Lara P Jr., Newman EM. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC). J Clin Oncol 28 (15S): 2527 (abstract), 2010

239. *Cohen EE, Sharma M, Janisch LA, **Stadler WM**, Kang SP, Fleming GF, Ratain MJ. A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies. J Clin Oncol 28 (15S): 2591 (abstract), 2010

240. *Dreicer R, Agus DB, MacVicar GR, Wang J, MacLean D, **Stadler WM**. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study. J Clin Oncol 28 (15S): 3084 (abstract), 2010

241. *Nallari AS, Karrison T, Rosner GL, Levine MR, Sit L, Wu K, **Stadler WM**, Ratain MJ, Cohen EE, Maitland ML. Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response. J Clin Oncol 28 (15S): 3091 (abstract), 2010

242. *Halabi S, Rini BI, **Stadler WM**, Small EJ. Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma. J Clin Oncol 28 (15S): 4525 (abstract), 2010

243. **Pili R, Haggman M, **Stadler WM**, DGingrich JR, Assikis VJ, Bjork A, Forsberg G, Carducci MA, Armstrong AJ. A randomized, multicenter, international phase II study of tasquinimod in chemo-therapy naïve patients with metastatic castrate-resistant prostate cancer. J Clin Oncol 28 (15S): 4510 (abstract), 2010*

244. * Dale W, Bylow KA, Hemmerich J, Mohile SG, Sajid S, **Stadler WM**. Association of ADT for older men with biochemical recurrence of prostate cancer with obese frailty and falls: A case-control study. J Clin Oncol 28 (15S): 4675 (abstract), 2010

245. *Szmulewitz RZ, Posadas EM, Manchen B, **Stadler WM**. A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer. J Clin Oncol 28 (15S): TPS241 (abstract), 2010

246. *Quinn DI, Aparicio A, Tsao-Wei DD, Groshen SG, Dorff TB, Synold TW, **Stadler WM**, Gandara DR, Lara P Jr., Newman EM. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)—Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial. J Clin Oncol 28 (15S): 4539 (abstract), 2010

247. * Hahn NM, **Stadler WM**, Zon R, Waterhouse DM, Picus J, Nattam SR, Johnson CS, Perkins SM, Waddell MJ, Sweeney C. Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma. J Clin Oncol 28 (15S): 4541 (abstract), 2010

248. **Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, **Stadler WM**, Morris MJ, Kantoff P, Monk JP III, Small. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 28 (15S): 4511 (abstract), 201*0

249. **Gschwen JE, Bukowski, R, Eisen T, **Stadler WM**, Szcylik CS, Oudard OS, Siebels MS Michel MS, Grimm MO, Escudier BE. Wirksamkeit und Vertraeglichkeit von Sorafenib bei Patienten mit fortgeschrifttenem klarzelligem Nierenzelkarzinom mit Knochenmetastasen: Ergebnisse der Phase II Targets-Studie. Deutsche Gesellschaft fuer Haematologie und Onkologie, 2010*

250. **Campbell NP, Wroblewski K, Maki RG, D'Adamo DR, Chow W, Gandara D, Antonescu CR, **Stadler WM**, Vokes EE, Kindler HL. Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST). Proc ASCO GI Symposium, Abst 4, 2011*

251. *Feifer A, Taylor JM, Shouery M, Steinberg GD, **Stadler WM**, Schoenberg M, Zlotta A, Lerner SP, Bajorin DF, Bochner B. Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I. J Clin Oncol 29: 2011 (suppl 7; abstr 240)

252. ***Stadler WM**, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Rosen PJ, Lin C, Mahoney JF, Zhao C, Carducci MA. Phase II study of single-agent volasertib (BI 6727) for second-line treatment of urothelial cancer. J Clin Oncol 29: 2011 (suppl 7; abstr 253)

253. *Chen JL, Li J, **Stadler WM**, Lussier YA. Use of protein-network modeling of prostate cancer gene signatures to investigate essential pathways in disease recurrence. J Clin Oncol 29: 2011 (suppl 7; abstr 46)

254. *Szmulewitz RZ, Wyche AJ, Posadas EM, **Stadler WM**. Fluorescence-activated cell sorting (FACS) and immunofluorescence (IF) detection and characterization of circulating tumor cells (CTC) from men with castrate-resistant prostate cancer (CRPC). J Clin Oncol 29: 2011 (suppl 7; abstr 41)

255. Ward JE, Limvorasak S, Karrison T, Chatta GS, Hussain M, Shevrin DH, Szmulewitz RZ, **Stadler WM**, Posadas EM. A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consortium study. J Clin Oncol 29: 2011 (suppl 7; abstr 170)

256. *Armstrong AJ, Haggman M, **Stadler WM**, Gingrich JR, Assikis VJ, Nordle O, Forsberg G, Carducci MA, Pili R. Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups. J Clin Oncol 29: 2011 (suppl 7; abstr 126)

257. *Stein MN, Khan I, Hussain M, Liu G, Wilding G, Posadas EM, **Stadler WM**, Jeyamohan C, Eddy S, DiPaola RS. Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC). J Clin Oncol 29: 2011 (suppl 7; abstr 137)

258. *Karrison T., Rosner G, **Stadler WM**, Ratain M. Estimation of survival for all treated patients in the randomized discontinuation trial design. Soc for Clinical Trials, 32nd Ann Meeting, May 15-18, 2011, Vancouver, BC

259. **Feifer A, Taylor J, Shouery M, Savage C, Steinberg G, **Stadler WM**, DeCastro J, Lerner S, Godoy G, Lotan Y, Feldman AS, Psutka S, Kassouf W, Yafi F, Zlotta A, Black P, Schoenberg M, Grubb R III, O'Donnell M, Rosevear H, Stephenson A, Patel A, Lee C, Weizer A, Bajorin D, Milowsky M, Dalbagni G, Basch E, Bochner B. Multi-Institutional quality of care initiative for non-metastatic muscle-invasive transitional cell carcinoma of the bladder: Phase 1. Proc Ann Meeting Amer Urol Association, abst 485, 2011*

260. *Kindler HL, Campbell NP, Wroblewski K, Maki RG, D'Adamo DR, Chow WA, Gandara DR, Antonescu C, **Stadler WM**, Vokes EE. Sorafenib in patients with imatinib and sunitinib -resistant gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. J Clin Oncol 29: 2011 (suppl; abstr 10009)

261. *Campbell NP, Kunnavakkam R, Leighl NB, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah ES, Thomas SP, **Stadler WM**, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: A phase II trial of The University of Chicago Phase II Consortium. J Clin Oncol 29: 2011 (suppl; abstr 7027)

262. ***Stadler WM**, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen PJ, Lin C, Mahoney JF, Modi SS, Lee P, Ernstoff MS, Su W, Spira AI, Ould Kaci M, Taube T, Vinisko R, Schloss C, Zhao C, Carducci MA. Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer. J Clin Oncol 29: 2011 (suppl; abstr 4567)

263. *Agus DB, **Stadler WM**, Shevrin DH, Hart L, MacVicar GR, Hamid O, Hainsworth JD, Gross ME, Wang J, de Leon L, MacLean D, Dreicer R. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer: Updated data from a phase I/II study. J Clin Oncol 29: 2011 (suppl; abstr 4531)

264. Chen JL, Appelbaum DE, Kocherginsky M, Rathmell K, McDermott DF, **Stadler WM**. FDG-PET as a predictive marker for therapy with everolimus in metastatic renal cell cancer. J Clin Oncol 29: 2011 (suppl; abstr e15047)

265. Maitland ML, Karrison T, Bakris GL, Fox K, Janisch LA, Karovic S, Levine MR, House L, Wright JJ, Cohen EE, Fleming GF, Seiwert TY, Villaflor VM, **Stadler WM**, Ratain MJ. Pharmacodynamic assessment of blood pressure (BP) in a randomized dose-ranging trial of sorafenib. J Clin Oncol 29: 2011 (suppl; abstr 3016)

266. *Armstrong AJ, Gingrich JR, Häggman M, **Stadler WM**, Damber JE, Belkoff L, Clark R, Brosman S, Nordle O, Forsberg G, Carducci MA, Pili R. Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer. 27th Annual Congress of the European Association of Urology, abstract 126, 2012

267. * Agus DB, **Stadler WM**, Shevrin DH, Hart L, MacVicar GR, Hamid O, Hainsworth JD, Gross ME, Wang J, Webb IJ, MacLean D, Dreicer R.. Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. J Clin Oncol. 2012 30(5_suppl):98. doi: 10.1200/jco.2012.30.5_suppl.98. PMID: 28143341

268. *Grivas P, Nanus D, **Stadler WM**, Daignault S, Dreicer R, Kohli M, Petrylak D, Vaughn D, Bylow K, Belldegrun A, Sottnik JL, Keller E, Smith D, Hussain M. Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma. Proc 2012 Genitourinary Cancer Symposium, San Francisco, abst 265, 2012

269. *Drake CG, Fishman MN, Curti BD, Kim JJ, **Stadler WM**, McNeel DG, Choueiri TK, Redman B, Hudes GR, Jure-Kunkel M, McDonald D, Gupta AK, Pathak AK, Wigginton J, Sznol M. An exploratory study to investigate the immunomodulatory activity of BMS-936558 in patients with metastatic clear-cell renal cell carcinoma. J Clin Oncol 30, 2012 (suppl; abstr TPS2613)

270. *Chugh R, Griffith KA, Brockstein B, Undevia SD, **Stadler WM**, Schuetze S. Phase I study of doxorubicin (D) plus anti-insulin-like growth factor 1 receptor (IGF-1R) antibody cixutumumab (IMC-A12) in advanced soft tissue sarcoma (STS). J Clin Oncol 30, 2012 (suppl; abstr 10028)

271. *Smith SM, Cohen KS, Kline JP, Zavala JD, Conner K, Thomas SP, Lesho P, Doyle LA, **Stadler WM**, Karrison T, Kimball AS. Phase I trial of temsirolimus and lenalidomide in pts with rel/ref lymphomas. J Clin Oncol 30, 2012 (suppl; abstr 8075)

272. *Small EJ, Halabi S, Carducci MA, Ryan CJ, George DJ, Mahoney JF, **Stadler WM**, Morris MJ, Kantoff P, Monk JP, Kelly WK. The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401). J Clin Oncol 30, 2012 (suppl; abstr 4667)

273. *Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, **Stadler WM**, Morris MJ, Kantoff PW, Monk JP, Small EJ. Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). J Clin Oncol 30, 2012 (suppl; abstr 4655)

274. *Armstrong AJ, Haggman M, **Stadler WM**, Gingrich JR, Assikis VJ, Polikoff J, Denmeade SR, George DJ, Andreou C, Clark WR, Sieber P, Agajanian R, Belkoff L, Damber J-E, Nordle O, Forsberg G, Carducci MA, Pili R. Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial. J Clin Oncol 30, 2012 (suppl; abstr 4550)

275. *Chen JL, Rathmell K, McDermott DF, **Stadler WM**. Circulating mir-21 and mir-378 are predictive of progression-free survival (PFS) in patients treated with everolimus in metastatic renal cell cancer (mRCC). J Clin Oncol 30, 2012 (suppl; abstr 4617)

276. *Pond GR, Sonpavde G, Choueiri TK, Qu AQ, Vaughn DJ, Fougeray R, Niegisch G, Albers P, Wong Y-N, Ko Y-J, Sridhar SS, Galsky MD, Petrylak DP, Beer TM, **Stadler WM**, O'Donnell PH, Sternberg CN, Rosenberg JE, Molins JB. Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy. J Clin Oncol 30, 2012 (suppl; abstr 4522)

277. *Catenacci DVT, Bahary N, Edelman MJ, Nattam SR, Marsh RdW, Kaubisch A, Wallace JA, Cohen DJ, Stiff PF, Sleckman BG, Thomas SP, Lenz H-J, Henderson L, Zagaya C, Vannier M, Karrison T, **Stadler WM**, Kindler HL. A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study. J Clin Oncol 30, 2012 (suppl; abstr 4022)

278. *Heery CR, Madan RA, Bilusic M, Kim JW, Singh NK, Rauckhorst M, Chen W, Dahut WL, **Stadler WM**, DiPaola RS, Stein MN, Hodge JW, Schlom J, Gulley JL. Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. J Clin Oncol 30, 2012 (suppl; abstr 2526)

279. *MacLean DB, **Stadler WM**, Shevrin D, Hart L, Wang J, Webb I, Dreicer R. Selective Inhibition of Androgen Synthesis by Orteronel (ortl), an Investigational 17,20-Lyase Inhibitor, in Men with Metastatic Castrate-Resistant Prostate Cancer (mCRPC). Proc Endocrine Society, 2012 (abst SUN-258)

280. *Brown RL, Karrison TG, Vokes EE, Seiwert TY, Heinlen P, Bozeman J, **Stadler WM**, Cohen EE. Phase I Study of Cediranib (CED) and Lenalidomide (LEN) in Patients (pts) with Advanced Differentiated Thyroid Cancers (DTCs) — A Trial of the University of Chicago Phase II Consortium. Proc Endocrine Society, 2012 (abst SUN-281)

281. **O'Donnell PH, Wyche AJ, Wing C, Koyner JL, **Stadler WM**, Murray PM. Urinary α-Glutathione S-Transferase (GST) May Identify Patients at Highest Risk for Renal Injury (AKI) During Cisplatin Chemotherapy. Amer Soc Nephrology Annual Meeting, 2012 (abst TH-OR037)*

282. *Sonpavde1 G, Pond GR, Choueiri TK, Fougeray R, Niegisch G, Wong Y-N, Sridhar SS, **Stadler WM**, Sternberg CN, Bellmunt J.. Prognostic Stratification of Advanced Urothelial Carcinoma Receiving Second-Line Systemic Therapy Including Time From Prior Chemotherapy as a Prognostic Factor. Eur Soc Clinical Oncol (ESMO), 2012 (abst 804P)

283. *Carducci M, Armstrong A, Häggman M, **Stadler WM**, Gingrich JR, Assikis V, Forsberg G, Olsson A, Nordle O, Pili R. Tasquinomod Mechanism of Action Biomarkers: Correlation With PFS and

Survival in Men With Metastatic Castrate Resistant Prostate Cancer Treated in a Randomized Phase 2 Trial. Eur Soc Clinical Oncol (ESMO), 2012 (abst 919P)

284. *Shevrin DH, MacVicar GR, Kuzel T, **Stadler WM**, Jovanovic B, Kaul K, Wang Z. Effect of dutasteride on tumor proliferation during the regrowth phase of intermittent androgen ablation therapy in men with advanced prostate cancer. Proc 2013 Genitourinary Cancer Symposium, Orlando FL (abst 21)

285. *Smith MR, Halabi S, Ryan CJ, **Stadler WM**, Hussain A, Vogelzang NJ, Hauke RJ, Sanford BL, Small EJ. Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). Proc 2013 Genitourinary Cancer Symposium, Orlando FL (abst 27)

286. *VanderWeele DJ, Taxy JB, **Stadler WM**, White KP. The molecular relationship among concurrent prostate cancer foci. Proc 2013 Genitourinary Cancer Symposium, Orlando FL (abst 43)

287. *O'Donnell PH, Alanee S, Cao H, Ostrovnaya I, Garcia-Grossman IR, Ganshert C, Smith ND, Steinberg GD, Offit K, **Stadler WM**, Bajorin DF. Prediction of pathologic complete response to neoadjuvant chemotherapy in urothelial cancer by genetic determinants of platinum sensitivity. Proc 2013 Genitourinary Cancer Symposium, Orlando FL (abst 290)

288. *Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu AQ, Fougeray R, Niegisch G, Galsky MD, Wong Y-N, **Stadler WM**, Sridhar SS, Sternberg CN, Sonpavde G. Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). Proc 2013 Genitourinary Cancer Symposium, Orlando FL (abst 301)

289. *VanderWeele DJ, Brown CD, Grossman RL, Taxy JB, **Stadler WM**, White KP. The genomic relationship among matched prostate cancer foci. J Clin Oncol 31, 2013 (suppl; abstr 5028)

290. Geynisman DM, Hlubocky FJ, Kocherginsky M, Duster SM, Gomez JX, **Stadler WM**, Daugherty C. Adherence (adh) to and beliefs about oral anticancer medications (OAMs) in metastatic renal cell carcinoma (mRCC) patients (pts): A single-center pilot study in the United States. J Clin Oncol 31, 2013 (suppl; abstr e17511)

291. *Armstrong AJ, Halabi S, Eisen T, **Stadler WM**, Jones RR, Vaishampayan UN, Garcia JA, Hawkins RE, Kollmannsberger CK, Lusk C, Broderick S, George DJ. ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma. J Clin Oncol 31, 2013 (suppl; abstr TPS4590)

292. *Armstrong AJ, Kaboteh R, Carducci MA, Damber J-E, **Stadler WM**, Mats H, Edenbrandt L, Forsberg G, Nordle O, Pili R, Morris MJ. Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod. J Clin Oncol 31, 2013 (suppl; abstr 5081)

293. *Catenacci DVT, Bahary N, Nattam SR, Marsh RdW, Wallace JA, Rajdev L, Cohen DJ, Sleckman BG, Lenz H-J, Stiff PJ, Thomas SP, Xu P, Henderson L, Horiba MN, Vannier M, Karrison T, **Stadler WM**, Kindler HL. Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic

pancreatic cancer (PC): A University of Chicago phase II consortium study. J Clin Oncol 31, 2013 (suppl; abstr 4012)

294. *Sonpavde G, Pond GR, Agarwal N, Choueiri TK, Qu AQ, Fougeray R, Salhi Y, Vaughn DJ, James ND, Niegisch G, Albers P, Galsky MD, Wong Y-N, **Stadler WM**, O'Donnell PH, Vogelzang NJ, Sridhar SS, Ko Y-K, Sternberg CN, Bellmunt J. Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC). J Clin Oncol 31, 2013 (suppl; abstr 4524)

295. *Byrn M, Martell BL, Crist RJ, **Stadler WM**. Processing Mapping of Study Initiation Phase: Creation of New "Activation Phase"CTSA- Sixth Annual Clinical Research Management Workshop "Putting the Pieces Together" Washington DC June 3-4, 2013

296. *Quevedo E, Crist RJ, Martell BL, **Stadler WM**. A Root-Cause Analysis of Contract Delays CTSA-Sixth Annual Clinical Research Management Workshop "Putting the Pieces Together" Washington DC June 3-4, 2013

297. *Geynisman DM, Hlubocky FJ, Kocherginsky M, **Stadler WM**, Daugherty CK. Adherence to and beliefs about oral anticancer medications in metastatic renal cell carcinoma patients. ASCO Quality Care Symposium, abst 25, 2013

298. **Quinn DI, Twardowski PW, Wei YE, Groshen SG, Dorff TB, Aparicio AM, **Stadler WM**, Gandara DR, Lara PN, Newman EM. Phase II study of eribulin in platinum-treated, tubulin naive advanced urothelial cancer (UC) - A California Cancer Consortium trial (NCI/CTEP 7435). ESMO, abst 2704, 2013*

299. *VanderWeele DJ, Taxy JB, **Stadler WM**, White KP. The molecular relationship among concurrent prostate cancer foci. J Clin Oncol 31, 2013 (suppl 6; abstr 43)

300. *O'Donnell PH, Alanee S, Cao H, Ostrovnaya I, Garcia-Grossman IR, Ganshert C, Smith ND, Steinberg GD, Offit K, **Stadler WM**, Bajorin DF. Prediction of pathologic complete response to neoadjuvant chemotherapy in urothelial cancer by genetic determinants of platinum sensitivity. J Clin Oncol 31, 2013 (suppl 6; abstr 290)

301. *Shevrin DH, MacVicar GR, Kuzel T, **Stadler WM**, Jovanovic B, Kaul K, Wang Z. Effect of dutasteride on tumor proliferation during the regrowth phase of intermittent androgen ablation therapy in men with advanced prostate cancer. J Clin Oncol 31, 2013 (suppl 6; abstr 21)

302. *Smith MR, Halabi S, Ryan CJ, **Stadler WM**, Hussain A, Vogelzang NJ, Hauke RJ, Sanford BL, Small EJ. Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). J Clin Oncol 31, 2013 (suppl 6; abstr 27)

303. *Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu AQ, Fougeray R, Niegisch G, Galsky MD, Wong Y-N, **Stadler WM**, Sridhar SS, Sternberg CN, Sonpavde G. Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). J Clin Oncol 31, 2013 (suppl 6; abstr 301)

304. *Mata DA, Groshen S, Skinner DG, **Stadler WM**, Cote RJ, Lerner SP. Surgical quality variability, time to recurrence, and overall survival following radical cystectomy and pelvic lymph node dissection for bladder urothelial carcinoma. 14th Ann Meeting Society of Urologic Oncology, Bethesda, MD, 2013 (poster 21)

305. *VanderWeele DJ, Isikbay M, Reyes E, Duggan R, Wyche AJ, **Stadler WM**, Vander Griend D, Szmulewitz RZ. Feasibility of multimodal molecular characterization of the androgen receptor (AR) in circulating tumor cells (CTCs) from patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 32, 2014 (suppl 4; abstr 133)

306. *O'Donnell PH, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Stratton KL, Manschreck C, Smith ND, Steinberg GD, Joseph V, Offit K, **Stadler WM**, Bajorin DF. Clinical evaluation of cisplatin sensitivity germ line polymorphisms in neoadjuvant chemotherapy (NAC) for urothelial cancer (UC). J Clin Oncol 32, 2014 (suppl 4; abstr 342)

307. *Bochner BH, Feifer A, Sperling D, Mashni JW, Bajorin DF, Shah JB, Kamat AM, Steinberg GD, **Stadler WM**, Grubb RI, Kibel AS, Schoenberg M, Black PC, Zlotta A, Kassouf W, Lerner SP, Lotan Y, Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa). J Clin Oncol 32, 2014 (suppl 4; abstr 298)

308. *Feldman DR, **Stadler WM**, Appleman LJ, Quinn DI, Costello BA, Schwartz GK, Reuter VE, Woo K, Patil S, Fusco A, Smith SC, Carlson J, Bosl GJ, Motzer RJ. Multicenter sequential phase II study of flavopiridol plus oxaliplatin (alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR). J Clin Oncol 32, 2014 (suppl 4; abstr 364)

309. *Lerario AM, Worden FP, Ramm CA, Hasseltine EA, **Stadler WM**, Shah MH, Agamah E, Rao K, Hammer GD. The Combination of Insulin-like Growth-Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane As a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: A Multi-Institutional NCI-Sponsored Phase II Study. ICE/ENDO 2014, Chicago, Illinois (https://endo.confex.com/endo/2014endo/webprogram/authora.html)

310. *Bochner B, Sperling D, Feifer A, Mashni Jr J, Bajorin D, Dalbagni G, Herr H, Donat SM, Milowsky M, Shah J, Kamat A, Grossman HB, Grubb III R, Brandes S, Bullock A, Strope S, Roth B, Kibel A, Weigand L, Steinberg G, **Stadler W**, Rutiaga N, Schoenberg M, Bivalacqua T, Rogers C, Black P, So A, Gleave M, Kassouf W, Bachir B, Yafi F, Lerner S, Godoy G, Amiel G, Zlotta A, Fleshner N, Jewett M, Kulkarni G, Sridhar S, Tanock I, Joshua A, Bostrom P, Kuk C, Lotan Y, Dallas. Multi-Institutional Quality Care Initiative to Improve the Care of Patients with Muscle Invasive Bladder Cancer AUA Ann Meeting, Abst OCC W315 (http://www.aua2014.org/abstracts/searchabstracts.cfm), 2014

311. *Jasielec J, Kimball AS, Cohen KS, Kline JP, Rapoport A, Petrich AM, Nabhan C, Thomas S, Doyle LA, **Stadler WM**, Karrison T, Smith SM. Temsirolimus (TEM) and lenalidomide (LEN) in relapsed/refractory Hodgkin lymphoma including in patients with prior exposure to brentuximab vedotin (BV). Amer Soc Clin Oncology Annual Meeting, abstract 8567, 2014

312. *Chawla A, Adkins D, Worden FP, Rao KA, Hu HS, Andress K, Price R, Zavala JD, Karrison T, **Stadler WM**, Villaflor VM, Lussier YA, Vokes EE, Cohen EEW, Seiwert TY. Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck cancers: Results of the randomized PII MAESTRO study. Amer Soc Clin Oncology Annual Meeting, abstract 6089, 2014

313. * Owonikoko TK, Hussain A, **Stadler WM**, Smith DC, Sznol M, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli J, Cohen LJ. A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL). Amer Soc Clin Oncology Annual Meeting, abstract 2558, 2014

314. *Hertz DL, Jiang C, Owzar K, Halabi S, Kelly WK, Mulkey F, Patel JN, Carducci MA, Kelley MJ, **Stadler WM**, Mohamed MK, Morris MJ, Nakamura Y, Zembutsu H, Ratain MJ, McLeod HL. A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). Amer Soc Clin Oncology Annual Meeting, abstract 9612, 2014

315. *Kunju LP, Palanisamy N, Daignault S, Mehra R, Siddiqui J, Carskadon SL, Twardowski P, Stein MN, Hahn NM, **Stadler WM**, Jacobson J, Davenport MS, Tomlins SA, Chinnaiyan AM, Feng F Y-C, Hussain M. Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: Data from NCI 9012, a randomized ETS fusion-stratified phase II trial. Amer Soc Clin Oncology Annual Meeting, abstract 5019, 2014

316. **Choueiri TK, Fishman MN, Escudier BJ, Kim JJ, Kluger HM, **Stadler WM**, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman LJ, Fong L, Drake CG, Cohen LJ, Srivastava S, Jure-Kunkel M, Hong Q, Kurland JF, Sznol M. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. Amer Soc Clin Oncology Annual Meeting, abstract 5012, 2014*

317. *Choueiri T, Fishman M, Escudier B, Kim J, Kluger H, **Stadler W**, Perez-Garcia J, McNeel D, Curti, B, Harrison M, Plimack E, Appleman L, Fong L, Drake C, Cohen L, Srivastava S, Jure-Kunkel M, Hong Q, Kurland, J, Sznol M. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. Ann Oncol. 2014 Sep 1;25(suppl_4):iv362. doi: 10.1093/annonc/mdu342.4. PMID: 28171273

318. *Choudhury N, Campanile A, Wade JL, Antic T, **Stadler WM**, Nakamura Y, O'Donnell PH. Association of HER2 and ErbB3 molecular alterations with afatinib sensitivity in platinum-refractory metastatic urothelial carcinoma (UC) in a phase II trial. J Clin Oncol 33, 2015 (suppl 7; abstr 312)

319. *Jelinek MJ, Wyche AJ, Wing C, Koyner JL, **Stadler WM**, Murray PT, O'Donnell PH. Urine cystatin C (uCyC) as a predictor for acute kidney injury (AKI) in urothelial cancer (UC) patients (pts) treated with cisplatin (CDDP). J Clin Oncol 33, 2015 (suppl 7; abstr 317)

320. *Monk P, Liu G, **Stadler WM**, Geyer SM, Sexton JL, Wright JJ, Villalona-Calero MA, Wade JL, Szmulewitz RZ, Gupta S, Mortazavi A, Dreicer R, Pili R, Cooney MM, Dawson NA, George S, Garcia JA. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 33, 2015 (suppl 7; abstr 146)

321. *Kunju LP, Palanisamy N, Daignault S, Mehra R, Siddiqui J, Carskadon SL, Twardowski P, Albany C, Stein MN, **Stadler WM**, Jacobson J, Davenport MS, Tomlins SA, Chinnaiyan AM, Feng FY, Hussain M. Concordance of ETS Fusion Status of Matched Metastatic Castration-Resistant Prostate Cancer and Primary Prostate Cancer: Data From NCI 9012, a Randomized ETS Fusion-Stratified Phase II Trial", abstract confirmation #979, to the United States & Canadian Academy of Pathology's 104th Annual Meeting, March 21-27, 2015 in Boston, MA

322. *Chen Y, Garrett M, Rini B, Motzer RJ, Dutcher JP, Rixe O, Wilding G, **Stadler WM**, Tarazi J, Pithavala YK. Effect of renal impairment on the pharmacokinetics and safety of axitinib. American Society for Clinical Pharmacology and Therapeutics (ASCPT), March 3–7, 2015, New Orleans, LA

323. *Quinn DI, Twardowski PW, Ruel N, Groshen SG, Dorff TB, Pal SK, **Stadler WM**, Gandara DR, Lara PN, Newman EM. Phase II study of eribulin in advanced urothelial cancer (UC) patients (pts) previously treated with platinum and anti-microtubule chemotherapy: A California Cancer Consortium trial (NCI/CTEP 7435). 7th Asia Oncology Summit, 2015

324. *Haas NB, Manola J, Uzzo R, Flaherty K, Wood C, Kane C, Jewett M, Dutcher J, Atkins M, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel T, Sexton W, Wong Y, Choueiri T, Pili R, Puzanov R, Koli M, **Stadler W**, Coomes B, DiPaola R. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol 33, 2015 (suppl 7; abstr 403)

325. *Choueiri TK, Fishman MN, Escudier B, **Stadler WM**, Chasalow S, Ross-Macdonald P, Jure-Kunkel M, Sznol M, Simon JS. Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC). Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; 2015. Abstract 1306

326. Choudhury N, Campanile A, Wade JL, Antic T, **Stadler WM**, Nakamura Y, O'Donnell PH. Association of HER2 and ErbB3 molecular alterations with afatinib sensitivity in platinum-refractory metastatic urothelial carcinoma (UC) in a phase II trial. J Clin Oncol 33, 2015 (suppl; abstr e15516)

327. Campanile A, Medved M, Oto A, Karrison T, Shevrin DH, Karczmar GS, **Stadler WM**, Szmulewitz RZ. A Phase II study of MRI based functional imaging of bone metastases in men with metastatic castrate resistant prostate cancer (mCRPC) receiving XL184. J Clin Oncol 33, 2015 (suppl; abstr e16112)

328. Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin PAS, **Stadler WM**. Dynamic contrast enhanced-MRI (DCE-MRI) as a pharmacodynamic biomarker for pazopanib (PZ) in metastatic renal carcinoma (RC). J Clin Oncol 33, 2015 (suppl; abstr e15623)

329. **Quinn DI, Ruel N, Twardowski P, Groshen SG, Dorff TB, Pal SK, **Stadler WM**, Aparicio A, Lara P, Newman EM. Eribulin in advanced urothelial cancer (AUC) patients (pts): A California Cancer Consortium trial—NCI/CTEP 7435. J Clin Oncol 33, 2015 (suppl; abstr 4504)*

330. *Dorff TB, Longmate J, Pal SK, **Stadler WM**, Fishman MN, Vaishampayan MN, Rao AR, Hu J, Quinn DI, Lara P. Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer (mRCC): A California Cancer Consortium clinical trial. J Clin Oncol 33, 2015 (suppl; abstr 4542)

331. *Vokes EE, Worden FP, Adkins D, Bauman JE, Lim D, Sukari A, Rao KA, Wagner SA, Curtis KK, Gitlitz BJ, Price KAR, Wade JL, Villaflor VM, De Souza JA, Karrison T, **Stadler WM**, Seiwert TY. A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer. J Clin Oncol 33, 2015 (suppl; abstr 6060)

332. **Choueiri TK, Fishman MN, Escudier B, McDermott DF, Kluger HM, **Stadler WM**, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman LJ, Fong L, Drake CG, Young TC, Chasalow SD, Ross-Macdonald P, Simon JS, Walker D, Sznol M. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. J Clin Oncol 33, 2015 (suppl; abstr 4500)*

333. **Scher HI, Morris MJ, **Stadler WM**, Higano CS, Halabi S, Smith MR, Basch EM, Fizazi K, Ryan CJ, Antonarakis ES, Corn PJ, Liu G, De Bono JS, Schwartz LH, Beer TM, Kelly WK, Hussain M, Sartor AO, Kantoff PW, Armstrong AJ. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). J Clin Oncol 33, 2015 (suppl; abstr 5000)*

334. **Haas NB, Manola J, Flaherty K, Uzzo RG, Atkins MB, Dutcher JP, Wood CG, Kane CJ, Jewett MAS, Coomes B, Matin SF, Kuzel T, Sexton WJ, Wong Y-N, Choueiri TK, Pili R, Puzanov I, Kohli M, **Stadler WM**, DiPaola RS. Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial. J Clin Oncol 33, 2015 (suppl; abstr 4508)*

335. **Armstrong AJ, Broderick S, Eisen T, **Stadler WM**, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, Halabi S, George DJ. Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). J Clin Oncol 33, 2015 (suppl; abstr 4507)*

336. *Galanina N, Smith SM, Liao C, Petrich AM, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost J, **Stadler W**, Doyle A, Karrison T, Gordon LI, Evens AM. Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial. Amer Society Hematology, abstract 3990, 2015

337. *Choudhury N, Campanile A, Antic T, Wade JL, **Stadler WM**, Nakamura Y, O'Donnel PH. Afatinib activity in platinum-refractory metastatic urothelial carcinoma (UC) patients with ErbB alterations: Results of a phase II trial. J Clin Oncol 34, 2016 (suppl 2S; abstr 459)

338. *Dorff TB,Longmate J, Groshen SG, **Stadler WM**, Fishman MN, Vaishampayan UN, Pinski JK, Pal SK, Hu J, Quinn DI, Lara P. Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC). J Clin Oncol 34, 2016 (suppl 2S; abstr 522)

339. *Harrison MR, Bhavsar NA, Wolf SP, Costello BA, **Stadler WM**, Hammers HJ, Vaishampayan UN, Appleman LH, Tsao C-K, Creel PA, Samsa GP, Richardson EM, Johnson KA, Borham A, George DJ. Front-line management patterns in the prospective metastatic renal cell cancer (MaRCC) registry. J Clin Oncol 34, 2016 (suppl 2S; abstr 617)

340. *Kyriakopoulos C, Harrison MR, Bhavsar NA, Wolf SP, Costello BA, **Stadler WM**, Hammers HJ, Vaishampayan UN, Appleman LJ, Creel PA, Samsa GP, Richardson EM, Johnson KA, Borham A,George DJ. Physician treatment selection in the prospective Metastatic Renal Cell Cancer (MaRCC) Registry. J Clin Oncol 34, 2016 (suppl 2S; abstr 563)

341. *Harshman LC, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, **Stadler WM**, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS. Exploring multidisciplinary practice patterns in the management of muscle invasive bladder cancer (MIBC) across the U.S. and Canada in 2015. J Clin Oncol 34, 2016 (suppl 2S; abstr 368)

342. *Szmulewitz RA, Nabhan C, O'Donnell PH,Kach J, Karrison T,Martinez E, **Stadler WM**. A phase I/II trial of enzalutamide plus the glucocorticoid receptor antagonist mifepristone for patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 34, 2016 (suppl; abstr TPS5091)

343. Sweis RF, Bao R, Spranger S, Paner G, **Stadler WM**, Steinberg GD, Gajewski T. Validation of activated molecular pathways in non-T cell-inflamed urothelial bladder cancer. J Clin Oncol 34, 2016 (suppl; abstr e23114)

344. Harrison MR, Bhavsar NA, Wolf SP, Costello BA, Vaishampayan UN, Kyriakopoulos C, **Stadler WM**, Hammers HJ, Appleman LJ, Tsao C-K, Pal SK, Hussain A, Jim HSL, Borham A, George DJ. Deferred systemic therapy (DST) in the prospective metastatic renal cell cancer (MaRCC) registry. J Clin Oncol 34, 2016 (suppl; abstr e16084)

345. Harrison MR, Bhavsar NA, Wolf SP, Costello BA, Vaishampayan UN, Kyriakopoulos C, **Stadler WM**, Hammers HJ, Appleman LJ, Tsao C-K, Pal SK, Hussain A, Jim HSL, Borham A, George DJ. Prospective front-line management patterns in the Real World Metastatic Renal Cell Cancer (MaRCC) Registry. J Clin Oncol 34, 2016 (suppl; abstr e16097)

346. *De Souza JA, Karrison T, Libao B, Worden FP, Krzyzanowska M, Hayes DN, Winquist E, Saloura V, Villaflor VM, Seiwert TY, **Stadler WM**, Cohen EEW, Schechter RB, Vokes EE. Randomized phase 2 trial of cediranib alone or cediranib plus lenalidomide in iodine 131-refractory differentiated thyroid cancer (DTC): A University of Chicago Phase 2 Consortium trial. J Clin Oncol 34, 2016 (suppl; abstr 6013)

347. **Hussain M, Daignault S, Twardowski P, Albany C, Stein MN, Kunju LP, Siddiqui J, Robinson D, Mehra R, Cooney KA, Montgomery RB, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, ***Stadler WM***, Feng FY-C, Chinnaiyan AM. Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)—A University of Chicago phase II consortium trial. J Clin Oncol 34, 2016 (suppl; abstr 5010)*

348. *Feng FY, Daignault-Newton S, Jendrisak A, Wang Y, Greene S, Rodriguez A, Lee J, Dugan L, Siddiqui J, Louw J, Johnson C, Twardowski P, Albany C, Stein M, **Stadler WM**, Kunju L, Chinnaiyan AM, Landers M, Dittamore R, Hussain M. Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial. Ann of Oncol, V27, supp6 730PD

349. *Pal SK, Motzer RJ, Fishman MN, McDermott RS, Passos-Coelho J, Kopyltsov E, Garcia del Muro X, Donas JG, Yildiz R, Wood L, Zalewski P, Costello BA, **Stadler WM**, Kuzel TM, Williamson SK, Kondo TA, Markby DM, Escudier B, Powles T, Choueir TK. Analysis of overall survival based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. J Clin Oncol 35, 2017 (suppl 6S; abstract 522)

350. *Szmulewitz RZ, Ibraheem AF, Peer CJ, Figg WD, Carthon BC, Kozloff M, Harvey D, Fishkin PAS, Yong WP, Chiong E, Nabhan C, O'Donnell PH, **Stadler WM**, Ratain MJ. A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics and pharmacodynamics of abiraterone acetate in men with castration-resistant prostate cancer. J Clin Oncol 35, 2017 (suppl 6S; abstract 176)

351. *Albany C, Daignault-Newton S, Skaar TC, Ipe J, Siddiqui J, Twardowski P, Stein MN, Kunju LP, Chinnaiyan AM, Montgomery RB, Antonarakis ES, Shevrin DH, Whang YE, Caram MV, Smith DC, Feng F Y-C, **Stadler WM**, Hussain M. Genetic polymorphisms to predict progression-free survival in patients with metastatic castration-resistant prostate cancer receiving abiraterone therapy: Results from the NCI 9012 trial. J Clin Oncol 35, 2017 (suppl 6S; abstract 145)

352. **McDermott DF, Atkins MB, Motzer RJ, Rini BI, Escudier BJ, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth JD, **Stadler WM**, Hutson TE, Ravaud A, Bracarda S, Suarez C, Choueiri TK, Choi Y, Huseni MA, Fine GD, Powles T. A phase II study of atezolizumab with or without bevacizumab (bev) versus sunitinib in untreated metastatic renal cell carcinoma patients. J Clin Oncol 35, 2017 (suppl 6S; abstract 431)*

353. **Atkins MB, McDermott DF, Powles T, Motzer RJ, Rini BI,Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth JD, **Stadler WM**, Hutson TE, Ravaud A,Bracarda S, Suarez C, Choueiri TK, Qiu J, Huseni MA, Schiff C, Escudier BJ. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol 35, 2017 (suppl; abstr 4505)*

354. **Hussain M, Daignault S, Twardowski P, Albany C, Stein MN, Kunju LP, Robinson DR, Cooney KA, Montgomery RB, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Tomlins SA, Knudsen KE, **Stadler WM**, Feng FY-C, Chinnaiyan AM. Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data. J Clin Oncol 35, 2017 (suppl; abstr 5001)*

355. **Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, **Stadler WM**, Donskov F, Lee J-L, Hawkins RE, Ravaud A, Alekseev BY, Staehler MD, Uemura M, Donaldson F, Li S, Huseni MA, Schiff C, Rini BI. IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma. J Clin Oncol 36, 2018 (suppl 6S; abstr 578)*

356. **Feldman DR, Hu J, Srinivas S, **Stadler WM**, Costello BA, Appleman LJ, Milowsky MI, Patil S, Bromberg M, Nolan P, Dorff TB, Reuter VE, Al-Ahmadie H, Funt S, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ. Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). J Clin Oncol 36, 2018 (suppl; abstr 4508)*

357. **Escudier B, Motzer RJ, Rini BI, Powles T, McDermott DF, Suarez C, Bracarda S, **Stadler WM**, Donskov F, Gurney H, Oudard S, Uemura M, Lam ET, Grüllich C, Ding B, Khaznadar T, Quach C, Piault E, Schiff C, Atkins MB. Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). J Clin Oncol 36, 2018 (suppl; abstr 4511)*

358. *Dittamore R, Wang Y, Daignault-Newton S, **Stadler WM**, Jendrisak A, Feng FY, Dago AE, Lee J, Graf RP, Landers MA, Chinnaiyan A, Hussain M; Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC. J Clin Oncol 36, 2018 (suppl; abstr 5012)

359. *Vaishampayan UN, McDermott DF, Matrana MR, Rha SY, Zurita AJ, Ho TH, Keam B, Lee J-L, Joseph RW, Ali S, **Stadler WM**, Haas NB, Sundararajan S, Park SH, Mowat RB, Picus J, Dudek AZ, Zakharia Y, Gan L, Atkins MB. A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma. J Clin Oncol 36, 2018 (suppl; abstr 4510)

360. *Wei XX, McKay RR, Gray KP, **Stadler WM**, McDermott DM, McGregor BA, Agarwal N, Kyriakopoulos C, Carneiro BA, Rose TL, Zakharia Y, Braun DA, Livak KJ, Wu CJ, Van Allen EM, Signoretti S, Lang JM, Hodi FS, Choueiri TK, Harshman LC; Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. J Clin Oncol 36, 2018 (suppl; abstr TPS4600)

361. *Desai A, Brewer JR, Medved M, Oto A, Gao G, Karrison T, Shevrin DH, Karczmar GS, **Stadler WM**, Szmulewitz RZ. Final analysis of a phase II study of MRI based functional imaging of bone metastases in men with metastatic castrate-resistant prostate cancer (mCRPC) receiving Cabozantinib. J Clin Oncol 37, 2019 (suppl 7S; abstr 213)

362. **Rosenberg JE, Ballman KV, Halabi S, Watt C, Hahn OM, Steen PD, Dreicer R, Flaig TW, **Stadler WM**, Sweeney C, Mortazavi A, Morris MJ. CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. J Clin Oncol 37, 2019 (suppl; abstr 4503)*

363. *Feldman DR, Hu JS, Patil S, Reuter VE, Srinivas S, **Stadler WM**, Costello BA, Milowsky MI, Appleman LJ, Dorff TB, Bromberg M, Joseph G, Funt SA, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ. Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT). J Clin Oncol 37, 2019 (suppl; abstr 4563)

364. *Alter RA, Fleming GF, **Stadler WM**, Patnaik A. A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer. J Clin Oncol 37, 2019 (suppl; abstr TPS2663)

365. **McKay RR, Wie W, McGregor BA, Braun DA, Wei XX, Kyriakopoulos C, Zakharia Y, Maughan BL, Rose TL, **Stadler WM**, McDermott DF, Harshman LC, Choueiri TK. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). J Clin Oncol 38: 2020 (suppl; abstr 5005)*

366. Yang H, Knoebel RW, Parsad S, Carroll E, **Stadler WM**. Evaluation of prescribing practices of denosumab and zoledronic acid in breast and prostate cancer patients at University of Chicago MedicineJ Clin Oncol 38: 2020 (suppl; abstr e24144)

Pamphlets, Brochures, Misc Publications, and Lay Press

1. Steinberg GD, **Stadler WM**. New approaches for the assessment and treatment of superficial and invasive bladder cancer. Univ of Chicago Clinical Comment, U of C press, 1996

2. **Stadler WM**, Coiffier B, Pazdur R. (advisory editors). Therapeutic advances in oncology: ASCO 1997 Congress Report Series. Colwood House Medical Publications (UK), Berkshire, United Kingdom, 1997

3. Bukowski RM, **Stadler WM**. Treatment of patients with renal cell carcinoma: The emergence of targeted agents. Oncology Consultations, Vol 2, No 2, 2005

4. **Stadler WM.** Interview for: "In Focus: Renal Cell Carcinoma, Angiogenesis Inhibition in Non-Clear Cell Renal Cancer." Clinical Advances in Hematology Oncology, 6:507-509, 2008

5. Roth BJ, Bajorin DF, **Stadler WM**. The Controversy: The Timing of Chemotherapy in Early-stage, Muscle-invasive Bladder Cancer. ASCO News & Forum. 2009; Vol. 4, 1, 16-19

6. **Stadler WM (Chair)**, Feldman D, Milowsky M, Rini BI, Ryan CJ. University of Chicago Pritzker School of Medicine Genitourinary Oncology Self Assessment Program (up to 35 AMA Category 1 CME credits). Professional Evaluation, Inc., Berwyn, PA © 2010

7. **Stadler WM.** How Do I Treat ….A Patient with Newly Diagnosed Metastatic Renal Cancer. Oncology Times v32, issue 24 (Dec 25, 2010)

8. **Stadler WM.** Key GU Takeaways, ASCO 2011. Oncology Times v33, issue 16 (Aug, 2011)

9. **Stadler, WM.** Key GU Takeaways, ASCO 2012. Oncology Times (online first posted 6/11/12)

FUNDING

Pending

Organization	Title	Role	Dates
2 P50 CA180995-06A1	SPORE in Prostate Cancer	Project Co-PI	pending

Current

Organization	Title	Role	Dates
NIH 2-P30-CA14599-35	Cancer Center Support Grant	Deputy Director	4/23/13-3/31/23
2 K12 CA139160-11	Developing an Oncology Workforce for the 21st Century	Co-PI	8/1/15 – 7/30/25
NIH P50CA180995	SPORE in Prostate Cancer	**Project Leader & Admin Core Co-director**	8/18/15 – 7/31/20

Past

Organization	Title	Role	Dates
American Cancer Soc. (Res. Training Award)	The 9p21-22 Tumor Suppressor Gene in Bladder Cancer	**Principal Invest.**	7/1/94 - 6/30/97
American Society of Clinical Oncology (Young Invest. Award)	The Role of the 9p21-22 Tumor Suppressor Gene in Bladder Cancer	**Principal Investigator**	7/1/94 – 6/30/95
Kettering Family Found.	NA	**Principal Invest.**	7/1/95 - 6/30/96
Cancer Res. Found.	The role of p16 in Human Urothelial Cell Senescence and Bladder Cancer Oncogenesis	**Principal Invest.**	7/1/96 - 6/30/97

Univ. Chicago Cancer Res. Center	Chemoprevention Pilot Project	**Principal Invest.**	7/1/97 - 6/30/98
American Cancer Soc. (RPG-97-171-01-CNE)	The CDKN2 Gene in Urothelial Senescence and Oncogenesis	**Principal Invest.**	7/1/97 - 6/30/00
NIH UO1 (U0-CA63187-04S2)	Phase II Trials of New Anti-Cancer Agents	Co-Invest.	7/21/99 – 3/31/00
NIH R21 (CA78883-01)	Biomarkers for Bladder Cancer Chemoprevention Trials	**Principal Invest.**	7/1/98 - 6/30/01
Mesothelioma Applied Research Foundation	Biologic markers for VEGF inhibitors in mesothelioma therapy	Co-Investigator	12/15/00 – 12/31/01
American Cancer Soc. (RPG-99-068-01-CSM)	Identification of Prostate Cancer Metastasis-Suppressor Genes on Human Chromosome 12	Co-Invest.	1/1/99 - 12/31/02
Kidney Cancer Assoc. (Stulberg Award)	Synergistic Activity of Gemcitabine and 5FU in Renal Cancer: A Translational Investigation	**Principal Invest.**	7/1/99 – 7/16/02
NIH P30 CA14599-28	Cancer Center Support Grant	Program Co-leader	4/1/02 – 9/1/03
DOD Prostate Program	Neoadjuvant Antiangiogenesis Therapy for Prostate Cancer	Co-Investigator	4/01/02 – 11/30/04
DOD Prostate Program	Planning grant for Clinical Trials; Androgen Replacement in Hormone Refractor Prostate Cancer	**Principal Investig.**	8/01/04 – 7/30/05
NIH RO1 1R01CA089569	Prostate Cancer Metastatic Colonization: Role of MKK4	Co-Invest.	4/1/01 – 3/31/06
University of Chicago Cancer Research Center Pilot Project	Experimental validation of a novel method for estimating the contrast agent arterial input function in dynamic contrast enhanced MRI studies	**Principal Invest.**	7/1/05 – 6/30/06
NIH RO1 (CA71921-02)	MVAC in Organ-Confined Bladder Cancer Based on p53 Status	Co-Invest.	7/01/01- 3/31/07
NIH R21 CA108184-01A2	Dynamic-contrast enhanced MRI as a BAY 43-9006 marker	**Principal Invest.**	7/1/05 – 6/30/07

NIH P30 CA14599-28	Cancer Center Support Grant	Clinical Trials Review Committee Chair	9/1/03 – 3/31/08
American Cancer Society – IL Division	Decision Making in Older Men Starting Androgen Ablation for Prostate Cancer	Co-Invest	9/1/08 – 8/31/10
P50 CA090386	Prostate Cancer SPORE	Co-Investigator & Executive Committee member	3/1/09 – 12/31/13
NIH UO1 CA69852-04	Phase I Clinical Trials of Anti-Cancer Agents	Co-Invest.	5/10/95 – 2/28/13
DOD Clinical Consortium PC081013	Clinical Trials Consortium	**Principal Invest.**	9/1/09 – 8/31/14
DOD W81XWH-13-1-0451	The Genomic Evolution of Prostate Cancer	**Mentor (Vanderweele)**	10/1/13 – 7/1/16 (mentee transferred)
NIH contract (N01-CM-62201)	Early Therapeutics Development with Phase II Emphasis	**Principal Invest.**	2/1/01 – 9/22/16
NIH 1 UM1 CA186705-01	Experimental Therapeutics: Clinical Trials Network with Phase I Emphasis	**Co-Invest**	3/26/14 – 2/29/17
Movember-PCF	Prostate Cancer Challenge Award	**Co-Invest**	8/1/14 – 8/1/16
DOD/ARDA – MSKCC W81XWH-15-2-0018	Prostate Cancer Research Program Clinical Consortium Award	**Principal Invest.**	6/5/15 – 6/14/18
Prostate Cancer Foundation 16CHAL12	Combinatorial Immunotherapy Strategies to Reverse Immunosuppression within PTEN-deficient Advanced Prostate Cancers	**Co-Invest**	12/31/16-12/31/18
Prostate Cancer Foundation 16CHAS04	Use of selective GR antagonists in castration-resistant prostate cancer	**Co-Invest**	12/31/16-12/31/18

Invited Speaking

Regional Tumor Board, Grand Rounds, and CME lectures (genitourinary oncology):

12/7/95: Univ. of Chicago CME course "Genitourinary Oncology: A Multidisciplinary Approach"

2/8/96: St. Catherine Hospital (also coordinated presentations by various UC cancer

physicians for St. Catherine's cancer CME program)

2/19/96: Elkhardt General Hospital
3/15/96: Rush Copley Health Center
5/23/96: Bronson Medical Center, Kalamazoo, MI
5/24/96: Merrilville Cancer Associates
10/22/96: Holy Cross Hospital
11/13/96: South Suburban Hospital
11/23/96: Univ. of Chicago CME course "New Developments in the Management of Solid

Tumors”

2/10/97:	Christ Hospital
2/20/97:	Lagrange Hospital
12/3/97:	Little Company of Mary Hospital
3/6/98:	Holy Cross Hospital
8/26/98:	St. Joseph Hospital, South Bend, IN
12/2/98:	Chicago Urologic Society (letter attached)
2/28/99:	St. Joseph Hospital, South Bend, IN
4/27/99:	Holy Cross Hospital
7/2/99:	Provena St. Marys, Kankakee, IL
7/799:	Munster Community Hospital, Munster, IN
10/20/99:	Rockford Oncology Assoc., Rockford, IL
11/30/99:	Oncology/Hematology Assoc. of Northern Illinois, Grayslake, IL
12/7/99:	Holy Cross Hospital
7/12/00:	South Suburban Hospital
4/10/01:	Preceptorship, Abbott Laboratories staff
7/12/01:	Oncology/Hematology Associates of Central Illinois, Decatur, IL
7/26/01:	University of Illinois Section of Hematology/Oncology, Chicago, IL
10/16/01:	Preceptorship, Abbott Laboratories staff
11/21/01:	Ingall’s Hospital Richard Desser Memorial Program, Harvey, IL
1/29/02:	Preceptorship, Abbott Laboratories staff
3/7/02:	Cook County Hospital, Chicago, IL
4/2/02:	MacNeal Hospital, Berwyn, IL
7/23/02:	Preceptorship, Abbott Laboratories staff
9/17/02:	Preceptorship, Roche staff
10/22/02:	Northwest Oncology/Hematology, Arlington Hts, IL
5/14/03:	Little Company of Mary, Evergreen Park, IL
10/17/03:	Central Illinois Oncology, Peoria, IL
10/29/03:	Lutheran General Hospital, Park Ridge, IL
3/23/04:	Holy Cross Hospital Tumor Board
4/1/04:	Prostate Cancer Outreach Event, Univ. of Chicago Gleacher Center
11/22/04:	South Suburban Hospital, Hazel Crest, IL
3/9/05: R	enal Cancer Update, Chicago, IL
4/23/05:	University of Chicago Prostate Cancer Symposium, Gleacher Center, Chicago, IL
12/14/05:	Renal Cancer Update, Evanston, IL
1/31/06:	Munster Community Hospital, Munster, IN
2/16/06:	Community practitioners, Tinley Park, IL
4/1/06:	Renal Cancer Challenging Case Conference, Chicago, IL
5/10/06:	Community practitioners, Rosemont, IL
6/21/06:	Community practitioners, Chicago, IL
12/6/06:	Chicago Urologic Association, Chicago, IL
4/25/07:	Univ. Of Ill/Chicago Urology Department, Chicago, IL
6/30/07:	KCA patient conference, Chicago, IL
7/26/07:	Community practitioners, Joliet, IL
7/28/07:	ASO ASCO highlights, Chicago, IL
2/9/08:	Community practitioners, Decatur, IL
4/4/08:	Phase II network conference, Chicago, IL
6/7/08:	KCA patient conference, Chicago, IL
8/23/08:	Imdex Emerging Therapies in Solid Tumor Oncology, Chicago, IL
9/6/08:	Second Annual Perspectives in Urologic Oncology, Chicago, IL
11/5/08:	Chicago Urologic Society, Chicago, IL

2/3/10: Chicago Urologic Society, Chicago, IL
4/22/10: Lutheran General Hospital, Park Ridge, IL
8/10/10: Glenbrook Hospital UsToo Chapter, Glenview, IL
10/22/10: Illinois Cancer Care, Peoria, IL
11/20/10: Lombard UsToo Chapter, Lombard, IL
12/2/10: NorthShore University Health System, Kellogg Cancer Center, Evanston, IL
4/19/11: Michiana Hematology/Oncology, Granger, IN
4/20/11: Chicago Urologic Society, Chicago, IL
9/27/11: Northern Indiana CME Foundation
10/29/11: University of Chicago Update in GU Oncology, Chicago, IL
11/9/11: Chicago Urologic Society, Chicago, IL
1/25/12: Visiting Professor, Rush University, Chicago, IL
3/10/12: Trends Hematology/Oncology, Lutheran General Hospital, Park Ridge, IL
7/12/12: Prime Oncology, ASCO Ancillary Conference, Chicago, IL
11/8/12: Gilda's Club, Chicago, IL
10/7/13: UsToo, Glenbrook Hospital, Glenview, IL
11/6/13: Chicago Urologic, Chicago, IL
11/16/13: UsToo, Lombard, IL
1/16/14: Gilda's Club, Chicago, IL
2/13/14: Lutheran General Hospital, Park Ridge, IL
4/30/14: Specialty Review in Urology, Naperville, IL
7/10/14: ASCO Update, Northwestern, Chicago, IL
7/10/15: ASCO Update, Northwestern, Chicago, IL
8/30/15: Society for Immunotherapy of Cancer, Symposium, Chicago, IL
11/16/15: Northwestern University Medical Center, Medical Grand Rounds, Chicago, IL
6/13/17: Medicine Grand Rounds, University of Chicago, Chicago, IL

<u>Invited National Tumor Board, Grand Rounds, and CME lectures (genitourinary oncology)</u>
10/15/96: Upstate New York Cancer Research Foundation, Rochester, NY
5/22/97: Gemcitabine in cancer, Washington DC
6/6/97: Association of Northern California Oncologists, Sacramento, CA
11/12/97: Chemotherapy Foundation Symposium XV, Mt. Sinai, New York, NY
2/11/98: New York University, New York, NY
3/12/98: Univ. of Pittsburgh, Pittsburgh, PA
5/1/98: Providence Hospital, Detroit, MI
9/26/98: Sacred Heart Cancer and Research Center, Spokane, WA
10/19/98: Optimizing Solid Tumor Therapy: Innovation, Advance, and Insights, Melville, NY
11/14/98: American Society Clinical Oncology Fall CME Conference, Chicago, IL
11/26/98: Community Hospital of Los Gatos, San Jose, CA
2/19/99: MetroHealth, Cleveland, OH
3/24/99: Cleveland Clinic, Cleveland, OH
4/22/99: John Muir Medical Center & Pacific Hematology/Oncolgy & Sisters of Mercy Hospital,

	Sacramento, San Francisco, & Redding, CA
4/29/99:	Spectrum Health Center, Grand Rapids, MI
5/28/99:	Mt. Sinai Hospital, Miami, FL
6/2/99:	Exploring Options for Advanced Lung and Bladder Cancer, St. Louis, MO
8/5/99:	St. Joseph Mercy, Ann Arbor, MI
10/7/99:	US Oncology, Scottsdale, AZ
10/9/99:	South Carolina Oncology Association, Myrtle Beach, SC
12/3/99:	Scripps Clinic, La Joya, CA
2/2/00:	Marion VA Hospital, Marion, IL
3/17/00:	Solid tumor update 2000, Vail, CO
5/4/00:	Beth Israel & St. Vincents, New York, NY
5/24/00:	American Society of Clinical Oncology Annual Meeting, Expert commentary on oral research presentations for bladder cancer.
5/26/00:	Oakwood Hospital, Dearborne, MI
6/15/00:	Good Samaritan Hospital, West Islip, NY
6/28/00:	Univ. of Oklahoma, Oklahoma City, OK
10/13/00:	Schering sponsored conference call update on metastatic renal cell carcinoma
11/9/00:	Cancer and Leukemia Group B continuing education series, renal cell carcinoma
11/13/00:	Upper Valley Medical Center, Troy, OH
1/17/01:	Muskegon Oncology Chapter (ONS), Muskegon, MI
2/21/01:	University of Texas, Galveston, TX
2/21/01:	Memorial Hermann Healthcare System, Houston, TX
2/22/01:	MDAnderson Cancer Center, Houston TX
3/16/01:	Challenging Cases in Patient Management, Atlanta, GE
5/23/01:	El Paso Oncology Consultants, El Paso, TX
5/24/01:	Del Sol Medical Center, El Paso, TX
5/26/01:	Brooke Army Medical Center, San Antonio, TX
5/26/01:	Univ. Texas, Health Science Center, San Antonio, TX
6/2/01:	Society of Urologic Oncology, Annual Meeting, Anaheim, CA
6/4/01:	Univ. of Southern California, Los Angeles, CA
6/29/01:	Lilly Global Oncology Young Investigator Meeting, Chair, Bladder Cancer Session
9/17/01:	Milwaukee oncologists
1/28/02:	Fairview Hospital, Cleveland, OH
1/28/02:	Cleveland Community Oncologists, Cleveland, OH
6/19/02:	Kidney Cancer Association Annual Patient Meeting
9/14/02:	ASCO Update, Dallas, TX
9/28/02:	Kaiser Permanente Annual Oncology Conference, Berkley, CA
10/30/02:	Missouri Baptist Medical Center, St. Louis, MO
12/5/02:	Private oncologist group, Minneapolis, MN
1/15/03:	GU Opinion Leader's Summit, St. Thomas, UVI
5/6/03:	Baylor College of Medicine, Department of Urology, Houston TX
6/1/03:	American Society of Clinical Oncology Annual Meeting, Expert commentary on poster

	presentations for renal cancer
6/13/03:	Post-ASCO Update, Pittsburgh, PA
7/15/03:	Decatur Memorial Hospital, Decatur, IL
7/18/03:	Chair, annual Kidney Cancer Association Patient Conference, Chicago, IL
8/15/03:	University of Iowa, Iowa City, IO
10/18/03:	Annual Fall Oncology Conference, Hilton Head, SC
11/13/03:	Introduction to Oncologic Product Development, Phase II trials, New York, NY
2/25/04:	Third International Symposium on Genitourinary Cancers, Santa Barbara, CA
3/19/04:	Innovations and Challenges in Renal Cell Cancer, Cambridge, MA
6/1/04:	ASCO annual meeting, Education session on renal cell cancer, Orlando, LA
6/24/04:	Genitourinary Malignancies, Translating Laboratory Discoveries Into Clinical Realities. Organizing Committee, Renal Cancer Session Moderator, and Speaker, Univ. Iowa, Iowa City, IA
813/04:	First International Congress on Kidney/Bladder Cancers, Organizing committee and speaker, Orlando, Fl
8/19/04:	St Louis, MO community oncologists, Clayton, MO
9/3/04:	Fourth International Congress on Antibodies in Cancer, Colorado Springs, CO
9/17/04:	Kidney Cancer: New Therapeutic Options, Washington DC
10/14/04:	Wassau Hospital and Marshfield Clinic, Wassau, WI
10/21/04:	St Louis, MO community oncologists, Clayton, MO
10/25/04:	Ohio State University, visiting professor, Columbus, OH
11/13/04:	International Kidney Cancer Symposium, Chicago, IL
1/26/05:	Fourth International Symposium on Genitourinary Cancers (Organizing Committee), Los Angeles CA
3/18/05:	Univ. of Nebraska Medical Grand Rounds, Omaha, NE
4/17/05:	AACR annual meeting: Educational session on bladder cancer, Anaheim, CA
5/17/05:	Post ASCO Symposium: Emerging Strategies for the Treatment of Advanced Kidney Cancer, Orlando, FL
5/24/05:	AUA plenary session: Renal Cancer Highlights, San Antonio, TX
6/24/05:	Emerging Trends in Oncology: A post-ASCO update, Seattle, WA
7/15/05:	Second International Congress on Kidney/Bladder Cancers, Organizing committee and speaker, Orlando, FL
9/16/05:	Kidney Cancer: New Therapeutic Options, Washington DC
10/22/05:	Kidney Cancer Assoc. International Conference, Chicago, IL
11/13/05:	International Oncology Network, Dallas, TX
11/20/05:	CALGB meeting, GU committee, update on RCC, Amelia Island, FL
1/27/06:	5th Multidisciplinary Symposium on Genitourinary Cancers (Organizing Committee),

	Dana Point, CA
2/9/06:	Marshfield Clinic, Marshfield, WI
2/13/06:	Private practioners, Minneapolis, MN
3/15/06:	University of Miami Sylvester Cancer Center, Miami, FL
3/20/06:	University of Minnesota, Minneapolis, MN
4/11/06:	Memorial Medical Center, Springfield, IL
5/16/06:	Ohio State University, Columbus, OH
5/24/06:	Walter Reed Army Hospital, Bethesda, MD
6/6/06:	ASCO, Industry Sponsored Satellite Symposium on RCC, Atlanta, GA
7/29/06:	Post-ASCO update, Chicago, IL
8/5/06:	3rd International Kidney/Bladder Cancer Congress, Orlando, FL (organizing committee)
9/23/06:	Kidney Cancer Association International Symposium, Chicago, IL
10/7/06:	AUA Conference on Kidney/Bladder Cancers, Miami, FL
10/9/06:	Private practioners, Virginia Beach, VA
11/4/06:	NMCR Challenges in Genitourinary Cancer, San Francisco, CA
11/18/06:	Current Trends in Genitourinary Cancer, New York, NY
12/1/06:	Radiology Society of North America, Chicago, IL
1/27/07:	Paul Peters Urology Symposium, Univ Texas Southwestern, Dallas, TX
2/11/07:	NCI/AACI IRAT Network meeting, Phoenix, AZ
6/2/07:	ASCO – Poster discussion leader, RCC, Chicago, IL
10/6/07:	Update on GU Malignancies, Boston, MA
10/12/07 :	KCA International Symposium, Chicago, IL
11/16/07:	Visiting Professor, Cleveland Clinic, Cleveland, OH
11/27/07:	RSNA/NCI Interventional Oncology Series, RSNA, Chicago, IL
11/29/07:	Private practioners, Minneapolis, MN
12/1/07:	Society of Urologic Oncology, Bethesda, MD
1/11/08:	Visiting Professor, Roswell Park University
2/16/08:	ASCO GU, Bladder Cancer Trial Design, San Francisco, CA
4/30/08:	Yale Annual Prostate and Urologic Malignancies Conference, New Haven, CT
5/5/08:	Infusion Nurses Society, Phoenix, AZ
5/17/08:	NOCR continuing medical education, Miami, FL
5/31/08:	ASCO National Meeting, Beyond Response Rate: Novel Clinical Endpoints and Trial Designs, Chicago, IL
6/2/08:	ASCO National Meeting, Rational Choices for RCC Therapy, Education session chair
10/3/08:	Research-to-Practice: Renal Cancer Experts Roundtable, Miami, FL
10/10/08:	Oncology Symposium, St. Joseph, MI
12/2/08:	RSNA, Interventional Radiology Course, Renal Cancer
1/22/09:	Karmanos Cancer Institute Grand Rounds, Detroit, MI
2/27/09:	Masters Class, Renal Cancer, Orlando, FL
4/20/09:	AACR National Meeting, New Concepts in Organ Site Research, Renal Cancer: Co-

	opting the Hypoxia Pathway for Oncogenesis and Taking It Back for Therapeutics, Chair
7/17/09:	PER Congress on Genitourinary Malignancies, Renal Cancer Speaker, Washington DC
9/2/09:	Dana Farber Cancer Center, GU Cancer Grand Rounds
5/20/10:	Cancer*Care* teleconference – Progress in the Treatment of Renal Cell Cancer.
8/12/10:	Dana Farber Kidney Cancer SPORE invited speaker
8/13/10:	Annual Innovations and Challenges in Renal Cancer, Cambridge, MA
11/29/10:	Radiologic Society of North America (RSNA), Focus on Imaging Biomarkers
2/11/11:	NOCR – Renal cancer therapy update, Las Vegas, NV
3/15/11:	Univ of North Carolina, Chapel Hill, NC
6/6/11:	ASCO National Meeting, Poster Discussion, Renal Cancer Therapeutics
7/16/11:	ImDex ASCO Update Meeting, Houston, TX
7/25/11:	Forsyth Regional Cancer Center, Winston-Salem, NC
8/30/11:	University of Vermont Cancer Center, Burlington, VT
10/15/11:	International Kidney Cancer Association Meeting, Chicago, IL
10/30/11:	The Angiogenesis Foundation, Boston, MA
11/8/11:	City of Hope Hematology/Oncology Grand Rounds, Duarte, CA
11/28/11:	Radiologic Society of North America (RSNA), Chicago, IL
3/16/12:	Oncology Grand Rounds, Cleveland Clinic, Cleveland, OH
7/21/12:	Highlights in Oncology from ASCO, San Francisco, CA
10/11/12:	ASCO/EORT/NCI Molecular Markers Meeting, Scientific Program Chair
4/17/13:	BCAN webinar
6/17/13:	Research to Practice Audio and Video Roundtable on Renal Cell Cancer
2/15/14:	Oncology Meetings Innovations, Dallas, TX
2/20/14:	Imedex NOCR, Las Vegas, NV
10/4/14:	Regional Prostate Cancer Summit, Dava Oncology, NY, NY
2/27/15:	Urothelial Cancer Tumor Board, ASCO GU, Orlando, FL
2/27/15:	Clinical Challenges in Castrate Resistant Prostate Cancer, Orlando, FL
3/14/15:	NOCR, Las Vegas, NV
3/21/15:	Southeast Wisconsin Cancer Conference, Milwaukee, WI
6/2/15:	Discussant, ASCO annual meeting, GU Oral Session, Chicago, IL
9/18/15:	Comprehensive Board Review in Hematology & Medical Oncology (Bladder Cancer), MD Anderson, Houston, TX
11/6/15:	Kidney Cancer Association, Miami, FL
11/21/15:	Research to Practice, Santa Monica, CA
6/6/16:	ASCO annual meeting, Poster Discussant, Chicago, IL
6/18/16:	ASCO update, Nebraska Oncology Society, Omaha, NE
7/23/16:	ASCO Highlights, Aurora Health, Milwaukee, WI
9/9/16:	West Hawaii Cancer Symposiu, Kona, Hawaii
9/19/16:	MDAnderson Oncology Board Review Course
10/21/16	Genitourinary Cancer Summit, New York, NY
10/15/16	Kidney Cancer Association Annual Symposium, Miami, FL
10/21/16	GU Cancer Summit, NY NY (Chair)
11/5/16	Kidney Cancer Association Annual Symposium, Miami, FL
2/17/17	Immune Checkpoint Inhibitors in Advanced Bladder Cancer, Orlando, FL
11/3/17	Correletives Associated with Bevacizumab/Atezolizumab, Kidney Cancer Association

	International Kidney Cancer Symposium, Miami, FL
6/1/18	OncLive, Renal Cancer Therapy (online); Chicago. IL
7/11/18	AACI meeting, Clinical Research Infrastructure and the CCSG, Chicago, IL
7/28/18	ASCO/AACR Clinical Trials Course, Vail, CO
8/11/18	Aurora Healthcare ASCO Highlights, Milwaukee, WI
9/7/18	West Hawaii Cancer Symosium, Kona, HI
9/20/18	OncLive GU Oncology, Chicago, IL
5/4/19	SBUR/SUO symposium at AUA, Therapeutic Advances in Multimodality Therapy in Urologic Malignancies, Chicago, IL
5/5/19	AUA 18th International Prostate Forum, Chicago, IL
6/22/19	Best of ASCO, Omaha, NE
7/31/19	ASCO/AACR Clinical Trials Course, Vail, CO
8/22/19	University of Kentucky Oncology Grand Rounds
8/24/19	Best of ASCO, Milwaukee, WI
10/26/19:	Aurora Health System Annual Cancer Symposium, Green Bay, WI
1/24/20:	Univ of North Carolina, Chapel Hill, NC
9/10/20:	DAVA Oncology, Recent Advances in Urothelial Cancers (Virtual)

Invited International lectures (genitourinary oncology)

2/28/97:	Update on gemcitabine in cancer, St. Thomas, Virgin Islands
9/3/97:	Lilly-International advisory meeting, Stockholme, Sweden
7/10/99:	International Baltic Uro-oncologic Symposium, Kiel, Germany
10/15/99:	Mexican National Cancer Institute, Puerto Vallarta, Mexico
2/21/00:	Live satellite TV broadcast to South American Oncologists
3/21/00:	Deutscher Krebskongress (Annual meeting of German Oncology Society), Berlin, Germany
4/18/02:	Targeted Therapies in the Treatment of Genitourinary Cancers, Barcelona, Spain
10/31/03:	Heinrich Warner Foundation, Hamburg, Germany
6/11/05:	Best of ASCO in Japan, Tokyo, Japan
8/20/05:	15th Bayer Symposium on Advances in Urology, Fukuoka, Japan
9/24/05:	Deutsche Gesellschaft für Urologie (German Urology Society)
3/24/06:	Deutscher Krebskongress (Annual meeting of German Oncology Society), Berlin, Germany
6/14/06:	European Spring Oncology Meeting, Marbella, Spain
10/4/06:	Princess Margaret Hospital, New Developments in Cancer Management, Toronto,

Canada
10/18/06: Japan Society of Clinical Oncology
12/14/06: Clinical Oncologists, Madrid (and other Spanish cities via satellite)
4/14/07: Japan Urologic Association
5/5/07: Tawain Joint Cancer Conference
9/11/08: World Molecular Imaging Conference, Nice, France
11/20/08: Tom Baker Cancer Center, Calgary, Canada
11/21/08: British Columbia Cancer Agency Community Oncologists, Vancouver, Canada
5/14/09: V Curso Interdisciplinario de Oncologia: Tumores Urologicos, Oviedo, Spain
4/22/11: Oncology Congress Brno, Brno, Czech Republic
9/22/12: International Bladder Cancer Network, Neijmegan, Netherlands
11/8/13: ASCO/EORTC/NCI Molecular Markers Meeting, Scientific Program Committee
9/23/15: GU Malignancies Summit, Banf, Canada
10/21/17: International Bladder Cancer Network, Lisbon, Portugal
12/8/17: International Conference on Onconephrology, Naple, Italy
10/11/18 International Bladder Cancer Network, Rotterdam, Netherlands
11/1/18 OMI GU Conference, Banff, Canada
12/14/18 International Conference on Onconephrology, Milan, Italy
10/12/19: DAVA GU Conference, Banff, Canada

Editorial Activities:

Ad hoc Reviewer: Cancer, Clinical Cancer Research, Journal of Clinical Oncology, Cancer Investigation, Investigational New Drugs, British Journal Cancer, JAMA, PNAS, J Clin Oncol
Guest Editor: Seminars in Oncology "Bladder Cancer", V23, No 5, Oct. 1996
Reviewer: AHFS Drug Information, 1998
Reviewer: ABIM certifying examination questions in oncology, 1998, 1999
Reviewer: AUA annual meeting abstracts: 2007
Reviewer: AUA bladder cancer guidelines: 2007
Guest Editor: Kidney Cancer Journal, Vol 6, No1, 2008
Editorial Boards:
Nexcura: 2000-2005
Journal of Clinical Oncology: 2001-2004
Clinical Genitourinary Cancer: 2001- 2009
UpToDate Oncology Peer Review Board: 2003-
Medscape, Genitourinary Oncology "Journal Scan Author": 2004-2006
British Journal of Urology: 2006-2010
Kidney Cancer Journal: 2006-2010
The Oncology Report: 2010-2012
Oncology Real Time: 2011-2013
Cancer (GU section editor): 2011 –
Bladder Cancer: 2014 -

Teaching Activities (in addition to housestaff, fellow education)

Undergraduate teaching

1996-2005: Laboratory Assistant, Clinical Pathophysiology, 2nd yr medical students:
1997-1999: Guest lecturer, Frontiers in Cancer Research: Malignant Progression and its Treatment, Graduate seminar

Graduate, Post-graduate teaching

1996-2002	Laboratory Instructor, Hematology section, Clinical Pathophysiology (2nd yr medical students)
1997-2001	Cancer Biology Course #315 "Frontiers in Cancer Research" (Cancer Biology Graduate Students) One lecture each year on translational research
1/00	Cancer Biology Committee Retreat, Development of Targeted Therapeutics
11/5/10	Cancer Biology Personalized Genomics Course: Lecture on Biomarkers
2007-2014:	Essentials of Patient Oriented Research, Annual lecture on principal investigator responsibilities
2012	Clinical Protocol Development Workshop (CCTS 44100), One of 3 preceptors for workshop designed for fellows/junior faculty to write a protocol
7/31 –	ASCO/AACR Annual Clinical Trials Workshop Preceptor

Hematology/Oncology Fellow Lecture Series

Annual educational lectures on prostate, bladder, testes and renal cancer

Urology Resident Lecture Series

Annual lecture on renal cancer, testes cancer

Multidisciplinary Uro-oncology Conference

Weekly Conference of genitourinary cancer cases

Laboratory trainees:

1995-96:	Evan Goldfischer, MD
1996-97:	Edward Kirsch, MD
1996-97:	Mark Chien (Undergraduate Research Thesis)
1997:	Donald VanderGriend (Summer Undergraduate Student)
1997-1998:	Craig Turner, MD (AFUD Scholar Award)
1998:	Julia Sorisho (High school summer intern – 1st prize city-wide science fair)
	Janet Roddick (Howard Hughes Medical Institute summer research fellowship)
1999:	Jason Balthius (Summer Undergraduate Student)
1999-2004:	Thelma Tenent (PhD thesis committee)
1999-2005:	Donald VanderGriend (PhD graduate trainee)
2001:	Hyo Lee (Summer Undergraduate Student)
2001:	Russ Wright (Summer Undergraduate Student)
2011-2014:	Steve Kregal (PhD thesis committee)
2012-2013:	Erin Mowers (PhD thesis committee)
2018-2019:	Matt Trendowski (PhD thesis committee)

Advanced GU clinical research fellows:

1998-2000:	Christopher Ryan, MD
1999-2001:	Brian Rini, MD
2000-2001:	Apurva Desai, MD
2000-2003:	Christopher George, MD
2001-2003:	Nancy Davis, MD
2002-2004:	Andrew Artz, MD
2002-2004:	Mebea Aklilu, MD
2003-2004:	Amy Peterson, MD
2003-2004:	Stacy Gray, MD
2003-2005:	Supriya Gupta, MD
2004-2006:	Ou (James) Jin, MD, Ph.D.
2004-2005:	Blase Polite, MD

2005-2007: Katherine Bylow, MD
2005-2007: Olwen Hahn, MD
2006-2007: David Knight, MD, Ph.D.
2007-2009: Russell Szmulewitz, MD
2007-2010: Peter O'Donnell, MD
2008-2009: Elizabeth Chung, MD
2009-2012: James Chen, MD
2010-2013: David Vanderweele, MD, PhD
2010-2011: Tobi Nwizu, MD
2011-2013: Dan Geynisman, MD
2012-2015: Saleha Sajid, MD
2015-2019: Randy Sweis, MD
2015-2018: Jamie Brewer, MD
2018- 2020: Brian Heiss, MD
2020- : Priyanka Chablani, MD

Junior faculty GU research mentees:
2000-2003: Christopher Ryan, MD
2001-2006: Apurva Desai, MD
2004-2006: Amy Peterson, MD
2005-2011: Edwin Posadas, MD
2006-2010: William Dale, MD, PhD (Geriatrics)
2007-2013: Olwen Hahn, MD
2007-2009: Stacy Lindau, MD (Gynecology)
2008-2010: Aytekin Oto, MD (Radiology)
2009-2018: Russell Szmulewitz, MD
2010-2018: Peter O'Donnell, MD
2013-2015: David Vanderweele, MD, PhD
2016- : Akash Patnaik, MD, PhD
2019: Arpita Desai
2019- : Randy Sweiss, MD
2020- : Brian Heiss, MD

Service

Internal Committees/Programs/Centers:
1985-1987: Thesis Committee
1985-1988: Basic Science Curriculum Committee
1988: Task Force for Curriculum Evaluation
1996: Ad hoc Committee on Oncology Outpatient Clinic, Chair
1998-1999: Univ. of Chicago, Div. Biological Sciences, Ad hoc committee on Core Facilities
1999-2001: Univ. of Chicago, Dept. of Medicine, Assist. Professor Advisory Committee
1995- : Univ. Chicago Comprehensive Cancer Center (UCCCC)
- 1995-2001: Molecular Genetics Program Member
- 1995-2003: Prostate/GU Cancer Program Member
- 1998-2007: Clinical Trials Review Committee Member
  - 1999-2003: Vice-Chair
  - 2003-2007: Chair
- 2000- : Clinical and Experimental Therapeutics Program Member (Renamed: Pharmacogenomics and Experimental Therapeutics in 2011)
  - 2009- 2019: Program co-leader
- 2000-2003: Assoc. Director, GU Cancer Program

2001- : Executive Committee Member
2003-2007: Clinical Research Oversight Committee
2009- : Clinical Research Oversight Committee
2013 – : Deputy Director

2004-2010: MRI Core Facility Faculty Oversight Committee
2006-2013: Pharmacology Core Facility Oversight Committee, chair
2010-2015: Epidemiologic Research Core Facility Oversight Committee
2010-2014: Cancer Advisory Committee
2000-2001: Hospital "Triad" Committee member (Patient care committee formed to coordinate activities of Hematology/Oncology and inpatient hospital oncology floor staffs)
2000: Ad hoc Search Committee for new Chair of Radiology
2000-2003: Section Hematology/Oncology Data Manager Committee
2000-: Section Hematology/Oncology Fellowship Selection Committee
2000-2008: Faculty Fund Raising Working Group
2006-2008: Chair
2001-: Hematology/Oncology Fellowship Training Grant, Executive Committee
2002-2004: Institutional Biosafety Committee
2002-2004: Tissue Collection and Utilization Steering Committee
2002 -: Committee on Cancer Biology
2005: Ad hoc committee on reorganization of inpatient services
2005-2007: Department of Medicine Clinical Research Advisory committee
2006-2019: Biostatistics Facility Faculty Advisory Committee
2007-2010: University Council of the Senate (Faculty Advisory Committee to University President)
2007-2013: Biomedical Imaging Institute Steering Committee
2007-2013: Clinical Research Policy Committee, Chair
2008-2011: BSD Committee on Appointments and Promotions
2009-2010: University of Chicago/NorthShore University Research Subcommittee
2009-2011: Cancer Clinical Care Operations Committee
2010-2013: Human Immunology Monitoring Facility Faculty Advisory Committee
2010-2017: Institute for Translational Medicine, Executive Committee
2011-2016: Human Biofluids Collection Facility Faculty Advisory Commitee
2011: Ad Hoc Committee on Evaluation of the Imaging Research Institute
2011-2012: New Hospital Pavilion, Transformational Leadership Committee
2011-2012: AURA (University Research Informatics System) Steering Committee
2011-2014: Tissue Allocation and Distribution Committee
2011-2014: Electronic Health Records (EHR) Advisory Committee
2011-2012: LCME Task Force
2012-2016: Research Informatics Governance Committee
2013- 2018: Molecular and Clinical Pathology Laboratory Clinical Working Group
2013-2014: Post-acute care advisory committee
2013 - : Divisional Compliance Committee
2014: Ad hoc advisory committee on cGMP Facility
2014- 2019: Divisional Cancer Strategy Committee, Steering Committee member
2015-2017: MRI Research Center Faculty Advisory Commitee

External Boards/Committees

1995: Review panel member (molecular biology): United States Army Breast Cancer Research Program
1999- : Kidney Cancer Association
1999- : Medical Advisory Board
2006-2010: Board of Directors

1998- : Cancer and Leukemia Group B (CALGB) – Changed name to ALLIANCE 2012
1998- : GU Core Committee Member
2000-2010: CALGB GU Core, Renal Cell Cancer Cadre Leader
2007-2010: Genitourinary Cancer Intergroup, Renal Cancer Subcommitee
2000-2004: American Cancer Society, Illinois Division, Research Advisory Committee
2001: NCI Kidney/Bladder Cancer Progress Review Group, Subcommittee Chair
2003: NCI GU/Prostate SPORE Application Review Panel
2003: Case Western Reserve/Ireland Cancer Center, external advisor, annual faculty retreat
2003-2006: Data safety monitoring committee, Wyeth CCI-779 phase III trial
2004-2006: American College of Radiology Imaging Network, GU committee
2004: International Consensus Committee on Neoadjuvant and Adjuvant Therapy of Bladder Cancer
2004-2008: External Advisory Board, MD Anderson Bladder Cancer SPORE
2005- : NCI Special Emphasis Panel, Loan Repayment Program reviewer
2005-2007: American Joint Committee on Cancer (AJCC) Genitourinary Cancer Task Force
2005- : Bladder Cancer Advocacy Network Medical Advisory Board
2006-2008: American Society of Clinical Oncology – Scientific Program Committee,
2006-2008: GU Track Member
2007-2008: GU Track Leader
2006-2008: Data safety monitoring committee, Novartis RAD001 RCC trial
2008-2010: Chair, data safety monitoring committee, Wyeth temsirolimus vs sorafenib RCC trial
2008-2012: RSNA Quantitative Imaging Biomarker Alliance
2008: Ad Hoc advisory committee, Huntsman Cancer Institute
2008: Ad Hoc external review committee member: Dana Farber Cancer Institute
2008: Ad Hoc reviewer, NCI P01 Discovery and Development Panel
2008-2013: Oncology Drug Advisory Committee to FDA
2008-2017: Chair, External Advisory Board: Northwestern Hematology Oncology T32 Training Grant
2009-2016: NCI/CTEP Investigational Drug Steering Committee
2006-2015: NCI/CTEP Biomarkers Task Force
2008-2015: Co-chairman
2009-2012: Review Panel, Cancer Prevention and Research Institute of Texas (CPRIT)
2010-2012: Aveo phase III renal cancer trial Data Safety Monitoring Committee
2010: Ad Hoc reviewer, Cancer Center Review Panel (Subpart A)
2010: ASCO-NCI-EORTC Molecular Biomarkers Meeting, (Markers in Cancer)
2010-2011: Scientific Program Committee Member
2012: Scientific Program Committee Chair
2011: Kansas “Rising Star” review committee
2012: Ad Hoc reviewer, Cancer Center Review Panel (Subpart A)
2012-2017: NCI Board of Scientific Councilors (Clinical Sciences and Epidemiology)
2012: Ad Hoc reviewer, NIH Developmental Therapeutics Study Section
2014-2016: American Joint Commission on Cancer (AJCC), 8th edition, Kidney/Urinary Tract expert panel, Chair
2014- : Chair, Data Safety Monitoring Committee Sotio Phase 3 prostate cancer clinical trial
2014: Ad Hoc reviewer, NIH Special Emphasis Panel, ZCA1 RPRB-7 (O3) NCI
2014: International Society of Urological Pathology, Prostate Cancer Grading Meeting
2014 - : Review Panel, Cancer Prevention and Research Institute of Texas (CPRIT)
2014: Review Panel, DOD Genetic and Cancer Research – Kidney Cancer
2014: Prostate Cancer Foundation, Challenge Awards Program Review Panel
2016: NIH ad hoc SPORE Review Panel, Co-Chair

2016 -	Data Safety Monitoring Committee, Eisai, Phase 3 trial of levantinib/everolimus or levantinib/pembrolizumab vs sunitinib in renal cancer
2016 -	Data Safety Monitoring Committee, Astra-Zeneca, Phase 3 Durvalumab vs Durvalumab + Tremelimumab vs standard chemo in first line metastatic urothelial cancer
2016 - :	Data Safety Monitoring Committee, Bayer, Phase 3 Study of ODM-201vs Placebo plus Standard Androgen Deprivation and Docetaxel in Prostate Cancer
2017:	NIH ad hoc SPORE Review Panel, Co-Chair
2017 - 2019:	Data Safety Monitoring Committee, Astra-Zenece, Phase 3 Durvalumab vs Durvalumab/Tremelimumab vs Standard Chemotherapy in Bladder Cancer
2018 - :	Data Safety Monitoring Committee, Astra-Zeneca, Phase 3 Durvalumab + BCG versus BCG for non-muscle invasive bladder cancer
2018 - :	Data Safety Monitoring Committee, Astra-Zeneca, Phase 3 Durvalumab +/- Tremelimumab +/- Standard Chemotherapy
2018 - :	Data Safety Monitoring Committee, Astra-Zeneca, Phase 3 Gemcitabine/Cisplatin w/wo Durvalumab for Neoadjuvant therapy of Bladder Cancer
2019 - :	Data Safety Monitoring Committees, Merck prostate cancer pembrolizumab program (3 separate phase 3 trials)
2019:	Chair, DOD Kidney Cancer Clinical Trials Consortium Review Panel
2019:	ASCO Conquer Cancer Foundation Young Investigator Award Review Panel
2020:	DOD Kidney Cancer Concept Award Review Panel